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Abstract 
 
The broad, long-term objective of this research is to develop drug leads for new 
antibiotics, antiparasitics, and cancer chemotherapeutics.  Two main areas of focus are 
inhibition of the Methyl Erythritol Phosphate (MEP; non-mevalonate pathway) pathway in 
bacterial and parasitic human pathogens and inhibition of isoprenoid synthases in human 
cancers.  For the development of antibacterials and antiparasitics, this research investigates the 
structure, function, and inhibition of the essential penultimate and ultimate enzymes of the 
MEP pathway, IspG (iron sulfur protein G; also known as GcpE and E-4-hydroxy-2-C-methyl-
erythritol pyrophosphate synthase) and IspH (also know as LytB and E-4-hydroxy-2-C-methyl-
erythritol pyrophosphate reductase), respectively.  Investigation of novel cancer drugs focuses 
on mono- and combination therapies targeting the farnesyl pyrophosphate synthase (FPPS) and 
GGPPS (geranyl geranyl pyrophosphate synthase) enzymes with drugs that interact with several 
pathways involved in autophagy and apoptosis. 
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Chapter 1 
Introduction 
 
1.1 General Perspective of Research 
 There is an ever increasing demand for novel pharmaceuticals that can specifically target 
bacterial and protozoan pathogens as well as different forms of cancer.  As the road to an FDA (Food & 
Drug Administration) approved drug is costly, conservatively upwards of $800 million (USD), this 
research is focused on studying the pre-clinical target and inhibitor design aspect of the drug discovery 
pipeline (1).  I have chosen to focus on studying and inhibiting enzymes in isoprenoid biosynthesis, 
specifically enzymes in the non-mevalonate or methyl erythritol phosphate (MEP) pathway and longer 
chain (C15, C20) isoprenoid synthases.  By investigating the structure and function of key enzymes in 
terpene (isoprenoid) biosynthesis pathways, I gain insight into ways to optimize inhibitors.  The tailoring 
of specific enzyme inhibitors is an important part of the drug discovery process as it will reduce possible 
off-target side effects later in the drug development pipeline.  The combined global economic and 
medical realities highlight the importance of developing new anti-microbial and anti-cancer drugs, 
particularly at the novel target level where this research is focused. 
 
1.2 Exigent Drug Development 
 In 2004, malaria infected 500 million people and killed over 1 million people every year (2).  
Since then, by 2012, a global network of governmental, private, and non-profit actors, such as Novartis 
(3), Medicines for Malaria Venture (MMV; a public-private partnership, (4)), PEPFAR (5), Drugs for 
Neglected Disease Initiative (DNDi, (6)), Ministries of Health from multiple African nations (Zambia, 
South Africa, Kenya, Nigeria, (4, 6)), and many more have worked to reduce the annual malaria mortality 
to 627,000 (7-9).  The danger from malaria, however, persists and the declining mortality statistics may 
not continue to drop.  Just like chloroquine resistance helped fuel the rise in malaria mortality, an 
emerging resistance to artemesinin in Plasmodium falciparum (the most lethal form of malaria), 
spreading through Southeast Asia (Vietnam, Cambodia, Thailand, and Myanmar), is threatening to do 
the same (7-9).   
 Another major infectious disease threat is from Tuberculosis (TB).  In 2012, 8.7 million people 
acquired tuberculosis (TB) and 1.3 million people died from TB (10).  Current TB treatments are also 
becoming less effective.  The World Health Organization (WHO) estimates that in 2012 there were 
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450,000 new cases of multi-drug resistant TB (MDR-TB), about 10% of which were also extensively drug-
resistant TB (XDR-TB) (10).  TB is the leading killer of people living with HIV/AIDS (human 
immunodeficiency virus, acquired immunodeficiency syndrome) (11, 12).  People who are immune 
compromised, with HIV/AIDS for example, are extremely vulnerable to opportunistic infections such as 
TB and the pneumonia caused by Pseudomonas aeruginosa (13-15). 
 Alarmingly, new therapies for tuberculosis and malaria have accounted for only 0.2% and 0.5%, 
respectively, of the 1556 new drugs commercialized between 1975-2004 (16, 17).  If we include other 
neglected infectious diseases that affect low and middle income countries, only 21 (1.3%) of 1556 new 
drugs have been developed between 1975-2004 (16, 17).  Yet, while the need for new antibiotics and 
other anti-infectives is increasing as a result of the emergence of multi-drug-resistant organisms 
(MDROs), the development of new chemical entities (NCEs) overall is decreasing (16-19).  Furthermore, 
there is a general lack of diversity of drug targets: only 58 distinct pathogen proteins are targeted by all 
FDA-approved drugs that fight infection (20).   
 In 2013, the CDC issued a special report on the threat of mounting bacterial antibiotic resistance 
(21).  In the “Urgent: Hazard Level,” they prioritized Clostridium difficile, carbapenem-resistant 
Enterobacteriaceae (CRE; such as Klebsiella spp. and E. coli), and Neisseria gonorrhoeae as major threats 
(21).  In the “Serious: Hazard Level,” they included Campylobacter, extended spectrum -lactamase 
producing Enterobacteriaceae (ESBLs; such as Klebsiella spp. and E. coli), Pseudomonas aeruginosa, non-
typhoidal Salmonella, Salmonella typhi, Shigella, and TB (21).  All of these bacteria utilize the essential 
MEP pathway.  A more complete list of pathogenic organisms that utilize the MEP pathway can be seen 
in Table 1.1.   
 A 2014 global report by the WHO (World Health Organization) found that 50+% of reported 
bacterial E. coli infections in 80% of WHO regions were resistant to 3rd generation cephalosporins and 
fluoroquinolones (10).  In all WHO regions, 50+% of reported K. pneumoniae infections were found 
resistant to 3rd gen. cephalosporins (10).  Additionally, fluoquinolone resistant non-typhoidal Salmonella 
and Shigella spp., as well as 3rd gen. carbapenem resistant N. gonorrhoeae, were found in 30-50% of 
WHO regions (10).  All of these organisms rely on the MEP pathway for survival, Table 1.1. 
 Other opportunistic infections, such as sexually transmitted diseases, are associated with drug 
resistance.  People with sexually transmitted diseases (STDs), such as chlamydia, gonorrhea, and syphilis, 
are at an increased risk for being infected with HIV/AIDS (22).  While treatments for chlamydia, 
gonorrhea, and syphilis exist, antimicrobial resistance has been observed for syphilis with macrolides, 
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clindamycin, and rifampin (23) and for gonorrhea involving all treatments, including the last-line 
treatment of cephalosporins (10, 24).   
 There is at the same time an important need to develop anti-cancer drugs.  In high income 
countries, lung, colon, and breast cancers are the 3rd, 6th, and 10th leading causes of death (5).  Table 
1.2 shows the US 2012 estimated new cases and deaths from breast, pancreatic, colon, lung and 
bronchial cancer (for both sexes) (25, 26). 
 
1.3 The Essential Methyl Erythritol Phosphate (MEP) and Isoprenoid Biosynthesis Pathways 
 The Methyl Erythritol Phosphate (MEP, a.k.a. non-mevalonate or Rohmer pathway) and 
Mevalonate (MVA) pathways both produce the essential isoprenoid precursors, isopentyl 
pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP), that are used for the synthesis of long 
chain isoprenoids involved in cell wall biosynthesis, sterol and carotenoid biosynthesis, and cell wall 
targeting via prenylation.  Importantly, the MVA pathway is found in mammals, fungi, and certain gram-
positive bacteria, and uses acetyl-CoA as a precursor.  In contrast, the MEP pathway is only found in 
certain gram-negative bacteria, protozoa, and plants, and uses pyruvate and glyceraldehyde-3-
phosphate as precursors (27-36).  Table 1.1 lists human pathogenic bacterial and protozoan organisms 
that utilize the MEP pathway. 
 The essentiality of the MEP pathway for bacteria/parasite pathogens and the non-existence of 
this pathway in humans further make this pathway an attractive target because of the potential to 
develop pathogen specific inhibitors, similar to how p-aminobenzoic acid (PABA) analogs have been 
successfully developed as bacteria specific dihydropteroate synthase inhibitors.  Proof-of-concept for 
targeting the MEP pathway is demonstrated by the current clinical trials involving inhibition of the 
second enzyme in the MEP pathway, DXR (1-deoxy-d-xylulose-5 phosphate reductoisomerase), by 
fosmidomycin and FR900098 (methylated analog of fosmidomycin) (37-39).  Additionally promising is 
the existence of similar 4Fe-4S cluster co-factors for both IspG and IspH enzymes, opening the possibility 
for targeted dual acting inhibition by a single agent.   
 I am investigating mono- and combination therapies targeting the farnesyl pyrophosphate 
synthase (FPPS) and GGPPS (geranyl geranyl pyrophosphate synthase) enzymes in the isoprenoid 
(prenyl) biosynthesis pathway.  Current usage of statins that target HMG-CoA reductase (3-hydroxy-3-
methyl-glutaryl-CoA reductase) in the MVA pathway (upstream from FPPS/GGPPS) for treatment of 
hyperlipidemia, hypercholesterolemia, and combination chemotherapies for various cancers (27, 36) 
substantiates the potential efficacy of this modality of cancer drug development.  As excitement for 
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targeting prenyl synthases mounts, there are ongoing clinical trials involving several farnesyl transferase 
inhibitors for the treatment of adenocarcinomas (40).   
 
1.4 IspG and IspH Enzymes 
IspG (2-C-methyl-D-erythritol-2,4-cyclo-diphosphate reductase; also known as GcpE) and IspH 
(E-4-hydroxy-2-C-methyl-erythritol pyrophosphate reductase; also known as LytB) are the penultimate 
and ultimate enzymes, respectively, in the MEP pathway (31, 41, 42).  Both IspG and IspH enzymes 
contain 4Fe-4S cluster co-factors that are essential for enzymatic redox activity.  Crystallographic and 
spectroscopic evidence shows that reduction of substrate occurs upon interaction with the iron sulfur 
clusters in IspG and IspH.  Both IspG and IspH catalyze 2e-/2H+ reduction reactions, but proceed via 
different intermediates, e.g. IspG is thought to proceed through a ferraoxetane intermediate that is not 
spectroscopically observed in IspH (43).  IspG reduces MEcPP (2-C-methyl-D-erythritol-2,4-cyclo-
diphosphate) into HMBPP (E-4-hydroxy-2-C-methyl-erythritol pyrophosphate) that is subsequently 
reduced by IspH into IPP (isopentyl pyrophosphate) and DMAPP (dimethylallyl pyrophosphate). 
 
 
 
 Two distinct structural classes of IspG enzymes can be found in bacteria, protozoa, and plants, 
those with either two- or three-domains, Figure 1.1.  Based on observation of the recently published x-
ray crystallographic structures, two domain bacterial IspG enzymes are thought to operate as dimers.  
Questions remain as to whether the three domain IspG enzymes also function as dimers and whether 
there are any differences in the mechanisms of catalytic activity as well as inhibition between the two 
and three domain forms.  This research answers those questions with multiple experiments using cross-
linking, SDS-PAGE, mutagenesis, column chromatography, homology modeling, low dose transmission 
electron microscopy, and tomographic single particle reconstruction.  The catalytic oligimeric states of 
two- and three- domain IspG enzymes were observed to indeed differ.  While the two domain bacterial 
IspG enzyme operates as a monomer, the plant/protozoan three domain IspG enzyme is active as a 
monomer. 
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EPR Spectroscopy.  We used CW-EPR and pulsed EPR techniques (HYSCORE and ENDOR) to determine 
whether the “X” intermediate observed with two-domain IspG enzymes is also observed with three-
domain IspG enzymes.  We used Davies ENDOR to detect strong (“strong” relative to the couplings 
detectable with Mims ENDOR) hyperfine couplings that are not affected by tau suppression effects to 
observe the MEcPP reaction intermediate “X” with AtIspG.  As seen with the dimer two-domain IspG 
proteins, with our AtIspG “X” intermediate, we observed a 12 MHz 1H hyperfine interaction with one of 
the C2′ methyl protons and a weaker 2 MHz hyperfine interaction with the other 2 C2’ methyl protons, 
Figure 1.2A.  We trapped the AtIspG “X” intermediate using [U-13C]-MEcPP and observed the hyperfine 
interactions with a HYSCORE experiment, Figure 1.2B.  Here again, we observe similar 13C hyperfine 
interactions between three-domain (AtIspG) and two-domain (TtIspG) enzymes.   
 
Electron Microscopy.  As the structures of three domain IspG proteins have not been discovered, I used a 
combination of bioinformatics and electron microscopy to help understand these structures.  After 
calibrating the Peltier-cooled Tietz CCD camera and Philips CM200 TEM for acquiring low dose ( 12 
e∕Å2) digital micrographs suitable for molecular modeling, I created software to assist with data 
collection, processing, and resolution analysis.  I manually performed low dose tomographic single-axis 
tilt series data collection.  I modified and improved software from EMAN2 (44) to extract multiple single 
particle tilt series using the TEM imaging parameters.  I created software, using EMAN2/Sparx (44, 45) 
libraries, to incorporate manual and automatic three dimensional electron density alignments.  I created 
software, using EMAN2/Sparx libraries, to analyze the resolution of the tomographic single particle 
reconstructions based off of the noise compensated leave-one-out in 2D (NLOO-2D) and tilt series 
Fourier shell correlation even/odd (FSCe/o) resolution criteria (46).  The final tomographic single particle 
reconstruction of AtIspG matched our cross-linking, SDS-PAGE, and gel-filtration chromatography 
experiments; AtIspG operates as a monomer, Figure 1.3. 
 
1.5 Small Compound Inhibition of IspG and IspH Enzymes 
 Recent Mössbauer spectroscopy experiments have demonstrated that amino-HMBPP (2) and 
thiol-HMBPP (3) analogs are inhibitors of IspH and bind directly to the oxidized diamagnetic [4Fe-4S]2+ 
(S=0) cluster in IspH (47).  We observe that the IspG product, HMBPP (1), produces a distinct EPR 
observable, S = ½, line that is characteristic of a -complex interaction between an alkene with Fe, for 
this case, the non-cys-coordinated apical Fe of the IspG 4Fe-4S cluster.  Conceivably, HMBPP analogs 
would also function as inhibitors of IspG.  As the Mössbauer experiments were carried out with oxidized 
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IspH, I am interested in the effects the HMBPP analog compounds have on reduced IspH.  Further, 
considering that IspG and IspH both contain 4Fe-4S clusters, but proceed via slightly different 
mechanistic pathways, I am curious as to the potency of these inhibitors and mode of interaction with 
IspG, as well as the differences/similarities in mode of inhibition.   
 
 
 Questions surrounding differences between two- and three- domain IspG enzymes also extend 
to whether inhibitors of two-domain IspG enzymes work similarly against three-domain IspG enzymes.  
If the extra domain in three-domain IspG enzymes is involved in catalysis, we might expect to observe 
differences in binding of substrate, catalytic mechanism, and strength of inhibitor potencies, all of which 
we may assess using UV-Vis and EPR spectroscopy.  Together with my lab mates, we tested a combined 
25 different inhibitors against two and three domain IspG enzymes using a dithionite and methyl 
viologen coupled redox reaction.  Only the shorter chain alkyne diphosphates, such as 4, were good 
inhibitors with ~0.8-10 µM IC50s.  We also observe a 6 MHz 
13C hyperfine coupling of [U-13C]-propargyl 
diphosphate with AtIspG with HYSCORE, Figure 1.2C; this 6 MHz 13C hyperfine coupling is also seen with 
two-domain EcIspG.    
 
1.6 Inhibition of Prenyl Synthases 
 Bisphosphonates are currently used to inhibit osteoclast mediated bone resorption by first 
binding to bone and subsequently, after entering the osteoclast, triggering apoptosis via inhibiting FPPS 
activity in the isoprenoid biosynthesis pathway.  By understanding how bisphosphonates are targeted 
towards bone, we may be able to use that information to design more potent inhibitors that target 
parasites and bacteria, as well as cancers that target tissues other than bone.  Our chemists synthesized 
bisphosphonate derivatives with modified functional groups that I tested for their bone binding 
thermodynamic properties using isothermal titration calorimetry (ITC).  I wanted to learn how certain 
functional groups (cationic head group, each phosphonate, hydrophobic group, and 1-hydroxyl group) 
help determine whether bisphosphonates bind to either one or two binding sites in bone, Figure 1.4.  
Experimental and computational analysis indicates that cationic short chain bisphosphonates with a 1-
OH group bind to both sites.  Removal of the 1-OH and cationic groups, plus the addition of a bulky 
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hydrophobic group, results in binding to only one site which has important implications for the next 
stages of drug design.  Taken together, these results lead to the idea of developing lipophilic 
bisphosphonates that target protozoal parasites and cancer since the compounds possess better body 
distribution profiles resulting from decreased bone binding affinity and have been optimized for prenyl 
synthase (FPPS and GGPPS) inhibition (48, 49).   
 In collaboration with the Institut-Pasteur-Korea, our lab has screened 450 compounds from our 
inhibitor library against the P. falciparum parasite and found 72 putative hits.  I began synthesizing 
derivatives of one of those hits, BPH-703.  The alkylated imidizolium bisphosphonate I synthesized was 
subsequently tested against Trypanosoma brucei (causative agent of African sleeping sickness) FPPS and 
found to have an IC50 of  ~80 nM.  A test of this compound in a DH5 E. coli cell growth inhibition assay 
showed it had a 16.0 M IC50.  
 Continuing work with bisphosphonate inhibitors of FPPS/GGPPS, I found several synergistic 
combinations against different cancer cell lines.  One collaboration with the Salk Institute has shown 
that the bisphosphonate and rapamycin combination is a potent and novel chemotherapy for 
adenocarcinomas. 
 
1.7 Chemo- and Radio-Therapy Resistant Mutant KRas/p53-/- Adenocarcinoma 
Ras is oncogenetically modified in 20-30% of all cancers and is considered a “star player” 
because it effects many different down-stream pathways (50, 51).  KRas mutations in adenocarcinomas 
have been associated with resistance to chemo- and radio- therapies (52-57).  Constitutively activating 
mutations in Ras render the Ras protein (also known as p21) in the “always-on” GTP-bound state, 
meaning that mutant KRas is continually activating all of its effector pathways, many of which lead to 
unregulated cell growth.  Without targeting to the plasma or an intracellular membrane by prenylation 
(farnesylation or geranylation) at its C-terminal CAAX motif, the Ras protein is rendered non-functional.  
Immediately, we can deduce that inhibitors of the MVA pathway and long chain isoprenoid synthases 
that produces IPP, DMAPP, FPP (farnesyl pyrophosphate), GGPP (geranyl geranyl pyrophosphate), could 
be potential good cancer drugs. 
p53 is a tumor suppressor protein encoded by the TP53 gene in humans (50).  As the name of 
the gene indicates, p53 is involved in many processes that suppress tumor formation, including cell cycle 
arrest, apoptosis, DNA repair, and inhibition of angiogenesis.  Because of p53’s importance in limiting 
the growth of potentially cancerous cells, it has been dubbed “guardian of the genome.”  Also as a result 
of p53’s importance, TP53 mutations are found in most cancers (50). 
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 We are interested in combining lipophilic FPPS/GGPPS bisphosphonate inhibitors with drugs 
that interact with the Ras pathway, macroautophagy, the PI3K (phosphotidyl inositol-3-phosphate 
kinase) pathway, the mTOR (mammalian target of rapamycin) pathway, mutant p53 pathways, 
Raf/MEK/ERK pathway, and cellular growth.  Rapamycin + 1222 combinations (fixed dose molar ratio 
1:1) show synergistic efficacy in vivo against KRasG12D/p53-/- murine tumors.  BPH-1222 alone is able to 
induce acidic vesicular organelle (AVO) formation, a characteristic of macroautophagy by formation of 
autolysosomes.   
 The PI3K-AKT-mTOR pathway has been implicated in many types of cancer, e.g. 
adenocarcinomas, and has been shown to be linked to autophagy (58).  PI3K (phosphatidylinositol 3-
kinase), AKT (protein kinase B), and mTOR (molecular target of rapamycin) are proteins in a pathway 
that interacts with the EGFR-MAPK (epidermal growth factor receptor; mitogen activated protein 
kinase) signaling pathway that involves Ras and p53 (50, 51, 58).  Inhibitors of phosphoinositides, PI3K, 
and other PI kinases have been shown to be effective targets for treating adenocarcinomas (51, 59-61).  
Inhibitors, such as bafilomycin A1, target the H+ATPase, preventing macroautophagy from proceeding by 
preventing the autolysosomal pH from lowering (62).  Up-stream to autolysosome formation, the 
compound 3-MA (3-methyladenine) inhibits the formation of the autolysome, thus preventing 
macroautophagy (62).  Chloroquine (CQ) is in clinical trials as a combination therapy because it has been 
shown in animal models to display synergy (63, 64).  As a weak base, chloroquine, a 4-aminoquinolone, 
is thought to localize to acidic organelles, as it similarly localizes to the acidic food (digestive) vacuole in 
malaria parasites, and may help prevent the acidification of the autolysosome (65, 66).  Thus, CQ is 
thought to inhibit macroautophagy by preventing the lowering of the autolysosomal pH similar to how 
bafilomycin A1 inhibits autophagy by disrupting autolysosomal function (67-69).  Further in vivo tests 
have shown that CQ combination treatments do not however inhibit tumorigenesis long-term, possibly 
because of its effect to inhibit macroautophagy.  In contrast, drugs such as rapamycin and BPH-1222 are 
shown to activate macroautophagy. 
 
1.8 Cheminformatics 
 We have developed a customizable, low-cost, web browser based cheminformatics system using 
open-source tools.  The multi-tiered software architecture is based on a MySQL relational database 
server backend to which all information is stored, including chemical structures.  The combined modular 
cheminformatics system allows our researchers to interact with all of the compound and assay data in a 
standardized format.  Computational chemistry and drug design can proceed as all data can be exported 
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in standard formats (SDF, MolFile, ASCII) for importing into commercial applications such as MOE (75), 
Sybyl (76), Schrodinger Maestro (77), ChemDraw (78), AutoDock (79, 80), AutoDock Vina (79-81), 
Chimera (82), Accelrys Discovery Studio (83), and more.  In turn, all of the desktop/server processing can 
be uploaded into the cheminformatic system. 
 
1.9 Research Methods 
 The following methods were used in this research: 
 Antibiotic and antiparasitic drug development:  isothermal calorimetry (ITC), multiple linear 
regression, multi-sequence bioinformatics, homology modeling, mutational analysis, enzyme 
inhibition kinetics, redox end-point and kinetics via UV-Vis spectrophotometry, CW-EPR (continuous 
wave electron paramagnetic resonance), pulsed EPR HYSCORE (hyperfine sublevel correlation 
spectroscopy) and ENDOR (electron nuclear double resonance spectroscopy), transmission electron 
microscopy, and single particle tomographic reconstruction. 
 Anti-cancer drug development:  mammalian cell culture, mammalian cell MTT ((3-[4,5-
dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assays, live cell light microscopy, live cell 
fluorescence microscopy, fixed cell light microscopy, fixed cell fluorescence microscopy. 
 
1.10 Chapter Descriptions 
Chapter 2:  Investigate the thermodynamic bone binding properties of bisphosphonates.   
 Determine the thermodynamic properties of bisphosphonates binding to human bone using ITC. 
 Develop a multiple linear regression model to describe the contribution of functional groups 
important for bone binding. 
 S. Mukherjee, C. Huang, F. Guerra, K. Wang, E. Oldfield.  JACS, 2009, 131, 8374-5. 
 
Chapter 3:  Investigate the structure, function, and inhibition of two- and three- domain IspG proteins. 
 Develop IspG inhibitors based on our recent discoveries that alkynes and aromatic bases (e.g. 
pyridines) inhibit both of these enzymes. 
 Use bioinformatics, mutagenesis, and electron microscopy to investigate the active oligimeric state 
and structures of two- and three- domain IspG proteins. 
 Y.L. Liu, F. Guerra, K. Wang, W. Wang, J. Li, C. Huang, W. Zhu, K. Houlihan, Z. Li, Y. Zhang, S.K. Nair., 
and E. Oldfield.  PNAS, 2012, 109, 8558-63.  
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Chapter 4:  Investigate the inhibition of IspG and IspH proteins with HMBPP analogs 
 Investigate the inhibition of IspG and IspH enzymatic activity by HMBPP analogs using UV-Vis 
spectroscopy. 
 Use CW-EPR and HYSCORE spectroscopy to investigate in more detail the mode of inhibition of 
HMBPP analog inhibitors against IspG and IspH. 
 F. Guerra, K. Wang, J. Li, W. Wang, Y.L. Liu, S. Amin, and E. Oldfield.  Chem. Sci., 2014, 5, 1642-49. 
 
Chapter 5:  Inhibitor Synthesis.   
 Synthesize a derivative of BPH-703, a putative hit from the high throughput screen against the P. 
falciparum parasite done in collaboration with the Institut-Pasteur-Korea. 
 Test enzyme inhibition against the T. brucei FPPS enzyme. 
 Test bacterial cell growth inhibition against DH5 E. coli cells. 
 
Chapter 6:  Investigate the inhibition of mutant KRas/p53-/-. 
 Develop novel FPPS and GGPPS inhibitors that are effective against mutant KRas / p53-/- cells. 
 Investigate combinations of FPPS/GGPPS inhibitors with drugs that target the same and other 
altered pathways in cancer cells. 
 Investigate the in vivo therapeutic efficacy of our compounds in mouse models with our 
collaborator, Yifeng Xia, at The Salk Institute. 
 Xia, Y.; Liu, Y.L.; Xie, Y.; Zhu, W.; Guerra, F.; Shen, S.; Yeddula, N.; Fischer, W.; Zhou, X.; Zhang, Y.; 
Oldfield, E.; Verma, I.M.  Manuscript submitted for review to Science Translational Medicine. 
 
Chapter 7:  Development of a chemoinformatics system.   
 Maintain, upgrade, and improve a chemical informatics system based in web technologies (HTML, 
Javascript, PHP, MySQL, Java Server Pages, ChemAxon Java libraries and web extensions, LDAP 
Server, Python, Apache HTTPD Server, Apache Tomcat Server, MySQL Server/Clients, Chemistry 
Development Kit Java libraries, JChemPaint Java applets). 
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1.11 Tables and Figures 
 
Table 1.1 Human pathogenic organisms that utilize the essential MEP pathway (27-35, 84, 85). 
 
Gram Negative Bacteria Gram Positive Bacteria 
Brucella abortus Bacillus anthracis str. Sterne 
Chlamydia trachomatus 434/Bu Clostridium difficile 630 
Chlamydia pneumoniae Clostridium botulinum B1 str. Okra 
Salmonella enterica serovar Typhimurium Clostridium perfringens E str. JGS1987 
Escherichia coli O157:H7  
Escherichia coli O127:H6 Mycobacteria 
Francisella tularensis Mycobacterium tuberculosis 
Pseudomonas aeruginosa Mycobacterium avium 
Vibrio cholera  
Klebsiella pneumoniae subsp. pneumoniae MGH 78578 Apicomplexan Parasites 
Bordetella pertusis Tahoma I Plasmodium falciparum 
Haemophilus influenzae Plasmodium vivax 
Helicobacter pylori Toxoplasma gondii 
Shigella flexneri  
Shigella dysenteriae Sd197  
Neisseria gonorrhoeae FA  
Neisseria meningitidis   
Campylobacter jejuni subsp. jejuni 81116  
Yersinia enterocolitica  
Treponema pallidum  
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Table 1.2 US 2012 estimated new cases and deaths from breast, pancreatic, colon, lung and 
bronchial cancer (for both sexes) (26). 
 
Types of cancer New Cases Deaths 
breast 229,060 39,920 
pancreatic 43,920 37,390 
colon 103,170 51,690 
lung & bronchial 244,180 164,770 
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Figure 1.1 Diagram of two- (A) and three- (B) domain IspG enzymes. The A domain is a TIM barrel. 
The B domain is the iron-sulfur containing domain. The A* domain appears to also be a TIM barrel. 
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Figure 1.2 ENDOR and HYSCORE spectra of AtIspG. (A) 1H-ENDOR of AtIspG X. The Aiso = 12 MHz 
proton signal is indicated. The inset is a Newman projection along C2-C2′, showing the dihedral angle-
dependent hyperfine coupling constants of the three C2′ methyl protons. (B) HYSCORE spectrum of 
AtIspG with [U-13C]-MEcPP. (C) HYSCORE spectra of [U-13C]-propargyl diphosphate (IC50 = 1.3 M) 
bound to AtIspG. 
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Figure 1.3 AtIspG models.  (A) Homology model of the A. thaliana catalytically active IspG 
monomer. Helices #7 of A/A* domains are highlighted in pink/red.  (B) AtIspG tomographic single 
particle reconstruction.  Rigid body fit of AtIspG homology model into electron density map created 
from single particle electron tomography.  
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Figure 1.4 Schematic of pamidronate binding to two sites on human bone. 
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Chapter 2 
Thermodynamics of Bisphosphonates Binding to Human Bone: A Two-
Site Model 
 
2.1 Notes and Acknowledgements 
 This chapter was adapted from:  Sujoy Mukherjee, Cancan Huang, Francisco Guerra, Ke Wang, 
and  Eric Oldfield. J. Am. Chem. Soc. 2009, 131, 8374-8375.  This work was supported by the U.S. Public 
Health Service (NIH Grant GM65307). S.M. was an American Heart Association, Midwest Affiliate, 
Predoctoral Fellow (Grant No. 0615564Z).  S.M. and E.O initiated the design for the research.  K.W. 
synthesized the compounds.  C.H and F.G. collected the ITC data.  F.G. designed and implemented the 
computational method with initial help from E.O regarding the design of the computational method. 
 
2.2 Introduction 
 Bisphosphonates are the major drugs used to treat bone-resorption diseases.(1)  They act by 
preventing osteoclastic bone resorption, inhibiting the enzyme farnesyl diphosphate synthase (FPPS).  
Bisphosphonates also kill tumor cells (2) and many parasitic protozoa (3) and can activate γδ T cells of 
the immune system (4) to kill tumor cells (5) and bacteria.(6) There is thus interest in their use for 
immunochemotherapy of cancer (7) and in the treatment of parasitic protozoan diseases (8), where less 
avid bone binding might be advantageous. In earlier work (9), we used NMR to probe how different 
bisphosphonates bind to bone. We found that the 31P magic-angle sample spinning NMR spectra of 
bound bisphosphonates exhibited a single broad peak and that there was ∼0.8 phosphate (Pi) released 
per bisphosphonate bound. These and other NMR results led to a model (9) in which a bisphosphonate -
PO3
2- group displaced Pi, while the cationic side chains interacted electrostatically with anionic surface 
groups. However, a puzzling observation was that the free energy for binding was low (∼ -4.3 kcal, for 
pamidronate). Here, we investigate this topic further, by using isothermal titration calorimetry (ITC), 
which might yield information on any additional, tight binding site(s) that, if at low occupancy, would be 
difficult to detect via NMR. 
 
2.3 Experimental 
 We investigated by ITC the interaction of the 12 bisphosphonates (1-12) shown above with 
human bone mineral, which enabled us to study the effects of having a 1-OH group removed (4, 6), 
changing the position of the ring nitrogen in risedronate (7), removing the ring nitrogen in risedronate 
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(8), and truncating the risedronate side chain (9), in addition to studying several other bisphosphonates 
of interest (10-12) (11).  Representative ITC results for three compounds (1, 3, 4), together with their 
corresponding fitting curves, are shown in Figure 2.2A-B (all 12 fitting curves are in Figure 2.4), and the 
ΔG, ΔH, and ΔS values so derived (10) are given in Table 2.1. 
 
 Isothermal titration calorimetry.  ITC experiments were performed on a VP-ITC calorimeter 
(Microcal, Inc., Northampton, MA). Human bone tissue (non-demineralized bone powder, 45-250 μm 
particle size,) was obtained from the Pacific Coast Tissue Bank (2400 S. Flower St., 5th Floor, Los Angeles, 
CA, USA. Phone number: 800-745-0034 Fax number: 213-745- 3031). Typically, the bisphosphonate 
samples were made by dissolving 10 mM bisphosphonate in 100 mM PH=7.0 HEPES buffer. The pH of 
the solution was then readjusted to 7.0. Bone samples were prepared by suspending 50 mg bone in 2 
mL 100 mM HEPES buffer at pH=7.0. We calculated the final concentration of bone sample in the 
calorimeter sample cell as approximately 40.4 mM, based on the observation that bone contains 60% 
hydroxyapatite (monomer FWt=502 g/mol)  (12).  Approximately 48 mg bone sample was transferred 
into the 1.42 mL sample cell, therefore, the final concentration is: 
           
   
  
              
           
All samples and buffers were degassed prior to calorimetry. The ITC experiments were conducted by 
sequentially titrating 10 μL bisphosphonate sample from a 250 μL syringe (rotating at 460 or 490 rpm) 
into the 1.42 mL sample cell containing bone at 37 °C. The initial delay was set to 300 s, each injection 
was 24 s long and was separated by a 300 s delay between injections so that the heat of reaction 
reached baseline prior to the next injection. Longer delays between injections did not affect the results 
obtained, consistent with full binding of the bisphosphonates into all accessible sites. For all 
experiments, the heats of dilution were obtained just prior to the bone experiments, and were obtained 
by titrating the bisphosphonate sample into 100 mM HEPES buffer (pH=7.0) using the same ITC 
parameters. The heat of dilution was then used as a reference, being subtracted from the experiment 
with bone by using Origin software (from Microcal, Inc., Northampton, MA). The subtraction curves 
were analyzed by using non-linear regression methods, and could be well fitted using either a one-site 
binding model (4, 6, 8, 10-12) or a two-site binding model (1-3, 5, 7, and 9) (13). 
 
 Computational approach to G, H, and S prediction.  We treat G, H, and S for 
bisphosphonate binding to bone each as a linear combination of variables: 
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 ⃑    ⃑       where          ∑      
 
    
For example, the total free energy ( ⃑) of binding is a linear combination of the ΔG values for: NH3
+, 
PO3(1), PO3(2) together with OH, and a general hydrophobic side-chain (1-H or phenyl group) term: 
       ∑                           ( )        ( )                   
The second PO3 and the OH group contribution are not separable (since all compounds that bind to site 
B have both PO3(2) and the 1-OH group), so we grouped their contributions together as      ( )    . 
 Applying a pseudo-binary descriptor linear regression analysis, we searched for the best fit, or 
linear combination of functional group individual free energies, that can predict the total free energy. 
The vector and matrix rank data is arranged in the order Site A, then Site B. 
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The columns of A are ordered: 
   [
      
 
 
          
 
 
    
       
 
 
    
           
 
 
] 
We set A as a pseudo-binary matrix of values, mirroring the relative contribution of each functional 
group to the total free energy: 
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in which 1 = an interaction is present, 0 = it is absent. 
 To take account of the different pKa values of the ammonium (1,2), imidazolium (3,4), and 
pyridinium (5,6) side-chains, we took the ammonium to be fully protonated (12), the pyridiniums to 
have pKa of 6.7 so at pH=7 there is a 0.33 mole fraction of these species present, and the pKa of the 
pyridiniums to be 5.5, resulting in a 0.03 fraction protonated species (at pH=7.0), implying that 
Coulombic interactions of these charged side-chains dominate the bone binding interaction. 
 
2.4 Results and Discussion 
There are several observations. First, there are only two types of ITC curve seen. Binding of half 
of the compounds (1-3, 5, 7, and 9) is characterized by both weak (Site A, Table 2.1) and strong (Site B, 
Table 2.1) interactions (two independent sites), while the other six compounds (4, 6, 8, 10-12) bind to 
only the weak Site A (e.g., 4, in Figure 2.2B). Second, in most cases, binding is overwhelmingly entropy 
driven, that is, G ≈ -TS. Third, there is a rather small range in S in both sites. In the weak binding Site 
A, Gavg is ∼ -5.2 kcal and Savg is 14 cal K
-1 mol-1, while in the strong binding Site B, Gavg is ∼ -8.5 kcal 
and Savg is 30 cal K
-1 mol-1, almost twice that seen in the weak binding site.   
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Based on these results, and those described previously (9), we propose the bisphosphonate 
binding model shown (for pamidronate) in Figure 2.3. The weak binding Site A originates via 
displacement of ∼1 Pi per bisphosphonate bound.  It is the one that is most highly populated (Table 2.2) 
and is that which is observed by NMR.  One phosphonate group binds into the bone mineral matrix, and 
most of the binding free energy arises due to release of Pi and corresponds to a S of ∼14 cal K-1 mol-1 (-
TSavg ) -4.2 kcal mol
-1; Gavg ) -5.2 kcal mol
-1). 
The observation that binding to the strong binding Site B is again overwhelmingly entropy driven 
(S ≈ 30 cal K-1 mol-1, -TS = -9.3 kcal mol-1) and that this S value is about twice that seen in the weak 
binding site, and that only the small 1-OH containing species bind to this site, strongly suggests the 
binding mode shown in Figure 2.3A (Site B). Here, both phosphonates (and OH) bury into the bone 
mineral, resulting in release of ∼2Pi (or 1 Pi + 1 CO3
2-) and, thus, a ∼2X increase in S (from ∼14 to ∼30 
cal K-1 mol-1).  A 1-OH group is thus critical for bone mineral binding (as seen in vivo) although, 
interestingly, is not required for FPPS inhibition. 
 The results shown in Table 2.1 also indicate that the ΔG for binding of alendronate (1) to Site B is 
very large (-10.4 kcal mol-1), followed by that for pamidronate (2; -9.3 kcal mol-1), while that for 
zoledronate (3) is less strong (-8.4 kcal mol-1) and that for risedronate (5, -7.3 kcal mol-1) is relatively 
weak.  This binding strength behavior is what might be anticipated based on the pKa values of the side 
chains.  That is, the strongly basic species (pKa ∼11) are fully protonated at pH ) 7, making a strong 
electrostatic contribution to binding; zoledronate (imidazole pKa ∼6.7) is ∼33% protonated, while 
risedronate is only weakly protonated (pKa ∼5.5).  In the case of the weak binding site, the G values for 
the OH containing species (3, 5) are only ∼0.2 kcal mol-1 different from those observed with the 
corresponding deoxy analogues (4, 6), consistent with a weak OH interaction with the surface.  Of 
course, based on this model, it might be expected that the phenyl analogue (8) of risedronate (5) should 
also bind to the strong binding site.  This appears not to be the case, however, presumably because the 
bulky phenyl group is involved in a net repulsive (anion-π) interaction with the bone surface.  Removal 
of this bulky phenyl group results in etidronate (9), which binds to both sites, consistent with this idea. 
The question then arises: can we construct a quantitative model to predict the G, H, and S 
for all 12 compounds binding into Site A and/or Site B?  To do this, we used a thermodynamic group 
approach combined with a linear regression method, assuming that there are transferable or additive 
group G, H, and S values for the cationic headgroup, each phosphonate, the 1-OH group, together 
with an additional term to describe the presence of a hydrophobic (1-H or phenyl) interaction. The 
matrix we constructed is shown in the Experimental section and simply represents the presence (1) or 
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absence (0) of an interaction, with the cation term (ammonium, etc.) scaled to account for pKa 
differences.  Four coefficients are derived from a partial least-squares analysis and are given in Table 
2.4.  Figure 2.3B,C show experimental vs predicted G (Figure 2.3B) and H, -TS (Figure 2.3C) results, 
and there is good accord between experiment and prediction (Table 2.3). For example, for G, we find 
the R2 value is 0.95, F-value = 88, p < 0.00001, and the error is 0.19 kcal, ∼3% of the overall range, using 
a -1.6 kcal G for binding for the -NH3
+ groups in alendronate and pamidronate, -4.8 kcal for the ∼ -2 
charged Site A phosphonate, -3.1 kcal for the Site B phosphonate plus the OH group, and -0.05 kcal for 
the hydrophobic group. Good results are also obtained for H, -TS, Figure 2.3C. 
Using a multiple linear regression analysis (described above and in the Experimental section), we 
determined the thermodynamic group properties for G, H, and -TS (Table 2.4).  Statistics for this 
regression when applied to all 18 (12 Site A, 6 Site B) compounds are also shown in in Table 2.4.  The H 
statistics are worse than the G, -TS statistics since the H range is smaller.  Eliminating the 
hydrophobic term had overall no effect on the G statistics (R2=0.95), since H (=0.93 kcal mol-1) ≈ TS 
(0.99 kcal mol-1). 
 
2.5 Conclusions 
 These results are of broad general interest since they provide the first detailed thermodynamic 
description of the binding of a widely used class of drug molecules, bisphosphonates, to human bone. 
We find the presence of two different binding sites, with binding to each being readily explained based 
on the structural features present in each molecule, opening the way to the design of novel, potent 
enzyme and cell growth inhibitors that have weak bone-binding affinity, of interest in the context of 
chemotherapy (11), immunotherapy (7), and anti-infective drug development (8). 
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2.6 Tables and Figures 
Table 2.1 Thermodynamic parameters for ligand binding. 
 
 
site Ab site Bc 
G H S TS G H S TS 
1 -6.5 -1.7 15 4.7 -10.4 0.6 35 11 
2 -5.7 -1.4 14 4.3 -9.3 0.41 31 9.8 
3 -5.4 -1 14 4.4 -8.4 0.54 29 8.9 
4 -5.2 0.49 18 5.6 - - - - 
5 -4.7 -0.69 13 4 -7.3 0.89 27 8.2 
6 -4.9 0.56 18 5.4 - - - - 
7 -5 -1.3 12 3.7 -8 0.68 28 8.7 
8 -4.8 0.86 18 5.6 - - - - 
9 -5.6 -1.4 14 4.2 -7.7 0.74 27 8.4 
10 -5.1 -2.4 8.7 2.7 - - - - 
11 -4.7 -2.1 8.4 2.6 - - - - 
12 -5.1 -1.6 11 3.5 - - - - 
avg -5.2 -0.96 14 4.2 -8.5 0.64 30 9.2 
 
a Units of ΔG, ΔH, and TΔS are kcal mol-1, for ΔS, cal deg-1 mol-1. 
b Site A is the weak binding, highly populated site.  
c Site B is the strong binding site. 
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Table 2.2 Isothermal titration calorimetry results for 1-12 binding to human bone showing G, H, S, and N (the site occupancy), 
together with (where applicable) their standard deviations (from two or three independent experiments). 
 
 site A site B 
G H S N1 G H S N2 
(kcal/mol) (kcal/mol) (cal/K/mol)  (kcal/mol) (kcal/mol) (cal/K/mol)  
1 (alendronate) -6.5(0.13) -1.7(0.16) 15(0.94) 0.040(0.0035) -10.4(0.70) 0.60(0.18) 35(2.9) 0.0038(0.00010) 
2 (pamidronate) -5.7(0.072) -1.4(0.17) 14(0.78) 0.040(0.0085) -9.3(0.30) 0.41(0.097) 31(0.67) 0.0022(0.00034) 
3 (zoledronate) -5.4(0.20) -1.0(0.0035) 14(0.67) 0.034(0.0032) -8.4(0.51) 0.54(0.086) 29(1.9) 0.0063(0.0006) 
4 (deoxyzoledronate) -5.2(0.095) 0.49(0.15) 18(0.79) 0.048(0.0054) a a a a 
5 (risedronate) -4.7(1.0) -0.69(0.44) 13(4.3) 0.028(0.0053) -7.3(0.89) 0.89(0.19) 27(2.3) 0.0080(0.0012) 
6 (deoxyrisedronate) -4.9 0.56 18 0.052 a a a a 
7 (ortho-risedronate) -5.0(0.48) -1.3(0.57) 12(3.3) 0.057(0.036) -8.0(0.23) 0.68(0.63) 28(1.42) 0.0048(0.0017) 
8 (desazarisedronate) -4.8(0.48) 0.86(0.36) 18(0.38) 0.02(0.0033) a a a a 
9 (etidronate) -5.6(0.17) -1.4(0.13) 14(0.95) 0.019(0.0044) -7.7(0.37) 0.74(0.088) 27(0.90) 0.0023(0.00023) 
10 (clodronate) -5.1 -2.4 8.7 0.04 a a a a 
11 (BPH-675) -4.7 -2.1 8.4 0.078 a a a a 
12 (BPH-715) -5.1 -1.6 11 0.02 a a a a 
 
a Second binding site not present 
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Table 2.3 Experimental and computed G, H, and -TS values for 1-12 binding to Site A, B. 
 
Compounds Site G 
(expt, kcal) 
G 
(calc, kcal) 
H 
(expt, kcal) 
H 
(calc, kcal) 
-TS 
(expt, kcal) 
-TS 
(calc, kcal) 
1 A -6.4558 -6.4199 -1.7175 -1.4221 -4.7384 -4.9978 
2 A -5.6842 -6.4199 -1.4000 -1.4221 -4.2842 -4.9978 
3 A -5.4241 -5.3493 -1.0035 -1.3601 -4.4206 -3.9894 
4 A -5.1566 -5.4032 0.4901 -0.4262 -5.6466 -4.9782 
5 A -4.6985 -4.8700 -0.6933 -1.3323 -4.0052 -3.5379 
6 A -4.8800 -4.9238 0.5600 -0.3985 -5.4467 -4.5266 
7 A -5.0015 -4.8700 -1.2517 -1.3323 -3.7499 -3.5379 
8 A -4.7671 -4.8759 0.8640 -0.3957 -5.6311 -4.4815 
9 A -5.6040 -4.8221 -1.3730 -1.3296 -4.2315 -3.4927 
10 A -5.0560 -4.8759 -2.3650 -0.3957 -2.6908 -4.4815 
11 A -4.7050 -4.8221 -2.0890 -1.3296 -2.6164 -3.4927 
12 A -5.0950 -4.8759 -1.5610 -0.3957 -3.5340 -4.4815 
1 B -10.406 -9.4841 0.5955 0.5857 -11.002 -10.070 
2 B -9.3487 -9.4841 0.4070 0.5857 -9.7557 -10.070 
3 B -8.3762 -8.4135 0.5430 0.6476 -8.9187 -9.0611 
5 B -7.3342 -7.9342 0.8860 0.6754 -8.2202 -8.6096 
7 B -8.0108 -7.9342 0.6754 0.6754 -8.6862 -8.6096 
9 B -7.6600 -7.8863 0.7410 0.6782 -8.4010 -8.5644 
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Table 2.4 Computed G, H, and -TS functional group coefficients (contributions) determined 
from partial least squares (multiple linear regression) analysis. 
 
 
Functional Group G (kcal/mol) H (kcal/mol) -TS (kcal/mol) 
NH3
+ -1.60 -0.0925 -1.51 
PO3(1) -4.82 -1.33 -3.49 
PO3(2) + OH -3.06 2.01 -5.07 
hydrophobic -0.0538 0.934 -0.989 
    
R2 0.95 0.57 0.91 
F-value (p-value) 89 (< 0.00001) 6.1 (< 0.0070) 47 (< 0.00001) 
Error variance 
estimate 
0.19 0.71 0.73 
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Figure 2.1 Small library of 12 synthesized bisphosphonate compounds. 
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Figure 2.2 (A) ITC data for bisphosphonates 1, 3, 4 binding to human bone. (B) Representative 
fitting curves. 
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Figure 2.3 (A) Schematic of the weak (Site A, left) and strong (Site B, right) pamidronate binding 
sites on human bone; (B) G and (C) H, -TS experimental versus calculated results for 1-12 binding to 
bone. 
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Figure 2.4 Isothermal calorimetry results for 1-12 binding to human bone.  Molar ratio values 
calculated assuming that bone is 60% hydroxyapatite (monomer FWt = 502 g/mol). 
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Chapter 3 
Structure, Function, and Inhibition of the Two- and Three-Domain 
4Fe-4S IspG Proteins 
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Abbreviations.  MEcPP, 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate; IPP, isopentenyl diphosphate; 
DMAPP, dimethylallyl diphosphate; IspG, (E)-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate synthase 
(EC1.17.7.1, also known as GcpE ); AaIpG, IspG from Aquifex aeolicus; TtIspG, IspG from Thermus 
thermophilus; AtIspG, IspG from Arabidopsis thaliana; EcIspG, IspG from Escherichia coli; IspH, (E)-1-
hydroxy-2-methyl-but-2-enyl-4-diphosphate reductase (EC 1.17.1.2, also known as LytB); HMBPP, (E)-1-
hydroxy-2-methyl-but-2-eny-l4-diphosphate; TIM, triose phosphate isomerase; EM, electron 
microscopy; EPR, electron paramagnetic resonance; ENDOR, electron-nuclear double resonance; 
HYSCORE, hyperfine sublevel correlation. 
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3.2 Introduction 
IspG [(E)-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate (HMBPP) synthase; EC1.17.7.1, also 
known as GcpE] is a 4Fe4S cluster containing protein (1) involved in isoprenoid biosynthesis in the 
methylerythritol phosphate pathway (2–4). It converts 2-C-methyl-D-erythritol-2,4-cyclo diphosphate 
(MEcPP, 1) to HMBPP (2), which is then converted by a second 4Fe4S protein, IspH [(E)-1-hydroxy-2-
methyl-but-2-enyl-4-diphosphate reductase; EC 1.17.1.2, also known as LytB], to form isopentenyl 
diphosphate (3) and dimethylallyl diphosphate (4) in an approximately 5∶1 ratio, Fig. 3.1 (3).  IspG is 
found in most bacteria as well as in malaria parasites and plants and, because it is essential for pathogen 
survival and is not produced by humans, is of interest as a drug target.  There are, however, two 
different types of IspG.  In most bacteria, IspGs contain two domains: an N-terminal catalytic domain (A) 
and a C-terminal 4Fe4S reductase domain (B), as shown in Fig. 3.2A (5).  In plant and in malaria parasite 
IspGs, the A,B domains are again present, but there is also a third or insert domain, A*, located between 
the A,B domains, as shown in Fig. 3.2B (5, 6).  This insert domain is also found in some photosynthetic 
green sulfur bacteria, algae, mosses, as well as in numerous intracellular pathogens such as Babesia 
bovis, Theileria parva, Chlamydia trachomatis, and Leptospira interrogans, but the structure and 
function of this domain is not known. 
A direct role in catalysis, that is, one involving processing of the MEcPP substrate, seems 
unlikely. As shown in Fig. 3.8, there are few conserved residues in the A* domain between 10 plant, 
malarial, and bacterial 3-domain IspGs; while in the 2-domain proteins, there are large numbers of 
conserved residues that are essential for catalytic activity, as shown via site-directed mutagenesis (7).  
This observation leads to the idea that the A* domain might play a more passive, structural role, linking 
the two (A,B) “catalytic” domains together for catalysis.  If this view is correct, then it would be 
predicted that all A* domains—even though they lack high sequence homology—would adopt a similar 
structure in order to link the A and B domains together.  Likewise, it would be predicted that the EPR [as 
well as (ENDOR), electron nuclear double resonance and (HYSCORE), hyperfine sublevel correlation 
spectroscopy] spectra of the 2- and 3-domain proteins containing the reactive intermediate “X” (8) (as 
well as bound inhibitors) would be very similar because the A* domain is not directly involved in ligand 
bonding. 
In recent work, X-ray crystallographic structures of IspG from Aquifex aeolicus and Thermus 
thermophilus (called here AaIspG and TtIspG) have been reported (7, 9) and these provide important 
clues as to the likely nature of the 3-domain proteins. The structure of the (A,B) 2-domain protein 
AaIspG is illustrated in Fig. 3.2C and consists of a dimer of IspG molecules.  There are two domains in 
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each monomer, with the N terminus (A, blue) having close structural homology with the TIM (triose 
phosphate isomerase) barrel in dihydropteroate synthase, and the C terminus (B, orange) having close 
structural homology to sulfite/nitrite reductase (7, 9).  Based on these results, it was proposed that the 
dimer (AB)2 is the catalytically relevant structure, with the C terminus (4Fe4S cluster, B) of one molecule 
in the dimer interacting with the open mouth of the TIM barrel (A) in the second molecule in the dimer 
in such a way that the MEcPP substrate is trapped between the two domains, interacting with both.  As 
can be seen in Fig. 3.2D, a ConSurf (10) analysis reveals many highly conserved residues (dark pink) in 
the TIM barrel and at the A/B interface in the dimer.  IspG could, however, also in principle function as a 
monomer (or higher multimer), although the dimer model is more satisfying because the distance 
between the center of the TIM barrel is only approximately 15 Å from the 4Fe4S cluster (in AaIspG; 
approximately 20 Å in TtIspG) as compared with an approximately 50 Å distance to the TIM barrel in the 
same chain, and can be “bent” to be even closer (9), as seen in Fig. 3.2 E and F.  These observations then 
raise two key questions: First, is the catalytic dimer model in fact correct?  Second, if it is correct, might 
this structure suggest the role of the insert domain (A*) in the plant, malaria, and other 3-domain 
proteins? 
If the 3-domain IspGs function as dimers, then the observation that the highly conserved 
catalytic residues are primarily found in the A and B domains would require an architecture along the 
lines of that illustrated in Fig. 3.2G, in which there would be no obvious role for the insert (A*) domain.  
If, on the other hand, the three-domain catalytically-active structures are monomeric, then a structural 
organization similar to that shown in Fig. 3.2H could be envisaged, in which the insert domain would 
play a similar “structural” role to the TIM barrels in the bacterial IspGs in which there is a large A/A 
contact patch in the (AB)2 dimer interface (7, 9) that stabilizes the protein’s structure. The AA* domain 
would thus act as a rigid rod with the B domain moving onto the rod to effect reduction of the reaction 
intermediate, then off of it to permit product release: a “cup-and ball” model. 
 
3.3 Experimental 
Computational Aspects 
Homology Modeling 
Homology modeling was carried out using a variety of programs (39-45) to predict the structure 
of the A* insert domain in AtIspG.  To select the appropriate insert domain sequence, we first carried 
out a sequence alignment of all of the IspG proteins from different organisms shown in Table 3.1, 
assigning AtIspG insert region residues (amino acids 365-635 in AtIspG) to the A* domain.  We then 
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submitted this sequence to the following homology modeling servers: FUGUE (39) (single sequence-
structure homology modeling based on HOMSTRAD database similarities and environment specific 
amino acid substitution tables); I-TASSER (40) (de novo protein fold prediction); LOMETS (41) (structure 
prediction meta-threading server that incorporates 8 different prediction programs into a final metric of 
fitness for the predicted structure); FFAS (42) (a profile-profile alignment and fold-recognition server 
that uses MODELLER for structure rendering); and @TOME (43) (a meta-threading server that ranks 
multiple homologous sequence alignments and again uses MODELLER (44) for structure rendering).  We 
also used ClustalW2 (45) to obtain a multiple sequence alignment comparing the A (comprising residues 
1-364 of AtIspG) and A* (comprising residues 365-635 of AtIspG) domains for all organisms listed in 
Table 3.1.  This ClustalW2 multiple sequence alignment was then used to create a homology model of 
the AtIspG A* insert domain with MODELLER, using the Aquifex aeolicus IspG (PDB code 3NOY) A-
domain as a template.  All modeled domains were passed through DSSP (46) to standardize the 
assignment of secondary structures.  Additionally, the final models were assessed with the Verify3D 
structure evaluation server (47), ensuring that essentially all residues had positive scores.  For example, 
only amino acids 389-398 and 427-454 of the AtIspG TIM barrel structure created from the ClustalW2-
MODELLER-DSSP method had a negative Verify3D score, while the amino acids corresponding to helix 7 
and the surrounding area (residues 589-619) had the highest scores.  All final 3 domain models were 
rigidly aligned, as described in the text, with MOE (48) and images were rendered with PyMOL (49).   
 
Computational Docking 
The closed conformation of TtIspG was calculated by using the RosettaDock server 
(http://rosettadock.graylab.jhu.edu/) (50).  Based on the closed TtIspG conformation, the homology 
models for AtIspG and PfIspG were aligned and superposed.  The top-ranked conformation was chosen 
and was then used for ligand docking.  Initial docking poses for MEcPP, the ferroxetane “X”, HMBPP, and 
7 were determined by using the Glide program (51). These docking results were then refined by using 
molecular mechanics in MOE (52).  All figures were generated by using PyMOL (49). 
 
Quantum Chemical Calculations 
To investigate the electronic structure of the ferroxetane intermediate “X”, we used density 
functional theory.  The basic model was [Fe4S4(SMe)3(-C(CH2OH)(CH3)-CH(CH2OH)-O-]
2- with S=1/2. The 
model was fully geometry optimized by using the Gaussian 09 program (53) with a Wachters’ basis 
41 
 
(62111111/3311111/3111) for Fe, 6-311G(d) for other heavy atoms, 6-31G(d) for hydrogens, and the 
BPW91 (54,55) functional, as used previously (56,57). 
In addition, to further investigate the binding to Fe, we used Bader’s Atoms-in-Molecules (AIM) 
theory to help analyze some of the results.  For convenience, we give here a very brief overview of this 
approach.  According to AIM theory, each nucleus in a molecule is surrounded by a region called an 
atomic basin that is bounded by a zero-flux surface in , the gradient of the charge density, that 
defines an atomic boundary.  When two atoms share some portion of their surfaces, a line of maximum 
electronic charge density is formed between the nuclei, and at the point where the shared surfaces 
intersect this atomic interaction line there is a saddle point in the charge density, (r), called a bond 
critical point.  At this point, (r) is at a minimum along this atomic interaction line and at a maximum in 
the plane perpendicular to this line. In this manner, AIM theory identifies a unique line of 
communication between two chemically interacting nuclei, and provides a unique point at which to 
probe or characterize the nature of the interaction.  Every chemical bond has a bond critical point at 
which the first derivative of the charge density, (r), is zero (58,59). The (r) topology is described by a 
real, symmetric, second-rank Hessian-of-(r) tensor, and the tensor trace is related to the bond 
interaction energy by a local expression of the virial theorem: 
 
Tr(Hessian) = 2(r) = [2G(r) + V(r)] (4m/ħ2), 
 
where (r) is the Laplacian of (r), and G(r) and V(r) are electronic kinetic and electronic potential 
energy densities, respectively.  Negative and positive (r) values are associated with shared-electron 
(covalent) interactions and closed-shell (electrostatic) interactions, respectively. In the latter case, one 
can further evaluate the total energy density, H(r), at the bond critical point: 
 
H(r) = G(r) + V(r). 
 
A negative H(r) is termed partial covalence, while a positive H(r) indicates a purely closed-shell, 
electrostatic interaction (58-60). The bond critical point described above is also called a (3,-1) critical 
point, since it has three non-zero curvatures of (r), one of which is positive and two of which are 
negative.  This type of critical point is associated with every chemical bond.  All critical point properties 
were calculated by using the AIM2000 program (61). As shown in Table 3.3, Fe-C/O bonding is similar to 
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that found in other coordination complexes (62), that is an electrostatic interaction (r)>0) with 
partial covalence (H(r)<0). 
 
Mutagenesis and Chimera Formation 
The pQE60-TtIspG plasmid was a gift from Drs. H. Jomaa and J. Wiesner.  The TtIspG gene was 
then cloned as a C-terminal His-tag fusion into the pET29b vector with the forward primer 5’-
GACATATGGAAGGTATGCGTCGTCCGACCC-3’ and the reverse primer 5’-
GGCTCGAGCGCTTTCGGCGCGAAACG-3’.  Site-directed mutagenesis for each TtIspG mutant (using the 
pEQ60-TtIspG as a template) utilized the QuikChange II Site-Directed Mutagenesis protocols.  The C-
terminal His-tag of the pQE60-N346A and pQE60-C297S mutants was further replaced by a C-terminal 
Strep-tag (forward primer: 5'-GACCCATGGAAGGTATGCGTCGTCCGACCC-3'; reverse primer: 5'-
CGGAGATCTTTATTTTTCGAACTGCGGGTGGCTCCAAGCGCTCGCTTTCGGCGCGAAACGCGTTTTCACGTAG-3'). 
The mutants E232A-(His)6, N346A-Strep tag and C297S-Strep-tag were cloned into a pRSF-Duet vector as 
pRSFDuet-E232A-(His)6/N346A-Strep tag and pRSFDuet-E232A-(His)6/C297S-Strep tag by using NcoI and 
SacI in the MCS1 (forward primer: 5'-GACCCATGGAAGGTATGCGTCGTCCGACCC-3'; reverse primer: 
GAGCTCTTATTTTTCGAACTGCGGGTGGCTCC) and NdeI and XhoI in the MCS2 (forward primer: 5'-
GACATATGGCCTTCGCCCCAG-3'; reverse primer: 5’-
TATCTCGAGTCAGTGGTGGTGGTGGTGGTGCGCTTTCGGCGCGAAACGC-5’). 
 
Protein Expression, Purification, Reconstitution and Activity Determination 
TtIspG (2-Domain) Protein Preparation.  The wild-type TtIspG, mutants or chimeras were 
transformed into BL21(DE3) competent cells together with pDB1282.  The inoculated bacterial culture 
was then grown in 100 mL LB supplemented with 0.2 % glucose, 0.5 mM CaCl2, 1 mM MgCl2, 100 μg/mL 
ampicillin (Amp) and 50 μg/mL kanamycin (Kan).  The inoculated culture was shaken at 260 rpm at 37 °C 
and incubated overnight, then transferred into 1L Luria-Bertani (LB) broth with 0.5 mM CaCl2, 1 mM 
MgCl2, 100 μg/mL Amp and 50 μg/mL Kan.  The 1L LB broth was shaken at 200 rpm at 37 °C until the 
OD600 reached 0.3, at which time 0.05% of L-arabinose was added to induce biosynthesis of the Fe4S4 
cluster. Once the OD600 reached 0.8, the temperature was lowered to 24 °C and 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG), 0.4 mM ferrous ammonium sulfate and 0.5% L-cysteine was added to 
facilitate holo-protein production.  The culture was incubated overnight and the cell pellet collected by 
centrifugation and stored at -80 °C.  All purification steps were carried out anaerobically.  The wild-type 
TtIspG and single residue mutants were purified by Ni-NTA chromatography in a glove box using wash 
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buffer (50 mM Tris, 500 mM NaCl, 50 mM imidazole, pH 8.0), then eluted using 100% elution buffer (50 
mM Tris, 500 mM NaCl, 500 mM imidazole, pH 8.0). The fraction containing the deep brown TtIspG 
fraction was collected and desalted using a desalting column with 100 mM Tris, pH 8.0.  The TtIspG was 
frozen in liquid nitrogen and kept at -80 °C. Purification of the chimera TtIspGs was similar to the 
procedure used with WT or mutants, but required an additional Strep-Tactin purification step.  The IspG 
fraction after eluting from Ni-NTA was loaded onto a Strep-Tactin column and eluted with elution buffer 
(100 mM Tris, 150 mM NaCl, 2.5 mM D-desthiobiotin, pH 8.0).  Measurements of TtIspG activity were as 
described previously (63), and were carried out by using 0.5 mM MEcPP as substrate.  Enzyme activity 
assays were conducted as described previously (63) in 96 well plates using a SpectraMax Plus 384 
spectrophotometer.  
 
EcIspG (2-Domain) Protein Preparation.  Expression and purification of EcIspG was carried out 
as described previously (63).  BL-21(DE3) cells overexpressing E. coli IspG (encoded in plasmid pASK- 
IBA5+) were grown in LB media at 37 °C, until the OD600 reached ~0.4-0.6. At this point, 400 μg/L 
anhydrotetracycline was added to induce overexpression of E. coli IspG.  Cells were grown at 20 °C for a 
further 15 hours, then harvested by centrifugation (14,334 g, 8 min, 4 °C).  The cell pellets were kept at -
80 °C until further use. 
All purification steps were carried out in a Coy vinyl anaerobic chamber (Coy Laboratories, Grass 
Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk line. Cell 
pellets were resuspended and lysed in B-PER (Thermo Scientific, Rockford, IL) protein extraction reagent 
for ~ 2 hrs at 4 °C.  The cell lysate was then centrifuged at 15,550 g for 20 min. The supernatant was 
purified on a IBA Strep-tag column equilibrated with buffer W (100 mM Tris-HCl, 150 mM NaCl, pH 8.0).  
After washing with buffer W, protein fractions were eluted using buffer E (buffer W containg 2.5 mM 
desthiobiotin).  Fractions were collected and dialyzed in pH 8.0 buffer containing 50 mM Tris-HCl, 150 
mM NaCl, 5% glycerol, and 1 mM DTT, three times.  The purified protein was flash-frozen in liquid 
nitrogen and stored at -80 °C until further use. 
All reconstitution steps were carried out in a Coy vinyl anaerobic chamber (Coy Laboratories, 
Grass Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk line.  
Typically, 10 mM DTT and ~0.5 mg of elemental sulfur were added to 3 mL 0.6 mM protein solution (in a 
buffer of 50 mM Tris-HCl, 150 mM NaCl, 5% glycerol, pH 8.0).  The solution was stirred for 1.5 h at a 
higher rpm.  Then, 6 molar equivalents of FeCl3 was slowly added (at a slower stir rate) from a 30 mM 
Stock solution.  After 3 h of stirring (at a higher stir rate), an aliquot of the solution was centrifuged.  The 
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UV-Vis spectrum at A410/A280 was typically ~0.4, indicating 4Fe4S cluster incorporation into the EcIspG 
apo-enzyme.  The IspG holo-enzyme was desalted on a PD10 column and concentrated by 
centrifugation.  Protein concentration was determined by using Bio-Rad (Hercules, CA) Protein Assay kit.  
The purified and reconstituted protein was flash-frozen in liquid nitrogen and stored at -80 °C until 
further use. 
 
AtIspG (3-Domain) Protein Preparation.  The pQE-31 plasmid containing an N-terminal 
truncated (signal- and transit- peptide cleaved) AtIspG gene was co-transformed with the KanR pDB1281 
plasmid in E. coli BL21 (DE3) RIPL competent cells.  Inoculated E. coli were grown aerobically in 100 mL 
sterile LB (50 g/mL Amp, 25 g/mL Kan, 11 g/mL Chloramphenicol (Cam)) for 12 hours at 37 C, 
shaking at 250 rpm.  A 50 mL inoculum was transferred to 1.5 L of sterile LB broth (50 g/mL Amp, 25 
g/mL Kan, 11 g/mL Cam) in 4 L flasks and shaken at 185 rpm at 37 C.  At OD600 ~ 0.2, 0.5 g/L D-
arabinose (to induce expression of pDB1281 genes), 200 M FeCl3, and 1 mM L-cysteine were added to 
each 1.5 L LB flask, then grown at 37 C with shaking at 185 rpm.  At OD600 ~ 1.0, protein expression was 
induced by adding 1 mM IPTG to each flask.  The cultures were grown at 28 C for 12-14 hours, shaking 
at 160 rpm.  Cells were harvested by centrifugation at 9000 rpm using an SLC-3000 rotor and a Sorvall 
Evolution centrifuge.  Cell pellets were stored at -80 C for later purification. 
All steps for anaerobic purification of AtIspG were performed in a Coy glove box at 4 C.  The cell 
pellet was lysed with 10 mg/mL lysozyme (chicken egg white), 62 U/mL benzoase nuclease (purity > 
90%), and 1 tablet/50 mL protease inhibitor cocktail, in a slowly stirred binding buffer (5 mM imidazole, 
100 mM HEPES, 200 mM KCl, pH 7.6).  The cell lysate was sonicated for 90 s at on/off intervals of 10 s / 
20 s, respectively, then centrifuged at 4000 rpm in an F-34-6-38 rotor in a table-top Eppendorf 5804 
centrifuge for 90 min.  The supernatant was filtered using a syringe-driven 0.45 m filter, and loaded 
onto a nickel affinity column, and purified as follows.  First, bound protein was washed with 100-200 mL 
50 mM imidazole (100 mM HEPES, 200 mM KCl, pH 7.6).  IspG was then eluted with 250 mM imidazole 
(100 mM HEPES, 200 mM KCl, pH 7.6) and concentrated using 10K-50K centrifugal filters.  The 
concentrated protein was then loaded onto a PD-10 desalting column, eluted with final buffer (100 mM 
HEPES, 200 mM KCl, pH 7.6), and concentrated by centrifugation.  All purified protein batches were run 
on SDS-PAGE gels to verify purity.  MALDI-TOF mass spectra of AtIspG exhibited a major peak at 82,247 
Da.  A BioRad protein concentration assay was used to determine final protein concentration.  Protein 
was stored at -80 C for activity measurements and inhibition assay. 
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Aerobic purification of AtIspG was followed by reconstitution and was found to be > 95% pure 
(to be compared with ~80-90% for the anaerobic system).  The aerobic system was used in the cross-
linking, gel filtration chromatography, and electron microscopy experiments.  For aerobic purification, 
the cell pellet was aerobically lysed with 10 mg/mL lysozyme, 62 U/mL benzoase nuclease (purity > 
90%), and 1 tablet/50 mL protease inhibitor cocktail in slowly stirred binding buffer (5 mM imidazole, 
100 mM HEPES, 200 mM KCl, pH 7.6).  The cell lysate mixture was sonicated for 90 s at on/off intervals 
of 10 s / 20 s, respectively.  The cell lysate was then centrifuged at 23000 rpm in a SA-300 rotor in a 
Sorvall Evolution centrifuge for 60 min.  The supernatant was filtered with a syringe-driven 0.45 m 
filter and loaded onto a nickel-charged FPLC column.  The protein was purified by Ni-NTA 
chromatography using an Amersham Pharmacia Biotech FPLC, at 4 C.  The column was washed with 
100 mL 50 mM imidazole (100 mM HEPES, 200 mM KCl, pH 7.6).  Subsequently, IspG protein was eluted 
using a gradient of 50-250 mM imidazole (100 mM HEPES, 200 mM KCl, pH 7.6).  Fractions showing 
peaks on the Ni-NTA FPLC chromatogram were run on SDS-PAGE.  Only those fractions from a single 
peak that showed > 90% purity on SDS-PAGE were consolidated.  The combined fractions were then 
dialyzed overnight in 4 L of buffer (100 mM HEPES, 200 mM KCl, pH 7.6), to remove imidazole.  The 
dialyzed protein was concentrated using 10K-50K centrifugal filters in an A-4-62 rotor in a table-top 
Eppendorf centrifuge, model 5810 R.  The Ni-NTA FPLC purified, dialyzed, and concentrated protein was 
then loaded onto a Hi-Prep 26/60 Sephacryl S-200 HR column and purified by gel filtration 
chromatography using FPLC.  The fractions showing peaks on the gel filtration FPLC chromatogram were 
then run on SDS-PAGE.  Only those fractions from a single peak that showed > 99% purity on SDS-PAGE 
were consolidated and concentrated by centrifugation.  This > 99% pure protein was then reconstituted, 
desalted, and concentrated. A BioRad protein concentration assay was used to determine final protein 
concentration.  Final protein product was stored at -80 C. 
Reconstitution of aerobically purified AtIspG was carried out in a Coy glove box at room 
temperature.  Concentrations of > 300 M AtGcpE were used for this procedure in order to keep the 
total volume small. The Ni-NTA FPLC purified, dialyzed, gel filtration FPLC purified AtGcpE was briefly 
degassed so as to remove as much O2 without removing buffer and altering the protein concentration.  
While the protein was stirred at 400 rpm on ice, DTT slowly added to a final concentration of 4 mM.  
Then, 9 molar equivalents of Na2S (9 moles Na2S to 1 mole protein) were slowly added.  The stirring 
speed was decreased to 100 rpm for 30 min between Na2S and FeCl3 additions, and raised to 400 rpm 
while adding each material.  After 30 min, 6 molar equivalents of FeCl3 were added, very slowly.  After 
30 min, 3 more molar equivalents of FeCl3 were added.  The 9 Na2S, 6 FeCl3, 3 FeCl3 molar equivalent 
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additions and wait steps were repeated to give 18:1 final molar equivalents.  This volume was 
centrifuged in a 1.5 mL microcentrifuge tube for 10 min and transferred to a PD-10 desalting column.  
The protein was eluted with the same final buffer (100 mM HEPES, 200 mM KCl, pH 7.6) and 
concentrated using 50k MWCO microcentrifuge filters.  A BioRad protein concentration assay was used 
to determine final protein concentration.  The 410 nm / 280 nm OD ratios for the reconstituted protein 
were 0.3–0.4.  
 
Size Exclusion Chromatography 
Oligomerization of both TtIspG and AtIspG was examined by using analytical gel filtration 
chromatography (Superdex 200 HR 10/30, GE Healthcare) on an AKTA FPLC system at a flow rate of 0.6 
ml/min. The concentrations of each protein were between ~1 – 2 mg/mL.  β-lactoglobulin (36.8 kDa), 
enolase (93 kDa), and alcohol dehydrogenase (150 kDa) were used as molecular weight standards. 
 
Cross-linking Experiment 
Wild-type TtIspG was desalted twice to remove Tris by using phosphate buffered saline (PBS).  4 
mg/mL wt TtIspG was then incubated with 0.05% glutaraldehyde at 25°C anaerobically, with or without 
dithionite. Reactions were incubated for 0 sec, 30 sec, 1 min, 5 min, 30 min, 1 hour, or 12 hours, and 
were quenched by adding 100 mM Tris, pH 8.0. The reactions were then frozen in liquid nitrogen, and 
stored at -80°C.  10 M AtIspG was incubated with degassed 0.05% glutaraldehyde for 30 sec, 1 min, 5 
min, 30 min, and 60 min, and cross-linking was stopped by adding 20 mM Tris.  The cross-linked 
products were again analyzed by using SDS-PAGE and MALDI-TOF mass spectrometry.  Lysozyme was 
used a control for the cross-linking experiments. 
 
Enzyme Inhibition 
Inhibition assays were all carried out as described previously (56).  All assays were carried out in 
a Coy vinyl anaerobic chamber (Coy Laboratories, Grass Lake, MI) with an oxygen level < 2 ppm, and all 
buffers were degassed by using a Schlenk line.  Various concentrations of inhibitor were added to IspG 
holo-enzyme with methyl viologen (MV) and sodium dithionite (DT) (5:1 MV:DT), and then incubated for 
10 min.  Initial reaction velocities were measured at 732 nm immediately following the addition of 140 
M MEcPP to the pre-incubated protein solutions.  Data were fit to the standard Hill equation using 
Prism (version 5.0, GraphPad Software, La Jolla, CA) and the IC50s were recorded. 
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Transmission Electron Microscopy (TEM) 
TEM Specimen preparation 
Aerobically purified and reconstituted AtIspG was diluted to 104.2 μg/mL in its original buffer 
(100 mM HEPES, 200 mM KCl, pH 7.6) and negatively stained with 2% uranyl formate (UF).  Ted Pella 
Ultrathin Carbon Type-A 400 mesh Cu grids were glow discharged for 70 sec in argon using a Denton 
DPG-1 Glow Discharge System.  All subsequent steps were performed immediately after glow 
discharging.  5 uL sample was applied to the grid, incubated at room temp for 60 sec, then blotted.  3 
wash steps were performed by adding 5 uL wash buffer (10 mM HEPES, 100 mM KCl, pH 8) to the grid, 
waiting 60 sec, and blotting.  The grid was stained twice with 2% UF by adding 4.5 uL stain, waiting 3 
min, then blotting.  After the final blot, the grid was allowed to air dry for > 10 min before inserting into 
the microscope.   
 
TEM Imaging 
All imaging was carried out using a Philips CM200 TEM operating at 120 keV that was equipped 
with a Peltier-cooled Tietz (TVIPS) 2k x 2k CCD camera.  All images were digitally recorded using TVIPS 
EMMENU 4.0 software.  The pixel sizes of different magnifications at 120 keV were calibrated using a 
Ted Pella beef liver catalase crystal calibration grid.  All images were recorded under low dose 
conditions, restricting the total dose per image to 12 e/Å2, or less.  Single-axis tilt-series were manually 
acquired at 88kX and 150kX using 1-2.5 degree tilt increments over a tilt range of 0-50 degrees.  The 
models displayed here were recorded over a tilt range of 0-40 degrees at a 2.5 degree increment at 
150kX (pixel size of 0.93 Å/pixel).  
 
TEM Image Reconstruction 
Tomographic single particle reconstructions were compared, aligned, and combined to give the 
final model (65,66).  Because of the missing wedge inherent in tomographic reconstructions involving 
single tilt series and a tilt series range of 0-40 degrees instead of +/-60 degrees, the final resolution of 
the reconstruction is anisotropic (67-69).  However, the resolution in the plane of the grid (looking on 
the grid surface in the direction of the beam) combined with the flat orientation of the protein on the 
surface was sufficient to allow conclusions about a general molecular shape.   
The tilt series taken at 150kX were combined into MRC stacks using ImageJ (70).  Preliminary tilt 
series alignment assessment was performed using TomoJ (ImageJ) (71).  The contrast transfer function 
(CTF) was estimated for each image in the tilt series using boxed out regions from each image using 
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EMAN2 (66).  The furthest defocused (underfocused) image in the tilt series had a defocus of 690 nm 
corresponding to a CTF first zero at 15.1 Å.  The tilt series alignment was performed by, first, using 
fiducialess cross-correlation alignment with Etomo (IMOD); second, by manual correction with Midas 
(72) (IMOD).  Using an EMAN2/Sparx (66,73,74) python script we calculated the noise-compensated 
leave-one-out in 2D (NLOO-2D) (67), then calculated NLOO-2D vs. tilt angle for each tilt series, and for 
the combined/aligned tilt series.  We also used EMAN2 to box out particles from an IMOD aligned tilt 
series (66,72).  Two tomographic single particle reconstructions were normalized at a specified 
visualization threshold assuming a protein volume mass of 0.81 Da/Å3, and low pass filtered at 16 Å.  
These 2 filtered reconstructions were then aligned in EMAN2 using a cross-correlation coefficient 3D 
alignment maximization algorithm that accounts for tomographic missing wedge information.  Once the 
3D → 2D alignment transforms were obtained for each tilt series (66,73,74), the 2 tilt series were 
combined and used to create the final model using the Central Slice Theorem or Projection Theorem 
(75) with a Fourier reconstruction method using a Gaussian kernel.  The FSCe/o (Fourier Shell 
Correlationeven/odd) (Fig.  3.9J) and NLOO-2D (0.5 FRC (Fourier Ring Correlation) cut-off) vs. tilt angle 
resolution estimates for the combined/aligned tilt series (Fig. 3.9K,L) were calculated for the final model 
(67).  These methods of resolution determination are similar to ones presented by Mastronarde (76) for 
dual-tilt tomography and for single particle electron tomography three-dimensional alignment (77).  The 
final reconstruction was created from all projections showing less than 30 Å on the NLOO-2D plot for the 
combined/aligned tilt series, Fig. 3.9L, and low pass filtered at 20 Å, Fig. 3.9J  (0.5 FSCe/o ~ 17.5 Å, (67)).  
Manual rigid body fitting of the AtIspG homology model into the final AtIspG EM model and all 3D EM 
figures were performed with Chimera (78). The 2D images were prepared using EMAN2 (66). 
 
Synthetic aspects  
All reagents used were purchased from Aldrich (Milwaukee, WI).  The purities of all compounds 
investigated were confirmed either via combustion analysis (for solid samples) or by using 1H and 31P 
NMR spectroscopy at 400 MHz on Varian (Palo Alto, CA) Unity spectrometers.  Cellulose TLC plates were 
visualized by using iodine or a sulfosalicylic acid-ferric chloride stain. The syntheses and characterization 
of compounds 5-9, 14-27 have been described previously (56,79).  Structures for the synthesized 
compounds are shown in Fig. 3.10. 
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General procedure for preparation of diphosphates 
Typically, 1 mmol of mesylate in a minimum amount of CH3CN (0.5 mL) was added drop-wise to 
a stirred solution of 2.70 g (3.0 mmol) tris(tetra-n-butylammonium) hydrogen diphosphate in CH3CN (4 
mL) at 0°C.  The reaction mixture was allowed to stir for 2-24 h at room temperature, and solvent 
removed under reduced pressure. The residue was dissolved in cation-exchange buffer [49:1 (v/v) 25 
mM NH4HCO3/2-propanol] and slowly passed over 60-100 milliequivalent Dowex AG50W-X8 (100-200 
mesh, ammonium form) cation-exchange resin, pre-equilibrated with two column volumes of the same 
buffer. The product was eluted with two column volumes of the same buffer, flash frozen, then 
lyophilized. The resulting powder was dissolved in 3 mL of 50 mM NH4HCO3.  9 mL of 2-Propanol/CH3CN 
[1:1 (v/v)] was added, and the mixture vortexed, then centrifuged for 5 min at 1, 600 x g. The 
supernatant was decanted. This procedure was repeated three times, and the supernatants combined. 
After removal of the solvent and lyophilization, then flash chromatography on cellulose, a white solid 
was obtained. 
 
Synthesis of individual compounds 
 
4-(prop-2-ynyloxy)benzyl diphosphate (10).  Flash chromatography on cellulose (2:1:1(v/v/v) 2-
propanol/CH3CN/50mM NH4HCO3) yielded 166 mg (44%) of a white solid. 
1H NMR (400 MHz, D2O): δ 
2.76 (t, J = 2.4 Hz, 1H), 4.77 (d, J = 6.8 Hz, 2H), 6.91 (d, J = 8.8Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H). 31P NMR 
(162 MHz, D2O): δ -10.06 (d, J = 20.8 Hz), -8.91 (d, J = 21.9 Hz). 
 
2-ethynlbenzyl diphosphate (11).  Flash chromatography on cellulose (2:1:1(v/v/v) 2-
propanol/CH3CN/50mM NH4HCO3) yielded 130 mg (38%) of a white solid. 
1H NMR (400 MHz, D2O): δ 
3.54 (s, 1H), 4.96 (d, J = 6.4 Hz, 2H), 7.14-7.17 (m, 1H), 7.24-7.29 (m, 1H), 7.36 (d, J = 7.2 Hz, 1H), 7.42 (d, 
J = 7.6 Hz, 1H); 31P NMR (162 MHz, D2O): δ -9.59 (d, J = 21.8 Hz), -5.61 (d, J = 20.7 Hz).  
 
3-(prop-2-ynyloxy)benzyl diphosphate (12).  Flash chromatography on cellulose (2:1:1(v/v/v) 2-
propanol/CH3CN/50mM NH4HCO3) yielded 156 mg (42%) of a white solid. 
1H NMR (400 MHz, D2O): δ 
2.75(t, J = 2.4 Hz, 1H), 4.81 (d, J = 6.8 Hz, 2H), 6.83-6.87 (m, 1H), 6.97-6.99 (m, 2H), 7.19-7.24 (m, 1H); 31P 
NMR (162 MHz, D2O): δ -9.97 (d, J = 20.7 Hz), -8.53 (d, J = 20.7 Hz). 
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undec-10-ynyl diphosphate (13).  Flash chromatography on cellulose (4:1:1(v/v/v) 2-
propanol/CH3CN/50mM NH4HCO3) yielded 180 mg (48%) of a white solid. 
1H NMR (400 MHz, D2O): δ 
1.10-1.22 (m, 10H), 1.28-1.36 (m, 2H), 1.43-1.48 (m, 2H), 2.01 (dt, J = 6.8 Hz, 2.4 Hz, 2H), 2.14 (t, J = 2.4 
Hz, 1H), 3.71-3.76 (m, 2H); 31P NMR(162 MHz, D2O): δ -9.58 (d, J = 20.7 Hz), -8.79 (d, J = 20.9 Hz). 
 
(1-methyl-1H-pyrazol-4-yl)methyl diphosphate (28).  Flash chromatography on cellulose (2:1:1(v/v/v) 2-
propanol/CH3CN/50mM NH4HCO3) yielded 108 mg (34%) of a white solid. 
1H NMR (400 MHz, D2O): δ 
3.66 (s, 3H), 3.87-3.90 (m, 2H), 7.31 (s, 1H), 7.39 (s, 1H); 31P NMR (162 MHz, D2O): δ -9.83 (d, J = 20.9 Hz), 
-8.82 (d, J = 20.7 Hz). 
 
2-(1H-imidazol-1-yl)ethyl diphosphate (29).  Flash chromatography on cellulose (2:1(v/v) 2-
propanol/50mM NH4HCO3) yielded 61 mg (19%) of a white solid. 
1H NMR (400 MHz, D2O) δ 4.03-4.08 (m, 
2H), 4.25 (t, J = 4.4 Hz, 2H), 7.18 (s, 1H), 7.30 (s, 1H), 8.55 (s, 1H); 31P NMR (162 MHz, D2O) δ -10.21 (d, J = 
21.0 Hz), -7.24 (d, J = 22.0 Hz). 
 
Scheme 1 (a) NBS, H2
17O, 4°C;   (b) NH3H2O; (c) TiCl4,  -90°C; (d) (n-Bu4N)3HP2O7, CH3CN; (e) Br2/H2O, (f) 
NH3H2O. 
 
 
[17O]-2-methyl-2-vinyloxirane.  To a stirred mixture of isoprene (1.36 g, 20 mmol) and N-
bromosuccinimide (178 mg, 1 mmol) was added H2
17O (72mg, 4 mmol) at 4°C. The mixture was stirred 
vigorously at that temperature for 10 h, then filtered and washed with hexane (5mL  4). The filtrate 
was dried with anhydrous Na2SO4, then evaporated under reduced pressure. The residue was dissolved 
in 7 ml of CH2Cl2, and 2 ml of ammonium hydroxide added. The mixture was then stirred vigorously at 
room temperature for 4 h. The organic layer was separated and dried with anhydrous Na2SO4, then 
concentrated by careful evaporation of the CH2Cl2 to a pale yellow liquid that was used for the next step 
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without further purification. 1H NMR (400 MHz, CDCl3): δ 1.43 (s, 3H), 2.70 (d, J =5.0 Hz, 1H), 2.79 (d, J = 
5.0 Hz, 1H), 5.20 (d, J = 10.5Hz, 1H), 5.33 (d, J =17.5 Hz, 1H), 5.58-5.63 (m, 1H). 
 
(E)-4-chloro-2-methylbut-2-en-1[17O]-ol.  (E)-4-chloro-2-methylbut-2-en-1[17O]-ol was synthesized 
according to a literature method (80).  To a solution of TiCl4 (285 mg, 1.5 mmol) in 3 ml of dry CH2Cl2 was 
added a solution of [17O]-2-methyl-2-vinyloxirane (85 mg, 1 mmol) )  in 0.5 ml of dry CH2Cl2  at -90°C 
under an atmosphere of nitrogen. The reaction mixture was stirred at that temperature for 2 h, then 
quenched by 5 mL of 1 N HCl. The organic layer was separated and the aqueous layer extracted with 
ether (5mL  4). The combined organic phase was dried with anhydrous Na2SO4, then evaporated under 
reduced pressure. The residue was purified by flash silica chromatography (hexane : EtOAc = 3:2) to 
yield  56 mg (46%) of a colorless oil. 1H NMR (400 MHz, CDCl3): δ  1.70 (s, 3H), 4.02 (s, 2H), 4.09 (d, J = 8.0 
Hz, 2H), 5.62-5.72 (m, 1H). 
 
(E)-4[17O]-hydroxy-3-methyl-2-butenyl pyrophosphate.  (E)-4[17O]-hydroxy-3-methyl-2-butenyl 
pyrophosphate was synthesized according to a literature method (64,81).  (E)-4-chloro-2-methylbut-2-
en-1[17O]-ol (24 mg, 0.2 mmol) was added dropwise to a stirred solution of  0.45 g (0.5 mmol) tris(tetra-
n-butylammonium) hydrogen pyrophosphate in CH3CN (1.5 mL) at 0 °C,  the reaction mixture was then 
allowed to warm to room temperature over 2 h, and then solvent was removed under reduced pressure. 
The residue was dissolved in 0.5 mL of cation-exchange buffer (49:1(v/v) 25mM NH4HCO3/2-propanol) 
and passed over 90 mequiv of Dowex AG50W-X8 (100-200 mesh, ammonium form) cation-exchanged 
resin pre-equilibrated with two column volumes of the same buffer. The product was eluted with two 
column volumes of the same buffer, flash frozen, and lyophilized. The resulting powder was dissolved in 
0.5 mL of 50 mM NH4HCO3.  2-Propanol/CH3CN (1:1 (v/v), 1 mL) was added, and the mixture mixed on a 
vortex mixer then centrifuged for 5 min at 1, 600 x g. The supernatant was decanted.  This procedure 
was repeated three times, and the supernatants were combined.  After removal of the solvent and 
lyophilization, a white solid was obtained.  Flash chromatography on a cellulose column (53:47 (v/v) 2-
propanol / 50 mM NH4HCO3) yielded  22 mg (35%) of a white solid. 
1H NMR (400 MHz, D2O) δ 1.53 (s, 
3H), 3.84 (s, 2H), 4.35 (t, J = 7.2 Hz, 2H), 5.45-5.51 (m, 1H); 31P NMR (162 MHz, D2O) δ -9.71 (d, J = 20.7 
Hz), -8.92 (d, J = 20.7 Hz). 
 
4[17O]-Hydroxy-3-methyl-2, 3-epoxybutanyl diphosphate.  4[17O]-Hydroxy-3-methyl-2, 3-epoxybutanyl 
diphosphate was synthesized according to a literature method (63).  To a solution of 5.0 mg (E)-4[17O]-
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hydroxy-3-methyl-2-butenyl diphosphate in 0.50 mL water was added 4-6 drops bromine water until the 
pale orange color persisted. The mixture was allowed to react at room temperature for 20 minutes, then 
the solution was lyophilized to afford a white solid. The white powder was dissolved in 1 mL water, and 
2-3 drops ammonium hydroxide added. The mixture was allowed to react at room temperature for 20 
minutes, then was lyophilized to afford a white solid.  δ 1H NMR (400 MHz, D2O): δ 1.20 (s, 3H), 3.25-
3.30 (m, 1H), 3.40 (d, J = 12.8Hz, 1H), 3.52 (d, J = 12.8Hz, 1H), 3.77-3.85 (m, 1H), 4.08-4.15 (m, 1H); 31P 
NMR (162 MHz, D2O): δ -9.58(d, J = 22.0Hz), -5.92 (d, J = 22.0Hz). 
 
CW-EPR, HYSCORE, and ENDOR Spectroscopy 
 All sample preparations were carried out in a Coy vinyl anaerobic chamber (Coy Laboratories, 
Grass Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk line.  
Samples for CW-EPR spectroscopy were typically 0.2-0.4 mM and those for HYSCORE/ENDOR were ~ 1 
mM.  Glycerol was added as a glassing agent to (20-)30% (v/v) prior to freezing.  20 equivalents of 
sodium dithionite (DT) were added to reduce the 4Fe4S cluster.  Ligands were typically added to 10 
equivalents.  To capture the “X” reaction intermediate from MEcPP, samples were frozen in liquid 
nitrogen within 1-3 min following addition of MEcPP to the reduced protein sample. 
All CW (continuous wave)-EPR experiments were performed on a Varian E-line 122 X-band 
spectrometer with an Air Products helium cryostat. Data acquisition parameters were typically: 
microwave frequency = 9.05 GHz; field center = 3250 Gauss; field sweep = 1000 Gauss; modulation 
frequency = 100 kHz; modulation amplitude = 5 Gauss; time constant = 32 milliseconds; temperature = 
10-20 K.   
Pulsed ENDOR/HYSCORE spectra were obtained on a Bruker ElexSys E-580-10 FT-EPR X-band 
EPR spectrometer using a Bruker RF amplifier (150W, 100 kHz–250 MHz, for pulsed ENDOR experiments) 
and an Oxford Instruments CF935 cryostat.  Davies pulsed ENDOR used a three-pulse sequence (πmw − T-
π∕2mw − τ − πmw-τ-echo; π∕2mw = 48 ns,with πRF applied during T). HYSCORE used a four-pulse sequence 
(π∕2mw − τ-π∕2mw − t1 − πmw − t2 − π∕2mw − echo; π∕2mw = 16 ns), 256 points for both t1 and t2, each at 
20 ns steps. Time-domain data were baseline corrected using a third order polynomial, then Hamming 
windowed, followed by zero-filling and 2D-Fourier transformation.  
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3.4 Results and Discussion 
 In the following, we focus first on the structure and function of the two-domain bacterial IspGs 
from Aquifex aeolicus and Thermus thermophilus, PDB ID codes 3NOY and 2Y0F. In particular, we wish to 
know if these proteins function in solution as monomers or dimers since a better understanding of the 
structure and function of these proteins might lead to a better understanding of the structure and 
function of the 3 domain proteins.  We then use a combination of spectroscopy and quantum chemistry 
to investigate ligand-binding to both 2 and 3 domain proteins – to determine if the same reactive 
intermediates and patterns of inhibition are found – probing functional equivalence. Finally, we use 
these results together with computational predictions and electron microscopy (EM) to develop a model 
for the A* insert domain which we propose is a second TIM barrel, leading to an AA*B structure 
prediction that is consistent with the observation that a plant (Arabidopsis thaliana) IspG, AtIspG, 
functions as a monomer. And finally, we consider briefly possible reasons for the evolution of the 3 
domain structure. 
 
IspG Quaternary Structures.  The two-domain bacterial IspG proteins exist as dimers in the crystalline 
solid state, but we wished to determine if they exist as catalytically active dimers, in solution, as well as 
determine whether the three-domain enzymes function as monomers or dimers, since this should help 
clarify the structural proposals illustrated in Fig. 3.2G,H.  To test the hypothesis that a bacterial IspG 
(TtIspG) functions as a dimer, we carried out a series of experiments.  First, we used glutaraldehyde 
cross-linking combined with SDS-PAGE and mass spectrometry, to see if dimer formation occurs in 
solution.  Cross-linking results for oxidized as well as reduced TtIspG (to see if there might be any 
difference in protein-protein interaction due to cluster reduction) are shown in Figs. 3.3A,B, together 
with results for lysozyme, as a control, Fig. 3.3C. These results clearly show that most IspG molecules 
present in solution are cross-linked after a 30 min incubation with glutaraldehyde, independent of redox 
state, while no dimer formation is found with lysozyme, even after 12 hours incubation, consistent with 
strong IspG dimer formation in solution, and only weak interactions in lysozyme. Mass spectrometry 
confirmed these results. Second, the results of gel filtration experiments (Fig. 3.3D,E) confirm that 
TtIspG exists in solution primarily as a dimer (MW= 94 kDa from experiment; 92 kDa expected for the 
dimer).  Next, we need to answer the questions: is catalysis effected by monomers, or by dimers, in the 
bacterial enzyme?  And if a dimer, is catalysis effected by individual molecules in the dimer (AB), or by 
both molecules in the dimer, (AB)2? 
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 To answer these questions, we constructed TtIspG chimeras (ABmAmB) consisting of two 
catalytically inactive mutants in which there was a mutation (m) that blocked activity in either the TIM 
barrel (AmB), or the 4Fe4S cluster (ABm), the idea being that even though neither monomers nor homo-
dimers would be active, chimeras or hetero-dimers would be active, since the TIM barrel domain in a 
4Fe4S cluster domain mutant (ABm) could still interact with the 4Fe4S cluster domain in the TIM barrel 
mutant (AmB).  But which mutants to make?  An obvious candidate for mutational analysis would be one 
of the Cys residues coordinated to the 4Fe4S cluster:  we used C297S (6).  We also need a TIM barrel 
mutant plus, ideally, an essential 4Fe4S domain mutant that does not prevent Fe-incorporation, since 
this might be more stable. To find suitable mutants, we used the SCORECONS program (11). We used a 
JPRED3 (12) alignment based on TtIspG as input to SCORECONS finding (Table 3.1) that  E232, in the TIM 
barrel (A), was the most essential residue, while N346, in the 4Fe4S cluster domain (B), ranked 3rd 
overall, Table 3.1. We thus made three single mutants:  E232A, C297S and N346A, none of which were 
active, Fig. 3.3F (columns b, c, d), consistent with previous results for the equivalent E232 and C297 
mutants in A. aeolicus (6,7). 
 Initial attempts to generate chimeras or to facilitate hetero-dimer formation using a mixture of 
two mutants (E232A + C297S), in the presence or absence of detergents, yielded no activity, perhaps 
because homo-dimer formation was too tight.  We thus co-expressed both mutants using His-tagged 
proteins, finding 52% (E232A/N346A) and 23% (E232A/C297S) activity, Fig. 3.3F (e,f). This suggested that 
the catalytically-active forms arise from the two individual mutants–which themselves are inactive, 
supporting the catalytic dimer model for the two-domain, bacterial IspGs. 
 In order to obtain pure chimeras containing a 1:1 ratio of each mutant, we next used a Duet 
vector to co-express E232A (His)6/C297S (Strep-tag) and E232A (His)6/N346A (Strep-tag) proteins. After 
Ni-nitrilo-triacetic acid followed by Strep-Tactin affinity chromatography (13), we obtained chimeras 
(ABmAmB) containing a TIM barrel mutation in one chain and a 4Fe4S cluster-domain mutation in the 
second chain, as illustrated in Fig. 3.3G. The two chimeras both exhibited ~50% activity Fig. 3.3F (g,h). 
These results confirm that the TtIspG homo-dimer is the catalytically active species in solution, and form 
the basis for further experiments, with the A. thaliana protein. 
 With wild type AtIspG, initial results of size-exclusion chromatography indicated protein 
aggregation and low catalytic activity, so we used size-exclusion chromatography to isolate non-
aggregated wild type AtIspG (Fig. 3.3H). The fraction of the protein that eluted as a monomer (MW 74 
kDa from experiment, Fig. 3.3E, 82 kDa expected) was found to have good activity (~8 mol min-1 mg-1), 
comparable to that obtained with E. coli IspG. In addition, there was no evidence for extensive dimer 
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formation using glutaraldehyde cross-linking, the major effect being polymer formation (Fig. 3.3I). Taken 
together, these results indicate that AtIspG exists and functions in solution as a monomer, consistent 
with an AA*B structure, Fig. 3.2H, while the bacterial two domain IspGs function as dimers. 
 
Protein-Protein and Protein-Ligand Interactions. At present, there are no crystallographic structures of 
the closed conformation of any bacterial IspG, so how the MEcPP substrate (and the reactive 
intermediate “X” (2)), the HMBPP product, as well as IspG inhibitors (2) bind, is uncertain.  We thus next 
explored whether computational docking might help answer some of these questions, with the two 
domain AaIspG. We first used the RosettaDock program (14) to dock the B domain (orange) of AaIspG to 
the A domain (blue), converting the open conformation (Fig. 3.2C,D) to the closed form (Fig. 3.2E,F), 
then used Glide (15) to dock the MEcPP substrate (with or without Glu-350 bound to the 4Fe4S cluster). 
The only docking poses returned were with MEcPP bound to the TIM barrel with electrostatic 
interactions between the MEcPP diphosphate and R101, K176 and R232, Fig. 3.9A. Based on the 
SCORECONS (11) conservation score ranking (Table 3.1), these residues are ranked as 20, 17 and 10 in 
terms of their conservation in a series of 310 IspG proteins.  We then used Glide followed by molecular 
mechanics to generate docked poses of the putative ferraoxetane intermediate “X” (16), as well as of 
the bound HMBPP product, Fig. 3.9B,C.  With “X,” binding was to R55, R101 and N103; with HMBPP, 
binding was to R55, R101, R128, R232 and K176, residues that are ranked 19, 20, 11, 10 and 17 in terms 
of their conservation score (Table 3.1). We then mutated R56, R141 and K204 in TtIspG (corresponding 
to R55, R128 and K176 in AaIspG) to Ala, finding in each case a ~95% reduction in catalytic activity, Table 
3.1. R55, R101 and R128 have been shown to be essential for catalysis in A. aeolicus IspG by Lee et al. (7) 
and R141 (Thermus numbering) is essential for survival in Salmonella enterica (17). So, based on the 
docking results, their conserved nature (Table 3.1) and the mutagenesis results, these residues are all 
likely to be involved in MEcPP, reactive intermediate or HMBPP product binding, via their diphosphate 
groups, while the reactive intermediate and HMBPP product also interact directly with Fe via Fe-O 
and/or Fe-C bonds, the HMBPP O-1 Fe interaction being similar to that seen with HMBPP binding to IspH 
(18).    
 
Spectroscopy and Quantum Chemistry.  We next investigated whether we could detect the reactive 
intermediate “X” that forms from MEcPP (2) with wild-type bacterial IspGs, in the mutant and chimera 
bacterial proteins, as well as in the three domain IspG from A. thaliana, using EPR, ENDOR and HYSCORE 
spectroscopy. With the C297S TtIspG protein, there is no 4Fe-4S cluster and hence, no signal. With the 
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E232A mutant, the (brown) sample has the UV-VIS spectrum expected, but we were unable to detect 
“X” using either MEcPP or HMBPP-epoxide as substrate, consistent with a key role for E232 in catalysis. 
However, with the E232A/N346A chimera, we observed the EPR spectrum of “X” arising from the MEcPP 
substrate, Fig. 3.4A, and at long incubation times, this intermediate converted to the bound-HMBPP 
product, Fig. 3.4B.  Similar results were found in the EPR spectra of MEcPP bound to the plant IspG, Fig. 
3.4C,D, with both the reaction intermediate “X” as well as to the HMBPP product being detected. There 
are slight differences in the g-values between the bacterial and plant proteins but this is not wholly 
unexpected and it is clear that “X” forms in both cases, as does the bound HMBPP product. We also find 
that the 1H ENDOR spectrum of MEcPP bound to AtIspG (Fig. 3.5A) is essentially identical to that of 
MEcPP bound to E. coli IspG (2), with a ~12 MHz 1H hyperfine interaction for one of the C2′ methyl 
protons, proposed elsewhere to be located in a ferraoxetane ring (16). Likewise, the 13C HYSCORE 
spectra of [U-13C]-MEcPP bound to both TtIspG chimeras (Fig. 3.5B,C) as well as AtIspG (Fig. 3.5D) are 
essentially identical to those seen with EcIspG (2), again indicating the same reaction intermediate forms 
with both 2 and 3 domain proteins. There is also only a very small (~0.15 MHz) hyperfine coupling 
observed with 17O1 labeled X (Fig. 3.5E), consistent with no direct Fe-O1 bonding. 
 Mechanistically then, it appears that MEcPP binds to the conserved Arg/Lys residues in the A 
domain and that the carbo-cation that forms on ring opening is located very close to the 4Fe4S cluster 
domain, which then leads to formation of the reaction intermediate, X (2,16). This intermediate is 
characterized by a large (~12 MHz) 1H hyperfine coupling constant for one of the C2′ methyl protons 
(16), and a ~17 MHz hyperfine coupling for the C2 carbon (16). To see to what extent it might be 
possible to predict these spectroscopic observables, we used density functional theory (DFT). The 
structural model used was [Fe4S4(SMe)3(-C(CH2OH)(CH3)-CH(CH2OH)-O-]
2- (Fig. 3.6A) with S=1/2. All 
calculations were performed with the Gaussian 09 program (19) using a Wachters’ basis 
(62111111/3311111/3111) for Fe, 6-311G(d) for other heavy atoms, 6-31G(d) for hydrogens, and the 
BPW91 functional, as reported previously (20).  
 We found good accord with experiment for the H2′, methyl protons, with computed hyperfine 
couplings of 9.1, 2.0, and 1.1 MHz for the three non-equivalent protons.  This large coupling is in good 
accord with experimental results (A(1H) ~12 MHz) and arises from the trans (Fe-C-C-H torsion angle = 
172) proton, while the gauche protons have much smaller couplings (and geometry optimized torsion 
angles of 52, -67) – similar to the observation of large 3J trans scalar couplings (mediated via Fermi 
contact interactions) in NMR spectroscopy.  Overall, there is a good correlation between the twelve 
computed hyperfine couplings determined with DFT and those determined experimentally, as shown in 
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Fig. 3.6A and Table 3.2, although there is a systematic error in the slope, due most likely to 
basis/functional deficiencies. The correlation coefficient, R = 0.87 is, however, very good. The computed 
spin densities are shown graphically in Fig. 3.6B and show, as expected, that significant spin density is 
transmitted from the cluster to the H2′-trans proton (indicated with an arrow). The results of AIM (21) 
quantum chemical calculations (Table 3.3) indicate that binding to Fe is primarily electrostatic (∇ 2ρ(r)>0) 
with partial covalence (21), just as found in simpler systems such as [FeF6]
3- and [Fe(CN)6]
3-, Table 3.3.    
 
Inhibitor Binding.  We next briefly consider the topic of the inhibition of the bacterial and plant IspGs, of 
interest in the context of drug discovery as well as in the context of the equivalence of the 2 and 3 
domain protein structures.  In previous work, we investigated the inhibition of AaIspH (LytB) by a series 
of compounds, alkynes and pyridines linked to diphosphates or bisphosphonates (22), as well as two 
alkyne diphosphates that inhibited IspG (2), finding in both cases that the alkynes bound close to the 
4Fe4S cluster.  Here, we tested 25 compounds (Fig. 3.10) for IspG inhibition. As with IspH, only the 
alkyne diphosphates proved to be good IspG inhibitors. But how might they bind? 
 In the case of IspH, there is a highly conserved SXN site that diphosphate (and malonate) ligands 
bind to (23), but are there any highly conserved residues in the 4Fe4S domain in IspG to which the 
alkyne inhibitor diphosphates might bind?  Based on the SCORECONS analysis (Fig. 3.8), the only highly 
conserved (non-cluster-bound) residues in the 4Fe4S cluster domain are N346 and R302 (corresponding 
to N303 and R270 in the A. aeolicus protein).  When mutated to Ala, there is only 0.75% wild-type 
activity for N346A (Table 3.1), and 3.9% for R302.  These residues are, however, ~10Å distant from each 
other, and it is not possible to dock a diphosphate group to them both. So, rather than the diphosphates 
binding to the 4Fe4S cluster-containing domain (B) as in IspH, it appears likely that the diphosphates 
interact with the Arg/Lys-rich cluster in the TIM barrel. This idea is supported by the computational 
docking results shown in Fig. 3.8D in which the diphosphate group in an alkyne inhibitor (5, IC50=770 nM 
TtIspG; Fig. 3.10) binds to R55, R101, R128, K176 and R232. In addition, the results of a HYSCORE 
experiment with  [U-13C] propargyl diphosphate (6) bound to AtIspG (Fig. 3.11) show a ~6 MHz hyperfine 
coupling (as with EcIspG), indicating that the side-chain binds close to the 4Fe4S cluster, in the B 
domain, just as in the two-domain bacterial IspGs. 
 
The Insert Domain (A*) is a TIM Barrel.  Finally, we propose a model for the three dimensional 
structures of the 3-domain IspGs using computational methods.  This approach has been successful with 
other prenyl synthases, in particular with the diterpene cyclases, where the use (24) of a variety of 
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computational tools enabled successful prediction of the three-helical αβγ domain structures, recently 
confirmed by two crystallographic investigations (25,26).  
 The main questions of interest are:  what is the structure of the insert domain, A*?  And how 
might it interact with the N-terminal (TIM barrel, A) and C-terminal (4Fe4S cluster, B) domains? To 
provide possible answers to these questions, we first used several different protein structure prediction 
programs (27-31) to make predictions of the structure of the insert domain, A*.  Remarkably, in all 
cases, the structure predictions for the A* insert domain converged to the known N-terminal TIM barrel 
fold (A) found in the two bacterial IspG structures (7,9). A representative structure (using a ClustalW2 
multi-sequence alignment and Modeller) (32,33) is shown in Fig. 3.7A for the A. thaliana (plant) IspG 
insert domain: results using other computer programs are shown in Fig. 3.12.   
 Clearly, the observation that all structure predictions of the insert domains indicate a TIM barrel 
strongly suggests that the plant (and other 3 domain) enzymes contain two TIM barrels: the catalytic N-
terminal A, and the insert A*. In addition, based on the proposals (7,9) that bacterial IspGs function with 
the C-terminus (B) of one molecule in the dimer interacting with the N-terminus (TIM barrel, A) of the 
second molecule in the dimer, and that the major contacts between the two AB molecules involve 
hydrophobic interactions between helices 7 and 8 in the two TIM barrels, it seemed likely that similar 
interactions might occur in the plant and other insert-domain-containing IspGs, so we next generated a 
simple three-dimensional model for IspG from A. thaliana, Fig. 3.7B, in which the structures of all three 
domains were generated computationally using Modeller (33), then aligned (in MOE (34)) to the AaIspG 
structure.  How A joins to A* and A* to B is not yet well defined.  Using a ClustalW2 alignment of ten 3 
domain IspGs, we then obtained the ConSurf prediction shown in Fig. 3.7C in which, as expected, the 
most highly conserved residues (dark pink) are at the AB interface while homology in the A* domain is 
low (white/blue, Fig. 3.7C).  More importantly, this computational model is in good accord with electron 
microscopy (EM) results for AtIspG, constructed (35,36) by aligning and combining two tomographic 
single particle reconstructions of negatively stained AtGcpE particles from low dose electron 
tomographic tilt series (Fig. 3.13), as can be seen in the EM (grey) superpositions shown in Fig. 3.13D. 
 If this structural arrangement is correct, it seems likely that the plant and other 3 domain IspGs 
may have originated via an initial gene fusion (A + B) to form a bacterial homo-dimer, (AB)2, followed by 
gene duplication, exon loss and recombination, eliminating one of the 4Fe4S clusters to form the (AA*B) 
proteins, as shown in Fig. 3.7E.  But why?  That is – why are there 3 domain IspGs?  What is well known 
about IspG is that it is hypersensitive to oxygen (37,38) and when we inspect all of the organisms that 
employ 3 domain IspGs there is clearly a common feature – essentially all are subject to oxidative stress. 
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In green plants, mosses and algae, reactive oxygen species are generated during photosynthesis and can 
be expected to contribute to breakdown of the 4Fe-4S clusters. In the Apicomplexan parasites P. 
falciparum and B. bovis, the parasites infect red blood cells where there is expected to be oxidative 
stress (due to O2 as well as other ROS), and with bacteria such as C. trachomatis and L. interrogans, 
these pathogens again infect mammalian host cells and are expected to be susceptible to host 
generated ROS. The possibility exists then that the additional TIM barrel may provide a degree of 
protection from host ROS by providing e.g. a higher protein/iron ratio.  
 
3.5 Conclusions   
The results we have described above are of broad general interest since they clearly indicate, 
based on gel filtration chromatography, cross-linking, chimera formation and spectroscopy, that most-
bacterial IspGs function as an unusual (AB)2 dimer in which a TIM barrel domain (A) of one chain 
interacts with the 4Fe4S cluster-containing domain (B) in a second chain to form the active site. In the 
case of IspGs from plants, algae, as well as malaria and other parasites, the A,B structural motifs are 
similar, but rather than a homo-dimer of four domains, we propose that there is TIM barrel insert 
domain (A*) that plays a primarily structural role. EPR, ENDOR and HYSCORE spectra indicate the same 
reactive intermediate forms with both two and three domain enzymes, with this intermediate binding to 
the 4Fe4S cluster, during catalysis. The most potent inhibitors of both two and three domain enzymes, 
alkyne diphosphates, also bind close to the 4Fe4S cluster, as evidenced by similar EPR/HYSCORE spectra, 
indicating the same mechanism of inhibition, proposed to be inhibitor binding to a “closed” form of the 
enzyme with the inhibitors binding to both the A and B domains. Overall, these results should be of help 
in inhibitor design, a topic of considerable interest in the development of novel anti-infectives that 
inhibit isoprenoid biosynthesis in most pathogenic bacteria, as well as in malaria and other 
Apicomplexan parasites. 
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3.6 Tables and Figures 
Table 3.1 SCORECONS results for T. thermophilus and A. aeolicus IspGs, together with mutant 
activities. 
Ranking Amino 
Acid 
Mutant Relative 
activity 
of 
TtGcpE 
mutant 
Residue 
number 
in TtGcpE 
Scorecons 
score of 
TtGcpE 
Residue 
number 
in 
AaGcpE 
Scorecons 
score of 
AaGcpE 
Reported Activity 
1 E E232A 0.63% 232 0.995 204 0.994 <0.094% (E204Q) 
2 S S202A 17.00% 202 0.993 174 0.997  
3 N N346A 0.75% 346 0.990 303 0.905  
4 R R302A 3.86% 302 0.985 270 0.899  
5 S S262A 20.77% 262 0.980 234 0.952  
6 N N112A 11.20% 112 0.978 103 0.978 0.5% (N103D) 
7 E   274 0.975 242 0.986 8% (E242Q) 
8 H H227A 3.93% 227 0.970 199 0.95  
9 N   145 0.956 132 0.978 no gene expression 
10 R   260 0.946 232 0.936  
11 R R141A 4.43% 141 0.942 128 0.961 <0.034% (R128K) 
12 S   148 0.938 135 0.978  
13 T T231A 7.76% 231 0.933 203 0.966  
14 E   350 0.931 307 0.908  
15 M   29 0.929 28 0.955  
16 T   258 0.926 230 0.927  
17 K K204A 4.80% 204 0.924 176 0.938  
18 L   282 0.921 250 0.857  
19 R R56A 5.10% 56 0.916 55 0.947 <0.043% (R55K) 
20 R   110 0.914 101 0.961 0.2% (R101K) 
21 Q   27 0.909 26 0.924  
22 D D87A 2.47% 87 0.904 81 0.919 <0.029% (D81N) 
23 I   255 0.901 227 0.885  
24 D   257 0.899 229 0.93  
25 L   251 0.887 223 0.922  
26 S   243 0.884 215 0.882  
27 H H89A 13.70% 89 0.879 83 0.866  
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Table 3.1  (cont.) 
 
Ranking Amino 
Acid 
Mutant Relative 
activity 
of 
TtGcpE 
mutant 
Residue 
number 
in TtGcpE 
Scorecons 
score of 
TtGcpE 
Residue 
number 
in 
AaGcpE 
Scorecons 
score of 
AaGcpE 
Reported Activity 
28 A   182 0.877 156 0.843  
29 S   28 0.874 27 0.852  
30 T   115 0.872 106 0.868 38% (N106D) 
111 E E53A 60% 53 0.645 52 0.672  
235 T T303A 100% 303 0.304 - -  
      26 0.924 0.9% (Q26E) 
      256 0.675 48% (R256K) 
      307 0.908 28% (E307D) 
      270 0.860 <0.0014% (C270S) 
      273 0.874 <0.0014% (C273S) 
      306 0.910 <0.0014% (C306S) 
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Table 3.2 Calculated Aiso for the ferraoxetane reaction intermediate model and Aiso or A 
determined by ENDOR/HYSCORE experiments. Aiso was obtained from spectral simulations of 
orientation-selective data; and, A was estimated from the ENDOR/HYSCORE spectra taken at g2.  
 
 Calculated  
Aiso (MHz) 
Experimental 
Aiso or A (MHz) 
C1H1 0.6 A  = 3.2 
C1H2 0.3 A = 3.2 
C2 38.9 Aiso = 17.7 
C2'H1 9.1 Aiso = 11.3 
C2'H2 2.0 A = 3.7 
C2'H3 1.1 A = 1.3 
C3 0.3 Aiso = 3 
C3H 3.6 A = 3.2 
C4H1 0.3 A = 3.2 
C4H2 0.2 A = 2.0 
O1 0.68 A = 0.15 
O3 11.4 A = 9 
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Table 3.3 Computed electrostatic properties at bond critical points evaluated by using atom-in-
molecules (AIM) theory. (unit: au) 
 
Model Bond 2(r) (au) G(r) (au) V(r) (au) H(r) (au) 
Ferroxetane Fe-C 0.1030 0.0543 -0.0828 -0.0285 
 Fe-O 0.4986 0.1392 -0.1537 -0.0145 
[FeF6]
3- Fe-F 0.5685 0.1432 -0.1442 -0.0010 
[Fe(CN)6]
3- Fe-CN 0.3236 0.1207 -0.1606 -0.0399 
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Figure 3.1  Natural substrate and products.  MEcPP (1), HMBPP (2), IPP (3), DMAPP (4). 
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Figure 3.2  Schematic view of IspG structures. (A) Bacterial two-domain IspG domain arrangement. (B) 
Plant and malaria parasite IspG three-domain arrangement. (C) Crystal structure of Aquifex aeolicus IspG 
(3NOY) with the interfacial contact helices 7 of both A domains highlighted in red.  (D) ConSurf 
representation of AaIspG dimer.  A,B domains are circled. (E) Rosetta A-B domain docked AaIspG dimer 
structure.  (F) ConSurf representation of the closed AaIspG structure shown in E.  (G) One possible 
mechanism of interaction between two monomers of a three-domain IspG enzyme. (H) A hypothesized 
intra-molecular mechanism of action of a monomor of a three-domain IspG enzyme. 
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Figure 3.3  Oligomerization and catalysis of IspGs.  (A) Cross-linking experiment with oxidized TtIspG.  (B) Crossing-linking experiment with 
reduced TtIspG.  (C) Cross-linking experiment with lysozyme.  (D) Gel filtration chromatography and SDS-PAGE of TtIspG and AtIspG. Blue line: 
monomeric AtIspG; black line: reconstituted monomeric AtIspG; red line: dimeric TtIspG; green line: β-lactoglobulin; purple line: enolase; orange 
line: alcohol dehydrogenase; M: protein standard; 1: AtIspG; 2: TtIspG.  (E) Molecular weight estimation of TtIspG and AtIspG. Red triangle: 
dimeric TtIspG (~94 kDa); blue square: monomeric AtIspG (~74 kDa).  (F) Activity measurement of TtIspG mutants and chimera. a: wild type; b: 
E232A-(His)6; c: N346A-(His)6; d: C297S-(His)6; e: coexpression of E232A-(His)6 and N346A-(His)6 chimera; f: coexpression of E232A-(His)6 and 
C297S-(His)6 chimera; g: Duet expression of E232A-(His)6 and N346A-Strep tag chimera; h: Duet expression of E232A-(His)6 and C297S-Strep tag 
chimera.  (G) Schematic of coexpressed/Duet TtIspG chimera.  (H) High resolution gel filtration chromatography of AtIspG. Blue line: monomer 
AtIspG; red line: aggregated AtIspG.  (I) Glutaraldehyde cross-linking experiment on AtIspG. 
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Figure 3.4  X-band EPR spectra of IspG with “X” or HMBPP. (A) TtIspG E232A N346A + MEcPP, 2 min 
incubation, with “X” being the major component in the EPR spectrum. (B) TtIspG E232A N346A + MEcPP, 
1 hour incubation. Most of the “X” was converted to HMBPP. (C) AtIspG + MEcPP, 3 min incubation. This 
spectrum shows a mixture of “X” and the HMBPP product. (D) AtIspG + HMBPP. 
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Figure 3.5  ENDOR and 
HYSCORE spectra of the 
reaction intermediate X formed 
with AtIspG, EcIspG, and TtIspG 
chimeras. (A) 1H-ENDOR of 
AtIspG “X”. The Aiso=12 MHz 
proton signal is indicated. The 
inset is a Newman projection 
along C2-C2′, showing the 
dihedral angle-dependent 
hyperfine coupling constants of 
the three C2′ methyl protons. 
(B) HYSCORE spectrum of 
TtIspG E232A C297S chimera 
with [U-13C]-MEcPP. (C) As (B) 
but TtIspG E232A N346A 
chimera. (D) HYSCORE 
spectrum of AtIspG with [U-
13C]-MEcPP. (E) HYSCORE 
spectrum of EcIspG + [1-17O]-
labled “X”. All spectra were 
recorded at 9.7 GHz and 18K. 
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Figure 3.6  HYSCORE and computational results for “X” reaction intermediate. (A) Correlation between 
computed hyperfine couplings (Aiso; Table 3.3) and experimental hyperfine couplings for H1(2), C2, H2′ 
(3), H3, H4(2), O1 and O3, based on experimental results in Ref. (2, 16) and Fig. 3.5E. The line is 
constrained through the origin and R=0.87, slope=1.55. The inset shows the model used for performing 
the calculation. (B) Spin density for the ferraoxetane model. One methyl proton (indicated by the arrow) 
has a very large (~12 MHz) coupling and originates from a trans (Fe-C2-C2′-H2′) hyperfine interaction. 
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Figure 3.7  Homology and EM models of AtIspG. (A) Homology model of the A. thaliana  A* (insert) 
domain showing TIM barrel fold.  (B) Homology model of the A. thaliana catalytically active IspG 
monomer.  (C) ConSurf representation of AtIspG homology model (in the open form) showing low 
sequence homology in the A* domain.  (D) AtIspG homology model docked into a 20 Å AtIspG electron 
density map created by single particle electron tomography (Fig. 3.13).  (E) Proposed evolutionary 
mechanism involving exon-loss and recombination that could explain how two domain catalytically 
active IspG dimers evolved into three domain catalytically active monomers. 
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Figure 3.8  ClustalW2 multiple sequence alignment for ten 3 domain IspG proteins.  The A* domain in A. 
thaliana IspG is defined as extending from K365-N635.  (At, AAO15446) Arabidopsis thaliana; (Gb, 
ABB78087) Ginkgo biloba; (Os, BAD19354) Oryza sativa; (Pp, EDQ68630) Physcomitrella patens; (Tp, 
XP_002292108) Thalassiosira pseudonana; (Ct, YP_002887686) Chlamydia trachomatis; (Li, AAS69566) 
Leptospira interrogans; (Bb, XP_001610211) Babesia bovis; (Pf, AAK12103) Plasmodium falciparum; 
(Ctep, AAM71395) Chlorobium tepidum. 
 
 
  
72 
 
Figure 3.8  (cont.) 
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Figure 3.9  Closed (Rosetta-docked) AaIspG structure docked with (A) MEcPP; (B) ferraoxetane “X”; (C) 
HMBPP (2); (D) BPH-1077 (7 in Fig. 3.10) and their interactions with the TIM barrel and 4Fe4S cluster. 
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Figure 3.10  IspG inhibition.  IC50 values of a various putative inhibitors. Only the alkynes have good 
inhibitory activity.   
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Figure 3.11  X-band (9.7 GHz) HYSCORE spectrum of [U-13C] 6 bound to AtIspG.  
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Figure 3.12  Homology models of Arabidopsis thaliana A* (# 365-635, GeneBank:AAO15446.1) domain 
using (A) FUGUE (B) I-TASSER (C) LOMETS (D) FFAS (E) @TOME (F) ClustalW2 multi-sequence alignment 
with modeling by MODELLER using the A. aeolicus (PDB code 3NOY) monomer  as a template. 
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Figure 3.13  The final AtIspG tomographic single particle reconstruction produced from 2 three-dimensionally 
aligned low dose tilt series of AtIspG particles negatively stained with 2% uranyl formate.  Two rotated orientations 
of the final model are depicted.  (A) Orientation 1 of AtIspG homology model.  (B) Schematic of AA*B connectivity 
and positioning for orientation 1.  (C) Schematic of orientation 2.  (D) Rotated orientation 2 of AtIspG homology 
model.  (E, F) Rigid body fit of AtIspG homology model into electron density map created from single particle 
electron tomography.  Shown in orientations 1 and 2, respectively.  (G, H) Electron density map created from single 
particle electron tomography.  Shown in orientations 1 and 2, respectively.  (I) Sample projections from the input 
tilt series image stack.  Shown are representative Euler angles, the original projection from the tilt series, the 
projection low pass filtered to 20 Å, a reprojection from a tomographic reconstruction from 1 tilt series, and a 
reprojection from the combined/aligned tilt series single particle reconstruction.  (J) Fourier Shell Correlation 
even/odd (FSCe/o)  resolution curve for the reconstruction of a single particle from 2 combined/aligned tilt series.  0.5 
FSCe/o = 17.5 Å.  (K) Noise-compensated leave-one-out in 2D (NLOO-2D) vs tilt angle resolution estimate for 2 single 
particle tilt series.  Resolution assessed at 0.5 FRC.  (L) NLOO-2D for the final combined/aligned tilt series displayed 
according to each input tilt series.  Resolution assessed at 0.5 FRC.   
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Figure 3.13  (cont.) 
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Chapter 4 
Inhibition of the 4Fe-4S Proteins IspG and IspH: Diversity in Binding 
Modes and Spectroscopic Behavior 
 
4.1 Notes and Acknowledgements 
 This chapter was adopted from Francisco Guerra, Ke Wang, Jikun Li, Weixue Wang, Yi-Liang Liu, 
Shivani Amin, and Eric Oldfield.  Chem. Sci., 2014, 5, 1642.  This work was supported by NIH Grant 
GM065307 (to E. O.). W.W. and J.L. were both supported by predoctoral fellow-ships from the American 
Heart Association, Midwest Affiliate (awards 10PRE4430022 to W.W. and 11PRE7500042 to J.L.). We 
would like to thank Dennis Dean for providing the isc protein expression system, Pinghua Liu for 
providing the E. coli IspG expression system, Manuel Rodriguez-Concepción for providing the A. thaliana 
IspG expression system, Hassan Jomaa and Jochen Wiesner for providing the A. aeolicus IspH, P. 
falciparum IspH, and T. thermophilus IspG expression systems, and Mark J. Nilges for assistance with the 
EPR spectroscopy.  F. Guerra and K. Wang contributed equally to this work.  F. Guerra performed half of 
the IspH work and all of the IspG work, except for the ENDOR experiments. 
 
4.2 Introduction 
 There is currently great interest in the structure, function and inhibition of the enzymes involved 
in the 2-C-methylerythritol 4-phosphate (MEP) or ‘non-mevalonate’ isoprenoid biosynthesis pathway.  
(1)  This pathway is present in most bacteria as well as in the protozoan parasite, Plasmodium 
falciparum, the causative agent of the most common and serious form of malaria.(2,3)  This pathway is 
not used by humans and is essential for survival and is, therefore, an important drug target. In addition, 
the MEP pathway is present in plants, making inhibitors of interest as potential herbicides. The last two 
steps in the pathway are 2H+/2e- reductions carried out by 4Fe-4S cluster-containing proteins (Scheme 
1) in which there are unique 4th iron atoms in the cluster that are not coordinated to protein Cys 
residues.   
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Scheme 1.  IspG- and IspH-catalyzed reactions and their inhibitors. 
 
 
The penultimate protein in the pathway is IspG, 2-C-methyl-D-erythritol-2,4-cyclo-diphosphate (1) 
reductase (also known as GcpE), which catalyzes the reduction of 1 to E-1-hydroxy-2-methyl-but-2-enyl 
4-diphosphate (HMBPP; 2). The last enzyme in the pathway is IspH, HMBPP reductase (also known as 
LytB) and catalyzes the reduction of HMBPP to isopentenyl diphosphate (IPP, 3) and dimethylallyl 
diphosphate (DMAPP, 4), in a ~ 5:1 ratio. The structures of both the bacterial IspG and IspH proteins are 
known.(4-7)  IspG contains two domains:  a TIM barrel (A) involved in binding the diphosphate group of 
1 as well as in providing H+, and a 4Fe-4S cluster containing domain (B), involved in reduction.  In recent 
work the structure of 1 bound to a bacterial IspG has been reported.(8)  The bacterial proteins function 
as “head-to-tail” dimers with the TIM (triose phosphate isomerase) barrel of one partner in the dimer 
associated with the 4Fe-4S cluster-containing domain of the other molecule in the dimer.(6-8)  In plant 
and malaria parasite IspGs, there is also a third domain (A*), located between the A and B domains. The 
A* domain has essentially no sequence conservation between different organisms, but has been 
proposed to again adopt a TIM barrel fold and act in a primarily structural capacity, enabling the A and B 
domains in a monomer to come together and function catalytically.(9)  IspH is also modular and contains 
three  domains, the 4Fe-4S cluster being buried at the center of the trimeric structure.(4,5)  
In previous work we reported that two classes of molecules, acetylenes and pyridines,(10-13) 
acted as modest IspH inhibitors, binding at or close to the 4th Fe of the 4Fe-4S cluster, with the 
acetylenes also inhibiting IspG(9,11) with IC50 values as low as 0.77 M (0.77 M 5 E. coli IspG; 1.3 M 6 
Arabidopsis thaliana IspG; ~ 1 M 5 Pseudomonas aeruginosa IspG).  More recently, the amine analog of 
2, 7 (E-1-amino-2-methyl-but-2-enyl 4-diphosphate) as well as the thiol analog 8 (E-1-mercapto-2-
methyl-but-2-enyl 4-diphosphate) have been reported (14) to be even more potent IspH inhibitors (7, 
IC50 = 0.15 M; 8, IC50 = 0.21 M) and it was shown via Mössbauer spectroscopy and quantum chemical 
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calculations that both bound to the oxidized ([Fe4S4]
2+) form of IspH, forming Fe-N and Fe-S bonds, 
respectively,  with the 4th Fe.  Here, we report that IspG is likewise inhibited by these compounds. We 
also present the results of EPR ( 15) and HYSCORE (hyperfine sublevel correlation spectroscopy (15,16)) 
investigations into the nature of the inhibition of both IspH as well as IspG by 7 and 8, in the presence of 
sodium dithionite; an ENDOR (electron nuclear double resonance (16,18)) spectroscopic examination of 
the inhibition of IspG by 5 using two selectively 13C-labeled species; and investigation of the binding of 2 
to IspG, using uniformly as well as three specifically 13C-labeled ligands. 
 
4.3 Experimental 
Chemical Synthesis general methods.  The NH2- (7) and SH- (8) analogs of HMBPP, as well as [1-
13C], [2-13C], and [3-13C]-HMBPP, were from batches described previously.( 31,32)  In addition, in order to 
investigate bonding of the acetylene 5, we synthesized both [3-13C]-5 and [4-13C]-5, as described in 
Schemes 2 and 3, in order to unambiguously determine the hyperfine coupling tensor elements, Aii, for 
each site.  All reagents used in chemical synthesis were purchased from Aldrich (Milwaukee, WI). The 
structures of all compounds investigated were confirmed by using 1H and 31P NMR spectroscopy at 400 
MHz or 500 MHz on Varian (Palo Alto, CA) Unity spectrometers. Cellulose TLC plates were visualized by 
using iodine or a sulfosalicylic acid-ferric chloride stain. 
 
Synthesis of [3-13C]-But-3-ynyl diphosphate ([3-13C]-5). The synthesis of ([3-13C]-5 was carried 
out as shown in the following Scheme 2. 
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Reagents and conditions: a) K13CN, EtOH-H2O, 80 °C, 12h; b) TBDPSCl, imidazole, CH2Cl2, 0 °C ; c) DIBAL-
H, - 40 °C, 4h; d) CBr4, PPh3, Zn, CH2Cl2, r. t., 48h; e) i. n-BuLi, THF, -78 °C, 1h; ii. H2O; f) TBAF, THF, r. t.; g) 
MsCl, Et3N, CH2Cl2, 0 °C;   h) (n-Bu4N)3HP2O7, CH3CN, 0 °C – r. t., 48 h. 
 
[1-13C]-3-Hydroxypropionitrile (11).  [1-13C]-3-Hydroxypropionitrile (11) was synthesized 
according to a literature method (36).  A flask was charged with 530 mg of K13CN (8 mmol) and 5 mL of 
water was added. A 10% solution of NaI in ethanol (15 mL) was added, followed by 1.6 g (20 mmol) of 2-
chloroethanol. The reaction was heated at 80 oC for 12 h then cooled to room temperature. A negative 
cyanide test, shown by no change in color upon addition of 1 drop of reaction mixture to 0.5 mL of a 1.0 
M solution of p-nitrobenzyaldehyde in DMSO, demonstrated the consumption of all cyanide. The solvent 
was removed in vacuo and the residue purified by flash silica chromatography (hexane : EtOAc = 1 : 1)  
yielding  430 mg (75 %) of [1-13C]-3-hydroxypropionitrile as a clear oil. 1H NMR (400 MHz, CDCl3): δ 3.89 
(dq, J = 0.9 Hz, 6.3 Hz, 2H), 2.64 - 2.58 (m, 2H), 2.10 - 1.80 (m, 1H). 
 
[1-13C]- 3-(t-butyldiphenylsilyloxy)propionitrile (12).  A solution of 355 mg (5 mmol) of 11 in 20 
mL of CH2Cl2 was cooled to 0 °C. 340 mg (5 mmol) of imidazole was added and the mixture stirred for 10 
min before addition of 1.37 g (5 mmol) t-butylchlorodiphenylsilane. The reaction mixture was then 
slowly allowed to warm to room temperature, over 12 h. Saturated aqueous ammonium chloride (10 
mL) was added and the layers separated. The aqueous layer was extracted with CH2Cl2, the combined 
organic layers concentrated in vacuo, and the residue purified by flash silica chromatography (hexane : 
EtOAc = 6 : 1) to give  1.41 g (91 %) of 12 as a colorless solid. 1H NMR (400 MHz, CDCl3): δ 7.66 - 7.64 (m, 
4H), 7.42 - 7.24 (m, 6H), 3.82 (q, J = 6.0 Hz, 2H), 2.56 - 2.50 (m, 2H), 1.05 (s, 9H). 
 
[1-13C]- 3-(t-butyldiphenylsilyloxy)propionaldehyde (13).  A stirred solution of 12 (920 mg, 3 
mmol) in dichloromethane (3.0 mL) was cooled to - 40 °C, and 3.0 mL of diisobutylaluminum hydride 
(1.0 M in hexanes) added dropwise. The reaction mixture was stirred at - 40 oC for 4 hrs and then 
quenched with aqueous acetic acid. The resulting insoluble materials were filtered through Celite and 
washed with acetone. The combined organic layers were concentrated in vacuo and the residue purified 
by flash silica chromatography (hexane : EtOAc = 6 : 1)  to give 0.51 g (55 %) of 13 as a colorless solid. 1H 
NMR (400 MHz, CDCl3) δ 9.80 (dt, 
1JH, C = 172.8 Hz, J = 2.0 Hz, 1H), 7.66 - 7.63 (m, 4H), 7.41 - 7.36 (m, 6H), 
4.01 (q, J = 6.0 Hz, 2H), 2.62 - 2.56 (m, 2H), 1.06 (s, 9H). 
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[3-13C]-t-Butyl-(4, 4-dibromo-but-3-en-1-yloxy)diphenylsilane (14).  [3-13C]-t-Butyl-(4, 4-
dibromo-but-3-en-1-yloxy)diphenylsilane (14) was synthesized according to a literature method (37).  A 
solution of 312 mg (1 mmol) of 13 in 1.5 mL of dry CH2Cl2 was treated at room temperature with 664 mg 
(2 mmol) of CBr4 and 132 mg (2 mmol) of zinc dust, followed by 262 mg (1 mmol) of PPh3, in small 
portions. The resulting mixture was stirred at room temperature for 48 h, diluted with 30 mL of hexanes, 
filtered, and washed with ether. The combined organic layers were concentrated in vacuo and the 
residue purified by flash silica chromatography (hexane : EtOAc = 25 : 1) to yield 360 mg (77 %) of 14 as 
a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.66 - 7.63 (m, 4H), 7.44 - 7.35 (m, 6H), 6.45 (dt, 
1JH, C = 161.2 
Hz, J = 6.8 Hz, 1H), 3.71 - 3.67 (m, 2H), 2.36 - 2.29 (m, 2H), 1.04 (s, 9H). 
 
[3-13C]-t-Butyl-(2-methylpent-3-ynyloxy)diphenylsilane (15).  To a solution of 188 mg (0.4 
mmol) of 14 in 4.0 mL of dry THF was added dropwise 0.30 mL of n-BuLi (1.6 M solution in hexanes) at -
78 oC. The reaction mixture was stirred at -78 oC for 1 h and then quenched with H2O and extracted with 
ether. The combined organic layers were dried over MgSO4, concentrated in vacuo and purified by flash 
silica chromatography (hexane : EtOAc = 25 : 1) to yield 116 mg (94%) of 15 as a colorless oil. 1H NMR 
(500 MHz, CDCl3): 7.69 - 7.66 (m, 4H), 7.44 - 7.37 (m, 6H), 3.80 - 3.77 (m, 2H), 2.48 - 2.43 (m, 2H), 1.95 
(dt, 2JH, C = 49.5 Hz, J = 2.5 Hz, 1H), 1.05 (s, 9H). 
 
[3-13C]-But-3-yn-1-ol (16).  15 (100 mg, 0.32 mmol) in 0.30 mL THF was added slowly at room 
temperature to 0.30 mL of tetrabutylammonium fluoride (TBAF, 1.0 M solution in THF). After 30 
minutes, the reaction mixture was quenched with water. The aqueous layer was extracted twice with 
EtOAc. The resulting organic layers were filtered, concentrated and purified by flash silica 
chromatography (hexane : EtOAc = 1 : 2) to provide 16 as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 
3.78 - 3.71 (m, 2H), 2.51-2.46 (m, 2H), 2.06 (dt, 2JH, C = 49.5 Hz, J = 2.5 Hz, 1H). 
 
[3-13C]-But-3-ynyl methanesulfonate (17).  [3-13C]-But-3-yn-1-ol (16) 14.2 mg (0.2 mmol) was 
dissolved in 0.5 mL CH2Cl2 and cooled to 0 °C. 23 mg (0.2 mmol) of methanesulfonyl chloride was added 
dropwise at 0 °C followed by the addition of 20 mg (0.2 mmol) of Et3N. The reaction mixture was stirred 
for 30 minutes at 0°C and then quenched with water. The aqueous layer was extracted once with CH2Cl2, 
the combined organic layers concentrated under reduced pressure, and then purified by flash silica 
chromatography (hexane : EtOAc = 1 : 2) to provide 23 mg (77 %) of 17 as a colorless oil. 1H NMR (400 
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MHz, CDCl3): δ 4.32 - 4.27 (m, 2H), 3.04 (s, 3H), 2.68 - 2.63 (m, 2H), 2.08 (dt, 
2JH, C = 50.0Hz, J = 2.4 Hz, 
1H). 
 
[3-13C]-But-3-ynyl diphosphate ([3–13C]-5).  [3-13C]-But-3-ynyl diphosphate ([3–13C]-5) was 
synthesized according to a literature method (38).  [3-13C]-but-3-ynyl methanesulfonate (17) (15 mg, 0.1 
mmol) in dry CH3CN (0.3 mL) was added  to a stirred solution of 0.27 g (0.3 mmol) tris(tetra-n-
butylammonium) hydrogen diphosphate in dry CH3CN (0.5 mL) at 0 °C. The reaction mixture was slowly 
allowed to warm to room temperature over 24 h, then solvent was removed under reduced pressure. 
The residue was dissolved in 0.5 mL of cation-exchange buffer (49:1(v/v) 25 mM NH4HCO3/2-propanol) 
and passed over 90 mequiv of Dowex AG50W-X8 (100-200 mesh, ammonium form) cation-exchange 
resin, pre-equilibrated with two column volumes of the same buffer. The product was eluted with two 
column volumes of the same buffer, flash frozen, and lyophilized. The resulting powder was dissolved in 
0.5 mL 50 mM NH4HCO3, 2-propanol/CH3CN (1: l (v/v), 1 mL) added, and the mixture mixed on a vortex 
mixer, then centrifuged for 5 min at 805 g. The supernatant was decanted. This procedure was repeated 
three times and the supernatants were combined. After removal of the solvent and lyophilization, a 
white solid was obtained. Flash chromatography on a cellulose column (2:1:1 (v/v/v) 2-
propanol/CH3CN/50 mM NH4HCO3) yielded 9 mg (30%) of [3–
13C]-5 as a colorless solid. 1H NMR (500 
MHz, D2O): δ 3.93 - 3.85 (m, 2H), 2.45 - 2.40 (m, 2H), 2.23 (dt, 
2JH, C = 50.5 Hz, J = 2.5 Hz, 1H). 
31P NMR 
(200 MHz, D2O): δ - 8.55 (m), - 10.0 (m). 
 
[4-13C]-But-3-ynyl diphosphate ([4-13C]-5).  [4-13C]-But-3-ynyl diphosphate ([3-13C]-5) was 
prepared in a similar manner to that used to prepare [3-13C]- 5),  as illustrated in the following Scheme 
3: 
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Reagents and conditions: a) 13CBr4, PPh3, Zn, CH2Cl2, r. t., 48h; b) i. n-BuLi, THF, -78 °C, 1h; ii. H2O; c) 
TBAF, THF, r. t.; d) MsCl, Et3N, CH2Cl2, 0 °C;  e) (n-Bu4N)3HP2O7, CH3CN, 0 °C – r. t., 48 h. 
3-(t-Butyldiphenylsilyloxy)propionaldehyde was synthesized following the procedure for [1-13C]-3-(t-
butyldiphenylsilyloxy) propionaldehyde (13) described above. 1H NMR (400 MHz, CDCl3): δ 9.82 (t, J = 2.0 
Hz, 1H), 7.70 – 7.66 (m, 4H), 7.45 – 7.38 (m, 6H), 4.03 (t, J = 6.0 Hz, 2H), 2.61 (td, J = 6.0, 2.4 Hz, 2H), 1.06 
(s, 9H). 
 
[4-13C]-t-Butyl-(4, 4-dibromo-but-3-enyloxy)diphenylsilane (18).  A solution of 114 mg (0.37 
mmol) of 3-(t-butyldiphenylsilyloxy)propanal in 0.5 mL of dry CH2Cl2 was treated at room temperature 
with 100 mg (0.3 mmol) of 13CBr4 and 40 mg (0.6 mmol) of zinc dust,  followed by 95 mg (0.36 mmol) of 
PPh3, in portions. The resulting mixture was stirred at room temperature for 48 h, diluted with 10 mL of 
hexanes, filtered, and washed with ether. The combined organic layers were concentrated in vacuo, and 
the residue purified by flash silica chromatography (hexane : EtOAc = 25 : 1) to yield  147 mg (85 %) of 
18 as a colorless oil. 1H NMR (400 MHz, CDCl3): δ 7.68 - 7.65 (m, 4H), 7.43 - 7.36 (m, 6H), 6.48 (dt, J = 6.8 
Hz, J = 1.2 Hz, 1H), 3.71 (t, J = 6.0 Hz, 2H), 2.38 - 2.30 (m, 2H), 1.06 (s, 9H). 
 
[4-13C]-t-Butyl-(2-methylpent-3-ynyloxy)diphenylsilane (19).  The procedure described for [3-
13C]-t-butyl-(2-methylpent-3-ynyloxy) diphenylsilane (15) was used for the synthesis of [4-13C]-t-butyl-(2-
methylpent-3-ynyloxy)diphenylsilane (19).  A solution of 94 mg (0.2 mmol) of 18 in 2.0 mL of dry THF 
was treated at -78 oC with 0.15 mL (0.24 mmol) of n-BuLi (1.6 M solution in hexanes). The reaction 
mixture was stirred at -78 oC for 1 h and quenched with H2O and then extracted with ether. The 
combined organic layers were dried over MgSO4, concentrated in vacuo, and purified by flash silica 
chromatography (hexane : EtOAc = 25 : 1) to yield  58 mg (94%) of 19 as a colorless oil. 1H NMR (400 
MHz, CDCl3): δ 7.67-7.65 (m, 4H), 7.42-7.32 (m, 6H), 3.76 (t, J = 6.8 Hz, 2H), 2.46 - 2.40 (m, 2H), 1.93 (dt, 
1JH, C =248.4 Hz, J = 2.8 Hz, 1H), 1.04 (s, 9H). 
 
[4-13C]-But-3-yn-1-ol (20).  [4-13C]-t-Butyl-(2-methylpent-3-ynyloxy)diphenylsilane (19)  (100 mg, 
0.32 mmol) in 0.30 mL THF was added slowly at room temperature to 0.30 mL of TBAF (1.0 M solution in 
THF). After an additional 30 minutes, the reaction mixture was quenched with water. The aqueous layer 
was extracted twice with EtOAc. The resulting organic layer was filtered, concentrated, and purified by 
flash silica chromatography (hexane : EtOAc = 1 : 2)  to provide a colorless oil. 1H NMR (400 MHz, CDCl3): 
δ 3.75 (t, J = 6.5 Hz, 2H), 2.50 - 2.45 (m, 2H), 2.05 (dt, 1JH, C = 249.0 Hz, J = 2.5 Hz, 1H). 
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[4-13C]-But-3-ynyl methanesulfonate (21).  [4-13C]-But-3-yn-1-ol (20) 14 mg (0.2 mmol) was 
dissolved in 0.5 mL CH2Cl2 and cooled to 0 °C. Then, 23 mg (0.2 mmol) of methanesulfonyl chloride was 
added dropwise at 0 °C, followed by the addition of 20 mg (0.2 mmol) of Et3N. The reaction mixture was 
stirred for 30 minutes at 0°C and then quenched with water. The aqueous layer was extracted once with 
CH2Cl2, the combined organic layers concentrated under reduced pressure, then purified by flash silica 
chromatography (hexane : EtOAc = 1 : 2) to provide 23 mg (77 %) of 21 as a colorless oil. 1H NMR (500 
MHz, CDCl3): δ 4.32 (t, J = 6.5 Hz, 2H), 3.07(s, 3H), 2.66 - 2.70 (m, 2H), 2.08 (dt, 
1JH, C = 250.5 Hz, J = 2.5 
Hz, 1H). 
 
[4-13C]-But-3-ynyl diphosphate ([4-13C]-5).  Following the procedure described for [3-13C]-but-3-
ynyl diphosphate ([3 – 13C] - 5), [4-13C]-but-3-ynyl methanesulfonate (21) (15 mg, 0.1 mmol) in dry CH3CN 
(0.3 mL) was added to a stirred solution of 0.27 g (0.3 mmol) tris(tetra-n-butylammonium) hydrogen 
diphosphate in dry CH3CN (0.5 mL), at 0 °C. The reaction mixture was allowed to warm to room 
temperature over 48 h. Flash chromatography on a cellulose column (2:1:1 (v/v/v) 2-propanol/CH3CN/50 
mM NH4HCO3) yielded 9 mg (30%) of [4-
13C]-5 as a colorless solid. 1H NMR (500 MHz, D2O): δ 5.51 - 5.45 
(m, 1H), 3.90 - 3.85 (m, 2H), 2.44 - 2.40 (m, 2H), 2.22 (dt, 1JH, C = 250 Hz, J = 3.0 Hz, 1H); 
31P NMR (200 
MHz, D2O): δ - 8.55 (d, J = 19.6 Hz), - 10.0 (d, J = 19.6 Hz). 
 
[U-13C]-E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate ([U-13C]-2).  Preparation of [U-13C]-2 
was described previously (39). 
 
E. coli IspG protein espression and purification.  Protein was expressed and purified basically as 
described in Ref. (39). BL-21(DE3) cells overexpressing E. coli IspG (encoded in plasmid pASK- IBA5+) and 
isc proteins (encoded in plasmid pDB1282) were grown in LB media supplemented with 100 mg/L 
ampicillin and 50 mg/L kanamycin at 37 °C, until the OD600 reached 0.3. Cells were then induced with 0.5 
g/L D-arabinose to initiate overexpression of the isc proteins. Cysteine (0.5 mM) and FeCl3 (0.1 mM) 
were added, and the cells grown until the OD600 reached 0.6. At this point, 400 μg/L anhydrotetracycline 
was added, to induce overexpression of E. coli IspG.  Cells were grown at 21 °C for a further 24 hours, 
then harvested by centrifugation (14,334 g, 8 min, 4 °C).  The cell pellets were kept at -80 °C until further 
use. 
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All purification steps were carried out in a Coy vinyl anaerobic chamber (Coy Laboratories, Grass 
Lake, MI) with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk line. Cell 
pellets were resuspended in 100 mM Tris-HCl, 150 mM NaCl buffer (pH 8.0). Lysozyme, benzonase 
nuclease (EMD Chemicals, San Diego, CA) and phenylmethanesulfonyl fluoride were added, and the 
slurry stirred for 1.5 hours at 10 °C, followed by sonication (Fisher Scientific Sonic Dismembrator, Model 
500) with 4 pulses, each of 7 sec duration at 35% power. The cell lysate was then centrifuged at 15,550 g 
at 10 °C for 30 min. The supernatant was purified by using Strep-tactin chromatography (43). Fractions 
having a brown color were collected and desalted in pH 8.0 buffer containing 100 mM Tris-HCl and 150 
mM NaCl. 
 
A. thaliana IspG protein expression and purification.  The pQE-31 plasmid containing an N-
terminal truncated (signal- and transit-peptide cleaved) AtIspG gene was co-transformed with the KanR 
pDB1281 plasmid in Escherichia coli BL21 (DE3) RIPL competent cells (Agilent Technologies) (9). E. coli 
cells were grown aerobically in 100 mL sterile LB (50 μg/mL ampicillin, 25 μg/mL kanamycin, 11 μg/mL 
chloramphenicol) for 12 h at 37 °C, shaking at 250 rpm.  A 50 mL inoculum was transferred to 1.5 L of 
sterile LB broth (50 μg/mL ampicillin, 25 μg/mL kanamycin, 11 μg/mL chloramphenicol) in 4 L flasks and 
shaken at 185 rpm at 37 °C. At an OD600 of ~ 0.2, 0.5 g/L D-arabinose (to induce expression of pDB1281 
genes), 200 μM FeCl3, and 1 mM L-cysteine were added to each 1.5 L LB flask, then the cells were grown 
at 37 °C with shaking at 185 rpm. At an OD600 of ~ 1.0, protein expression was induced by adding 1 mM 
IPTG to each flask. The cultures were then grown at 28 °C for 12-14 h, shaking at 160 rpm. Cells were 
harvested by centrifugation at 14,334 g using an SLC-3000 rotor and a Sorvall Evolution centrifuge. Cell 
pellets were stored at -80 °C for later purification. All steps for anaerobic purification of AtIspG were 
performed in a Coy glove box at 4 °C. The cell pellet was lysed with 10 mg/mL lysozyme (chicken egg 
white), 62 U/mL benzonase nuclease (purity > 90%), and 1 tablet/50mL protease inhibitor cocktail, in a 
slowly stirred binding buffer (5 mM imidazole, 200 mM Hepes, 100 mM KCl, pH 7.6). The cell lysate was 
sonicated for 90 s with on/off intervals of 10 s / 20 s, respectively and then centrifuged at 2,056 g in an 
F-34-6-38 rotor in a table-top Eppendorf 5804 centrifuge for 90 min (transferring the supernatant to 
new centrifuge tubes after 45 min to remove most of the precipitate). The supernatant was filtered 
using a syringe-driven 0.45 μm filter, loaded onto a nickel affinity column, and purified as follows. First, 
bound protein was washed with 100-200 mL 50 mM imidazole (200 mM Hepes, 100 mM KCl, pH 7.6). 
IspG was then eluted with 250 mM imidazole (200 mM Hepes, 100 mM KCl, pH 7.6) and concentrated 
using 10K-50K centrifugal filters. The concentrated protein was then loaded onto a PD-10 desalting 
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column, eluted with final buffer (200 mM Hepes, 100 mM KCl, pH 7.6), and concentrated by 
centrifugation. All purified protein batches were run on SDSPAGE gels to verify purity. MALDI-TOF mass 
spectra of AtIspG exhibited a major peak at 82,247 Da (expected 82,157). A BioRad protein 
concentration assay was used to determine final protein concentration.  Protein was stored at -80 °C. 
 
P. aeruginosa IspG protein expression and purification.  The pET-26b plasmid containing the 
PaIspG gene was co-transformed with the AmpR pDB1282 plasmid in E. coli BL21 (DE3) pLysS competent 
cells (Novagen). Inoculated E. coli were grown aerobically in 100 mL LB (with 50 μg/mL ampicillin, 25 
μg/mL kanamycin) for 12 h at 37 °C, shaking at 250 rpm.  A 50 mL inoculum was transferred to 1 L of 
sterile LB broth (50 μg/mL ampicillin, 25 μg/mL kanamycin) in 4 L flasks and shaken at 185 rpm at 37 °C. 
At an OD600 of ~ 0.2, 0.5 g/L D-arabinose (to induce expression of pDB1282 genes), 200 μM FeCl3, and 1 
mM L-cysteine were added to each 1 L LB flask, then the cells were grown at 37 °C with shaking at 185 
rpm. At an OD600 of ~ 1.0, 1 mM IPTG was added to each flask to induce protein expression. The cultures 
were grown at 28 °C for 14-18 h, shaking at 160 rpm. Cells were harvested by centrifugation at 14,334 g 
using an SLC-3000 rotor and a Sorvall Evolution centrifuge. Cell pellets were stored at -80 °C for later 
purification. All steps for anaerobic purification of PaIspG were similar to those used for the AtIspG 
anaerobic purification described above. 
 
A. aeolicus IspH protein expression and purification. A. aeolicus IspH was expressed and 
purified basically as described in Ref. (38). BL-21(DE3) cells (Invitrogen) expressing IspH from A. aeolicus 
were grown in LB media supplemented with 150 mg/mL ampicillin at 37 °C until the OD600 reached ~0.6. 
Cells were then induced with 200 μg/L anhydrotetracycline and grown at 20 °C for 15 h. Cells were 
harvested by centrifugation (14,334 g, 20 min, 4 °C) and kept at -80 °C until further use. Purification was 
then carried out in an anaerobic chamber in a 4 °C cold room. Cell pellets were re-suspended and lysed 
by sonication, then centrifuged at 15,550 g at 4 °C for 20 min. The supernatant was applied to a HisPur 
Ni-NTA spin column (Pierce) equilibrated with a pH 8.0 buffer containing 50 mM Tris · HCl and 150 mM 
NaCl. After washing with 6 mL of 25 mM imidazole-containing buffer 3 times, protein was eluted with 
buffer containing 250 mM imidazole. Dark-brown fractions were collected, pooled, concentrated and 
then desalted on a PD-10 column (GE Healthcare), to remove imidazole. Because AaIspH does not 
incorporate iron-sulfur clusters particularly well, even when purified in a glove box, cluster 
reconstitution was employed. To do this, protein was transferred to a room-temperature Coy vinyl 
anaerobic chamber, diluted to 1 – 2 mM, and incubated with 20 mM DTT for 1 hour. Then, 0.5 mM FeCl3 
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and 0.5 mM Na2S were slowly added to the protein solution with gentle stirring (~ 100 rpm), followed by 
incubation for 6 – 8 hours.  These additions and incubations of FeCl3 and Na2S were repeated five times. 
Care was taken that iron sulfide and protein precipitation were kept to a minimum. The protein solution 
was then centrifuged at 15,550 g for 20 minutes, the supernatant concentrated, desalted again (to 
remove excess metal and sulfide ions), and the purified, reconstituted protein stored in the anaerobic 
chamber at 4°C. 
 
15N-labeled A. aeolicus IspH expression and purification.  To express 15N-labeled protein, the 
above protocol for AaIspH was modified by substituting LB medium with M9 minimal medium (minus 
14N nitrogen source) supplemented with 4 g/L glucose, 1 g/L [15N2]-(NH4)2SO4 (Cambridge Isotope Labs), 
1% (v/v) MEM vitamin solution (Sigma-Aldrich), 0.5% (v/v) 15N-labeled BioExpress cell growth medium 
(Cambridge Isotope Labs), 0.2 mM trisodium citrate and 0.1 mM FeCl3. Protein expression was induced 
at 25 °C when the OD600 reached ~1.4, and cells were harvested 20 hours after. 
15N-labeled AaIspH 
protein was then purified and reconstituted as described above. 
 
E. coli IspH protein expression and purification.  BL21(DE3) (Invitrogen) cells harboring an E. coli 
IspH construct were grown in LB media at 37°C until the OD600 reached ~0.6. Induction was performed 
with 200 ng/mL anhydrotetracycline at 20 °C for 15 h. Cells were harvested by centrifugation at 14,334 g 
for 8 min and stored at -80 °C. Cell pellets were moved into a cold-room glove box as with AaIspH, then 
resuspended and lysed by sonication, and the lysate centrifuged at 15,550 g for 30 min. The supernatant 
was collected and loaded onto an IBA Strep-tag column equilibrated with buffer W (100 mM Tris · HCl, 
150 mM NaCl, pH 8.0). After washing with buffer W, protein was eluted using buffer E (buffer W 
containing 2.5 mM desthiobiotin). Fractions were collected and dialyzed in pH 8.0 buffer containing 50 
mM Tris · HCl, 150 mM NaCl, 5% glycerol, and 1 mM DTT, twice. The purified protein was flash-frozen in 
liquid nitrogen and stored at -80 °C. 
 
Plasmodium falciparum IspH protein expression and purification.  A pASK-IBA3plus (AmpR) 
plasmid containing a truncated PfIspH gene was co-transformed with the isc operon containing KanR 
pDB1281 plasmid into BL21 (DE3) pLysS (Novagen) competent cells.  The expression and purification 
procedure followed that for P. aeruginosa IspG (see above), except that at OD600 ~ 0.6-1.0, protein 
expression was induced by adding 200 μg/L anhydrotetracycline. 
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Thermus thermophilus IspG D87A mutagenesis, protein expression, and purification.  The 
TtIspG-D87A mutant has been described previously, Ref. (40).   
 
Enzyme inhibition assays.  All assays were performed inside a Coy vinyl anaerobic chamber with 
an oxygen level < 2 ppm. 0.3 μM IspG was added to 0.8 mM dithionite (DT) and 4.0 mM methyl viologen 
(MV) in 0.2 M HEPES, 0.1 M KCl, pH 7.6 buffer and incubated at room temperature, ~25 °C, for 10 min.  
140 μM MEcPP was then added to bring the total volume to 200 μL.  Initial velocity measurements of 
the oxidation of methyl viologen were made at 732 nm using a 96-well plate reader (a Molecular Devices 
SpectraMax Plus 384 Spectrophotometer).  Blanks, composed of MEcPP + DT + MV, were run 
concurrently with each assay, as were positive controls of IspG + MEcPP + DT + MV.  The final reaction 
velocities were baseline corrected, according to the blanks, and normalized to the positive controls.  
Data were fit to a standard Hill Equation in Matlab (version 2011b, the MathWorks Inc., Natick, MA) and 
Prism (version 5.0, GraphPad Software, La Jolla, CA) with the final plots made in Prism.  The error bars 
represent the standard deviations; the Hill coefficients varied from 0.98-1.6. In order to make 
comparisons between all of the IspGs tested, a uniform enzyme concentration of 0.3 µM was used.  
 
CW-EPR/ENDOR/HYSCORE Sample preparation. All samples were prepared inside a Coy Vinyl 
Anaerobic Chamber with an oxygen level < 2 ppm. Samples were typically 0.2-1.6 mM in IspG, and 
glycerol was added as a glassing agent to 20% (v/v). 20-80 equivalents of sodium dithionite were added 
as a reducing agent, and ligands were added to 15-20 equivalents. 
 
CW-EPR/ENDOR/HYSCORE Spectroscopy.  All CW (continuous wave)-EPR experiments were 
performed on a Varian E-line 122 X-band spectrometer with an Air Products helium cryostat. Data 
acquisition parameters were typically: microwave frequency = 9.05 GHz; field center = 3250 Gauss; field 
sweep = 1000 Gauss; modulation frequency = 100 kHz; modulation amplitude = 5 Gauss; time constant = 
32 milliseconds; temperature = 8-20 K.   
Pulsed ENDOR/HYSCORE spectra were obtained on a Bruker ElexSys E-580-10 FT-EPR EPR 
spectrometer equipped with an Oxford Instruments CF935 cryostat.  A Bruker RF amplifier (150 watts, 
100 kHz -250 MHz) was used for ENDOR experiments.  Davies ENDOR used a three-pulse sequence mw – 
t - /2mw –  – mw -  - echo; /2mw = 96 ns, with RF (10 s, 3 dB attenuation) applied during t.  HYSCORE 
used a four-pulse sequence /2mw –  - /2 mw – t1 – mw – t2 – /2mw – echo; /2mw = 16 ns and πmw = 32 
ns, 128 points for both t1 and t2, each using 24 ns steps. Time-domain data were baseline corrected 
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using a 3rd order polynomial, then Hamming windowed, followed by zero-filling, and 2D-Fourier 
transformation. Parameters were typically: microwave frequency = 9.65 – 9.70 GHz, temperature = 8-15 
K, microwave power attenuation = 6.5-9 dB. 
 
CW-EPR/ENDOR/HYSCORE Simulations general methods.  Simulations were performed in 
Matlab 7.12.0 (R2011a) with Easyspin 4.0.0 (and 4.5.0) (41).  Initial g tensors were interactively 
determined and used for subsequent refinements with Easyspin’s least squares fitting implementation.  
ENDOR/HYSCORE simulations were performed with EasySpin’s saffron function (42).  A 0.5 MHz 
uncertainty in hyperfine tensor assignments to HYSCORE data was determined using RMSD and 
normalized cross-correlation metrics between corresponding data and simulations.  The spin-projection 
coefficient previously reported for aconitase was taken to vary from 0.86 (Kmin) – 1.78 (Kmax) (43).    
 
CW-EPR Simulations.  Simulations were performed in Matlab 7.12.0 (R2011a) with Easyspin 
4.0.0 (and 4.5.0) (41).  Initial g tensors for 3 components were interactively determined and used for 
subsequent refinements with Easyspin’s least squares fitting implementation.  Generally, a global 
refinement was performed using a ‘genetic’ algorithm followed by a local refinement, using either a 
Nelder/Mead downhill simplex or Levenberg/Marquardt algorithm.  This global-to-local refinement of 
parameters was iteratively performed on the g tensors, g strains (anisotropic broadenings), peak-to-
peak linewidths (isotropic broadening), and weights for each component.  The errors of the data minus 
simulations were minimized for either the absorption or first derivative spectra.  Since the RMS error, 
being an average error, could give misleading guidance towards a fit, final visual inspections of the fits 
were necessary.  While some systems could be completely described by 1 component, e.g. AtIspG + 
HMBPP (2), other systems, such as PaIspG + HMBPP (2), could only achieve good fits with 3 components.  
Further investigation into this phenomenon may be warranted as it could indicate variability in binding 
capacities and/or modes between different IspG species. 
 
ENDOR Simulations.  Simulations were performed in Matlab 7.12.0.635 (R2011a) with Easyspin 
4.0.0 (41,42).  Initial g tensors were determined interactively and used for subsequent refinements with 
Easyspin’s least squares fitting implementation as described above (41). ENDOR simulations were 
performed with EasySpin’s saffron function (42).   
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HYSCORE Simulations.  Simulations were performed in Matlab 7.12.0 (R2011a) with Easyspin 
4.0.0 (and 4.5.0) (41,42).    Initial g tensors were determined interactively as described above.  HYSCORE 
simulations were performed with EasySpin’s saffron function assuming ideal pulses.  Dwell time was 24 
ns.  Both x and y dimensions were recorded with 128 points.  The t1 and t2 parameters of the HYSCORE 
pulse sequence were 80 ns.  The simulation excitation width for all 13C nuclei was assumed to be the 
inverse of the first pulse.  At least 2 τ values and 3 field positions (corresponding to each principle 
component of the anisotropic g tensor [g1 g2 g3]) were recorded for each labeled species; therefore, all 
of the spectra were individually simulated.  To match the processing of the empirical spectra, the 
simulation time domain signal was baseline corrected with a 3rd order polynomial, apodized with a 
Hamming window function, zero filled to 256 points in both x and y, and Fourier transformed in 2D.  The 
final simulated spectra were thresholded above a baseline noise contour level determined from visual 
inspection of the corresponding empirical spectra.  A 0.5 MHz uncertainty in hyperfine tensor 
assignments to HYSCORE data was determined using RMSD and normalized cross-correlation metrics 
between corresponding data and simulations. 
 
 
4.4 Results and Discussion 
 We first investigated the question of how 7 and 8 might bind to the reduced form of IspH, since 
they are known to bind via N or S to the oxidized ([Fe4S4]
2+) protein.  Is this also the case with reduced 
IspH?  To do this, we used EPR and HYSCORE spectroscopy.  We began by investigating binding of the 
amine ligand 7 to Aquifex aeolicus IspH (AaIspH), Plasmodium falciparum IspH (PfIspH), and E. coli IspH 
(EcIspH).  The 9.05 GHz EPR spectrum (at 10K) of dithionite-reduced AaIspH was reported previously (19) 
to be a mixture of an S = 1/2 and S = 
3/2 species, with the S = 
1/2 species having g-values of 2.040, 1.919, 
1.849 (Table 4.1).   
The g ~ 2 region in the absence of any added ligand is shown for reference in Figure 1A.  The 
spectrum is similar to that found with other 4Fe-4S proteins, such as aconitase (20). On addition of 7, a 
sharp new feature appears (having gi = 2.134, 2.006, 1.973, Table 1). With PfIspH and EcIspH, there is 
only very weak signal intensity in the absence of added ligands, but in both cases in the presence of 7 
intense and sharp signals with gi ~ 2.137, 2.007, 1.980, Table 4.1, are seen (Figure 1C,D) suggesting that 
the ligand binds at or close to the [Fe4S4]
+ cluster in all three IspHs.  The question then arises as to how 7 
binds. There are two main possibilities:  First, 7 binds via its NH2 group to the [Fe4S4]
+ cluster in basically 
the same manner as that proposed for binding to the oxidized cluster, i.e. by forming a Fe-N bond to the 
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4th Fe (14).  Second, 7 might bind to IspH with its aminomethyl group “rotated-out”, away from the 
cluster, interacting with E126, as proposed earlier (11) for the CH2OH group in the HMBPP substrate, as 
now seen crystallographically (21) with HMBPP, and  as confirmed by 17O-HYSCORE spectroscopy.(22)  
To help distinguish between these two possibilities, we obtained the HYSCORE spectrum of 7 
bound to AaIspH, Figure 4.2A, as well as to PfIspH and EcIspH, Figures 4.9 and 4.10. To distinguish any 
14N hyperfine interaction with the protein backbone from that with the ligand 7, we also obtained the 
HYSCORE spectrum of 7 bound to 15N-labeled AaIspH, Figure 2B.  If there were a Fe-N bond present in 
the complex, we would expect a sizeable 14N hyperfine coupling since there would be a strong metal-
ligand orbital overlap facilitating spin density transfer from the metal to the ligand.  For example, with 
the pyridine inhibitor 9 bound to IspH (13), as shown in Figure 4.2C, the 14N hyperfine interaction Aiso 
(14N) is ~ 8 MHz and we previously noted that, on average, Aiso (
14N) values were ~ 6 MHz for a series of 
proteins containing Fe-N bonds.(13)  Given that there is no large hyperfine coupling observed (Figure 2A 
and 2B), we conclude that there is no Fe-N bond in the reduced IspH + 7 complex. In addition, the gi, giso 
and ∆g values for IspH + 7 are essentially identical to those we find with HMBPP (2) bound to both E. coli 
and A. aeolicus IspH mutants (Table 4.1, shown graphically in Figure 4.3), supporting similar binding of 
both 2 and 7. Plus, the spectrum of the pyridine inhibitor 9 bound to IspH is very broad, quite different 
to the sharp spectrum found with 7. We thus propose that 7 binds to IspH in basically the same manner 
as does HMBPP (2), and a model based on the “rotated-out” HMBPP X-ray structure (21) in which the 
HMBPP ligand’s OH group is replaced by an NH3
+ group is shown in Figure 4.2D.  As can be seen in this 
(HMBPP X-ray based) structural model, the ligand’s CH2NH3
+ group can interact with the E126 
carboxylate, providing strong Coulombic interactions that may help account for its potent IspH inhibition 
(where assays are carried out under reducing conditions).  
As we reported previously,(22) there are three major clusters in this (Figure 3) and related ∆g 
/giso plots:(22) classic [4Fe-4S]
+ clusters where giso < ge , from proteins such as ferredoxins, aconitase, and 
ligand-free IspH/IspG; oxidized HiPIPs and synthetic [4Fe-4S]3+ models with giso > ge , and [4Fe-4S]
+ 
clusters with alkene or alkyne ligands where giso > ge ,but where the giso –values are generally smaller 
than those of typical HiPIPs.  Clearly, the amine inhibitor 7 falls in the “ligand free” region discussed 
earlier, that is, the nitrogen does not bind directly to Fe. 
Interestingly, there is a small feature centered close to (-1.5, 1.5) MHz in all three AaIspH + 7, 
PfIspH + 7, and EcIspH + 7 spectra that has not been seen previously with any other ligands.  It did not 
change when 15N-labeled AaIspH protein was used instead of natural abundance AaIspH (Figure 2B), so 
it does not arise from the 14N hyperfine coupling with the protein backbone.  The feature can be 
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simulated with 14N hyperfine interaction having Aii = [1.85, 1.25, 3.70] MHz, Aiso = 2.33 MHz, e
2qQ/h  = 
0.8 MHz,  = 0.2 (Figure 4.10).  The quadrupole coupling constant is consistent with that expected for an 
alkyl ammonium (23) group (e2qQ/h  = 0-1 MHz) and the hyperfine coupling anisotropy suggests close 
proximity  to the paramagnetic center, consistent again with the “rotated-out” model proposed above. 
We next investigated binding of the thiol ligand 8, to EcIspH.  The IC50 values for 7 and 8 in 
inhibiting EcIspH are very similar and both bind to the oxidized protein, forming Fe-N and Fe-S bonds, 
respectively, with the 4th Fe in the cluster (14).  However, the electronic structure of the complex with 8 
is spin-delocalized while that with 7 is spin-localized, suggesting that there might be significant 
differences in electronic structure between 7 and 8 when bound to reduced IspH. 
The EPR spectrum of AaIspH in the presence of sodium dithionite is shown in Figure 4.11A (in 
blue) and is characteristically broad, as is the case without the substrate. However, essentially no signal 
is seen in the g ~ 2 region (or at lower field, Figure 4.11A inset) for a sample incubated with dithionite in 
the presence of the thiol ligand 8 (Figure 4.11A, in red), unlike the situation with 7.  This suggested to us 
the possibility that in the presence of the thiol ligand, the cluster might not be reduced, that is, it 
remains in the oxidized, S = 0 state. This appears to be the case, as illustrated in the UV-VIS spectra 
shown in Figure 4.11B. The spectrum of oxidized ([Fe4S4]
2+) IspH (blue trace) shows a characteristic peak 
at ~420 nm, which disappears on dithionite reduction (green trace).  The spectrum of oxidized IspH + 8 
(red trace) is similar to that of the oxidized protein in the absence of 8; however, addition of dithionite 
minimally changes the spectrum; the shoulder at ~420 nm is still seen with IspH + 8 + dithionite.  We 
also find that addition of 8 to dithionite-reduced IspH generates the 420 nm shoulder (superimposed on 
the large dithionite background peak), suggesting that reduced IspH + 8 is relatively unstable, consistent 
with the lack of any EPR signal for this system, Figure 4.11A. 
 
Binding of amino, thiol inbhibitors and HMBPP to IspG.  We next investigated the inhibition of 
IspG (GcpE) by 7 and 8.  As can be seen in Figure 4.12, 7 and 8 both inhibit IspG. The IC50 values are in 
the range 0.8-2.5 M (Table 4.2). The EPR spectra of the thiol 8 bound to the (two-domain) bacterial 
IspGs (from E. coli and P. aeruginosa) are shown, together with their spectral simulations and data for 
the three domain Arabidopsis thaliana IspG, in Figures4. 4A-C. All three spectra have very similar gi 
(Table 4.1) and hence, giso (~ 2.03) and ∆g (~ 0.13) values (Figure 4.3), indicating little inter-species 
variability, as well as no differences between the 2- and 3-domain proteins. Very similar results are 
found with 2 (HMBPP, containing an OH group) bound to the same proteins, Figures 4.4D-F, although on 
average the giso and ∆g values found with 2 are slightly smaller, Table 4.1. It might be assumed that both 
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2 and 8 would bind to the unique 4th iron in the same way, via Fe-O or Fe-S bonds. However, it is also 
possible that there are no direct Fe-O or Fe-S bonds arising from these ligands, in reduced IspG. Of 
course, strong EPR signals are seen with e.g. 4Fe-4S ferredoxins, but there, g-values are rather different, 
on average g3 = 1.91, giso = 1.97 and ∆g ( = g1 - g3) ~ 0.15 (22,24), to be compared with the average values 
of g3 ~ 1.98, giso = 2.03 and ∆g ~ 0.12 for 2 and 8 bound to the IspGs, Table 4.1.   
To investigate HMBPP binding in more detail, we synthesized the [1-17O] analog of 2, labeled at 
the terminal (1-CH2OH) group, and obtained a HYSCORE spectrum, Figure 4.5A.  (For more spectra 
acquired at different field positions and  values, see Figure 4.13.) There is no evidence for any 17O 
HYSCORE signal, suggesting that there is no direct Fe-O bond to the ligand, 2. For purposes of 
comparison, the HYSCORE spectrum of the 17O-labeled IspG reactive intermediate “X”, shown in Figure 
4.5B, exhibits an intense signal (data from Wang et al.(10)), proposed earlier to arise from a ferraoxtane 
species (i.e. a species containing an Fe-O bond).  We thus propose that since we see no evidence for any 
17O hyperfine coupling that 2 (HMBPP) binds to the 4Fe-4S cluster by another mechanism, e.g. -
bonding. This would be similar to the mechanism proposed earlier for the isomer of HMBPP (10) binding 
to the EcIspH E126Q mutant (22) in which the g-values are essentially identical (with g1 ~ 2.09; giso ~ 
2.03, ∆g ~ 0.10, Ref. (22)) to those seen with 2 bound to EcIspG (g1 ~ 2.09, giso = 2.03, ∆g ~ 0.12, Table 
4.1).  The strong similarity in the EPR spectra of 2 and 8 bound to IspG would then suggest that the thiol 
ligand binds in a similar manner, consistent with the observation that these spectra are quite unlike 
those of reduced ferredoxins.(24)   
To investigate the interaction between HMBPP carbon atoms and the IspG [4Fe-4S] cluster, we 
obtained HYSCORE spectra of [U-13C], [1-13C], [2-13C], and [3-13C] HMBPPs bound to reduced IspG, Figure 
4.6. There were no large hyperfine couplings observed with the [U-13C] labeled ligand, Figure 4.6A, 
unlike the ~17 MHz hyperfine coupling seen for 1 bound to IspG.(25)  To assign the resonances that 
were observed we next investigated the three selectively 13C-labeled HMBPPs: spectra are shown in 
Figures 4.6B-D.  The results of spectral simulations (Figures 4.13-17) using EasySpin (26,27) yielded the 
hyperfine coupling tensors shown in Table 4.3: [1-13C], Aii = [-0.7, -0.9, 2.2] MHz; [2-
13C], Aii = [0.5, 0.7, 
4.9] MHz; [3-13C], Aii = [3.9, -0.3, -0.1] MHz.  Clearly, all three hyperfine interactions are quite small, 
although those for the 2 and 3-positions (the double bond) are larger than for C-1, consistent again with 
a weak -interaction. 
In sharp contrast to the results with 2 and 8, with the amine ligand 7 binding to EcIspG we find a 
very broad spectrum (Figure 4.18A) that has similar gi, giso and ∆g values to those found with the “un-
liganded” protein (Figure 4.18B, Table 4.1) - in which of course OH, H2O or a protein ligand might be 
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bound to the 4th Fe. We see no evidence for a Fe-N interaction in the HYSCORE spectrum, Figure 4.5C 
(also at 3 other fields, Figure 4.19), plus, we find that the amine ligand 7 displaces HMBPP (2) from 
PaIspG on a tens-of-seconds timescale, as shown in Figures 4.18C and D. Here, the HMBPP signals (red 
arrows, Figure 4.18C) arise from adventitiously bound HMBPP that co-purified with the PaIspG protein.   
What is surprising about the results with IspG is how different they are to those found with IspH, 
given that both proteins have similar 4Fe-4S clusters with unique 4th Fe atoms, and both carry out 
2H+/2e- reductions.  Specifically, with IspH, the amine ligand 7 binds to the reduced protein; the 
resulting EPR spectrum is very similar to that found with the IspH substrate HMBPP (2) bound to an 
E126Q mutant; and there is no 14N  HYSCORE signal – all suggesting -bonding of a “rotated-out” –
CH2NH3
+ species, while with the thiol inhibitor 8, the IspH 4Fe-4S cluster is not reduced, so inhibition is 
due to binding to oxidized protein.  With IspG, the cluster can be reduced in the presence of 2, 7, or 8.  
The EPR spectra of 2 (HMBPP) and 8 (the thiol ligand) bound to IspG are very similar to each other, but 
there is no 17O hyperfine coupling (or it is very small), suggesting no direct Fe-O bonding (or Fe-S 
bonding, with 8).  Plus, there are only weak interactions between the -bond in 2 and the cluster, based 
on the 13C HYSCORE results. With the amine-ligand 7, the EPR spectrum is similar to that seen with 
ligand-free protein (and the Δg, giso values cluster in the “ligand-free region” in Figure 4.3), and there is 
no evidence for Fe-N bonding, in which case it seems likely that water or protein ligands (or both) bind 
to the 4th Fe.  These results are also supported by the observation that spectra of 2 + PaIspG can be seen 
at both 10 and 20 K, Figure 4.20A, but only at 8 K with 7, Figure 4.20B.  That is, the HMBPP-bound 
spectrum is sharp and does not broaden at higher temperatures (as seen with other HiPIP-like spectra), 
while the spectrum of 7 bound to IspG is broad and readily saturates at 20K, as seen in conventional -
complexes. 
Based on computational docking (with AutoDock Vina (28)) we find that the ligand NH2 group 
can interact (in the NH3
+ form) with D87 in IspG, similar to the proposed E126/NH3
+ interaction for IspH 
(based on the X-ray structure of the rotated-out conformer), as illustrated in Figure 4.7A.  To help test 
this hypothesis we used a D87A Thermus thermophilus IspG mutant. With this mutant there is 
essentially no EPR signal observed in the absence of any ligand, Figure 4.21A and only a very weak signal 
in the presence of 7, Figure 4.21B). However, in the presence of HMBPP (2) the spectrum (Figure 4.21C) 
is essentially the same as that seen with the other, wild-type proteins, suggesting that D87 is involved in 
binding of the amino-HMBPP (7), but not HMBPP itself.  With HMBPP and the thiol ligand 8, we 
therefore propose that both bind as weak -complexes to the 4th Fe, as illustrated for 2 in Figure 4.7B. 
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Binding of acetylene inhibitors to IspG.  Finally, we investigated the EPR and ENDOR spectra of 
the two specifically 13C-labeled acetylene inhibitors, 5.  We show the EPR spectra of 5 bound to EcIspG in 
Figure 4.8A and B, as well as the Davies ENDOR spectra of [3-13C]-5 and [4-13C]-5 bound to EcIspG, in 
Figures 4.8C and D. The g-values found (by spectral simulation) for 5 bound to EcIspG are 2.087, 2.012 
and 2.003, leading to giso = 2.034 and ∆g = 0.085, Table 4.1 and Figure 4.3. These values are similar to 
those found with the reactive intermediate “X” bound to both EcIspG as well as T. thermophilus IspG, 
shown in Table 4.1 (g1 ~2.09, g2 ~2.02; g3 = 2.00; giso = 2.04; ∆g ~0.09) and Figure 4.3. In previous work 
(22) we proposed that “X” arose from a [Fe4S4]
3+ S = 1/2 HiPIP-like cluster and, based on these g-values, 
extensive charge transfer to the acetylene 5 due to metal-alkyne π interactions seems likely. 
We also find sizeable 13C hyperfine couplings, and from field dependence and spectral 
simulation results (Figure 4.8, green) we determined the principal components of the two hyperfine 
tensors. For [4-13C]-5 (i.e. labeled at the terminal carbon), we obtain Aii = [5.4, 1.5, 3.8] MHz, and for [3-
13C]-5, we find Aii = [4.5, 3.0, 10] MHz, Figures 4.8C, D.  These tensors indicate close proximity of the 
acetylene group to the reduced 4Fe-4S cluster, facilitating, we propose, a strong -interaction. To obtain 
estimates of the distances involved, we employed the point dipole approximation (29).  Using the largest 
diagonal component of the anisotropic hyperfine tensor together with previously reported spin-
projection coefficients for aconitase (29) leads to Fe-C3 distances in the range 2.0-2.6 Å, and Fe-C4 
distances in the range 2.6-3.2 Å. Since the sum of the Fe and C van der Waals radii is ~ 3.5 Å (30), these 
distances are indicative of Fe-C bonding.  For HMBPP, the Fe-C2 and Fe-C3 distances are in the range 
~2.3-2.9 Å, Table 4.3, again consistent with a weak -interaction.  
 
4.5 Conclusions 
In summary: the results we have presented here are of interest for several reasons. First, we 
find that in addition to inhibiting IspH, both the amine (7) and thiol (8) ligands inhibit IspG, with IC50 
values in the 0.8-2.5 µM range.  Second, we find that the EPR spectra of 7 bound to IspH as well as 2 or 8 
bound to IspG are indicative of -bonding, with the amino/hydroxyl/thiol groups not directly bonded to 
Fe.  The absence of a large 14N hyperfine coupling for 7 bound to reduced IspH as well as the absence of 
a large 17O hyperfine coupling for [1-17O]-2 bound to reduced IspG are consistent with these bonding 
proposals.  Third, we find that the g-values for the acetylene inhibitor 5 bound to IspG suggest a -
interaction between Fe and the alkyne group, (33,34) and the 13C hyperfine tensors for both carbons in 
the acetylene group of 5 in the complex with IspG also indicate Fe-C bonding.  Fourth, the binding of 7 to 
IspG (see Figure 4.20) as well as of 8 to IspH did not result in any -interaction type EPR spectra, and 
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with 8 it appears that the 4Fe-4S cluster in IspH is not reduced by dithionite.  These results show, then, 
an unexpected diversity in spectroscopic behavior – and hence binding modes – for three IspG/IspH 
inhibitors, results that are of interest in the context of anti-infective drug design targeting isoprenoid 
biosynthesis. In particular, the possibility of developing leads that inhibit both IspG as well as IspH is 
likely to be of importance in decreasing resistance, as well as reducing the pro-inflammatory effects of 2 
in acute infections (35) that would be expected to occur with solely IspH inhibition. 
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4.6 Tables and Figures 
Table 4.1 EPR g-values, giso, and ∆g for IspG and IspH. 
Enzyme + Ligand g1 g2 g3 giso
a ∆gb 
AaIspH reduced 2.041 1.919 1.849 1.936 0.191 
AaIspH + 7 2.134 2.006 1.973 2.038 0.161 
EcIspH reduced 2.037 1.924 1.921 1.960 0.116 
EcIspH + 7 2.138 2.005 1.978 2.040 0.160 
PfIspH + 7 2.136 2.008 1.982 2.042 0.154 
EcIspH E126Q + 2 2.132 2.003 1.972 2.036 0.160 
AaIspH E126A + 2 2.124 1.999 1.958 2.027 0.166 
EcIspG + 8 2.100 2.010 1.975 2.028 0.125 
PaIspG + 8 2.105 2.009 1.972 2.029 0.133 
AtIspG + 8 2.096 2.009 1.974 2.026 0.122 
EcIspG + 2 2.091 2.010 1.976 2.026 0.115 
PaIspG + 2 2.097 2.009 1.978 2.027 0.124 
AtIspG + 2 2.077 2.006 1.974 2.019 0.103 
TtIspG D87A + 2  2.098 2.012 1.978 2.029 0.120 
EcIspG  reduced 2.040 1.900 1.900 1.950 0.140 
PaIspG  reduced 2.032 1.901 1.899 1.944 0.133 
EcIspG + 7 2.022 1.875 1.870 1.922 0.152 
PaIspG + 7 2.029 1.892 1.848 1.923 0.182 
EcIspG “X” 2.092 2.018 1.999 2.036 0.093 
TtIspG “X” 2.070 2.019 2.000 2.035 0.087 
AtIspG “X” 2.097 2.019 2.000 2.039 0.097 
EcIspG + 5 2.087 2.012 2.003 2.034 0.085 
 
  a giso = (g1 + g2 + g3) / 3.  
b ∆g = g3 – g1 
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Table 4.2 IC50s for EcIspG, PaIspG, and AtIspG. 
Enzyme + Inhibitor IC50 (M) R
2 
EcIspG + 7 2.5 0.994 
EcIspG + 8 1.4 0.988 
PaIspG + 7 2.4 0.985 
PaIspG + 8 0.80 0.995 
AtIspG + 7 1.7 0.966 
AtIspG + 8 2.0 0.982 
 
 
Table 4.3   Hyperfine tensors determined from ENDOR and HYSCORE simulations of labeled 
substrates, 2 and 5, binding to IspG, and distances estimates. The uncertainties of distance estimates are 
based on an assumed uncertainty of 0.5 MHz for the tensors.   
Nucleus A11 
(MHz) 
A22 
(MHz) 
A33 
(MHz) 
Aiso 
(MHz) 
 (°)  (°)  (°) r (Kmin) (Å) r (Kmax) (Å) 
[1-13C] -2 -0.7 -0.9 2.2 0.2 -30 0 30 2.6 ± 0.4 3.3 ± 0.6 
[2-13C] -2 0.5 0.7 4.9 2.0 36 15 9 2.3 ± 0.3 2.9 ± 0.4 
[3-13C] -2 3.9 -0.3 -0.1 1.2 0 20 0 2.3 ± 0.3 2.9 ± 0.4 
[3-13C] -5 4.5 3.0 10.0 5.8 80 30 60 2.0 ± 0.2 2.6 ± 0.2 
[4-13C] -5 5.4 1.5 3.8 3.6 32 0 0 2.6 ± 0.4 3.2 ± 0.5 
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Figure 4.1 9.05 GHz CW-EPR spectra of IspHs.  (A) 1.3 mM AaIspH (reduced) + 20 eq dithionite, 2 
mW.  (B) 1 mM AaIspH + 40 eq dithionite + 28 eq 7, 2 mW.  (C) 1.1 mM EcIspH + 10 eq 7 + 30 eq DT, 1 
mW.  (D) 0.5 mM PfIspH + 20 eq 7 + 80 eq DT, 2 mW. Spectra acquired at 10-24 K.  
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Figure 4.2 HYSCORE spectra of IspH with nitrogen-containing inhibitors, and a model for the AaIspH + 7 
complex.  (A) AaIspH + 7.  T = 15 K, frequency = 9.706 GHz, magnetic field = 3455 G, sum spectrum of  = 136, 168, 
200, and 256 ns.  (B) 
15
N-labeled AaIspH + 7.  T = 15 K, frequency = 9.712 GHz, magnetic field = 3460 G, sum 
spectrum of  = 136, 168, 200, and 256 ns.   (C) AaIspH + 9 (adapted from Wang et al (12)). T = 8 K, magnetic field = 
3600 G,  = 136 ns.  (D) Model for binding of 7 (protonated, ammonium form) based on the X-ray structure of IspH 
+ 2 (PDB ID 3KE8 and 3SZU, Span et al  (21)). 
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Figure 4.3 Plot of Δg versus giso for IspH and IspG.  Points to the left are proposed to originate from 
proteins in the absence of exogenous ligands bound to the cluster and are all broad; points on the right 
are all from sharp spectra and are proposed to originate from / or HiPIP-like complexes. 
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Figure 4.4 9.05 GHz CW-EPR spectra (black) and spectral simulations (green) of E. coli (A, D), P. 
aeruginosa (B, E), and Arabidopsis thaliana (C, F) IspG in the presence of 8 (A-C) or 2 (D-F).  T = 8K, 
power = 5 mW. 500-600 M IspG + 80 eq. dithionite + 20-40 eq. 8 or 2. 
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Figure 4.5 9.66 GHz HYSCORE spectra of (A) [1-17O]-2 (HMBPP) bound to PaIspG.  T = 10 K, 
magnetic field = 3435 G,  = 136 ns.  (B) HYSCORE of [2,3-17O]-2 epoxide bound (as the ferraoxetane “X”) 
to TtIspG (adapted from Wang et al (10)). T = 18 K, magnetic field = 3420 G,  = 136 ns.  (C) HYSCORE of 7 
bound to PaIspG. T = 8 K, magnetic field = 3660 G, = 136 ns.   
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Figure 4.6 9.7 GHz HYSCORE spectra of 13C labeled 2 bound to PaIspG. (A) [U-13C]-2 + PaIspG. 
Magnetic field = 3315 G,  = 136 ns.  (B) [1-13C]-2 + PaIspG. Magnetic field = 3480 G,  = 136 ns.  (C) [2-
13C]-2 + PaIspG. Magnetic field = 3435 G,  = 136 ns.  (D) [3-13C]-2 + PaIspG. Magnetic field = 3315 G,  = 
136 ns. 1–1.7 mM PaIspG + 40 eq. dithionite + 16–20 eq. 13C labeled 2. T = 10 K. 
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Figure 4.7 Proposed binding of (A) 7 and (B) 2 to IspG (T. thermophilus residue numbering).  The 
nature of L in (A) is unknown. 
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Figure 4.8 9.7 GHz (A) CW-EPR and (B) field-swept-spin echo spectrum of EcIspG + 5, T = 15 K. 
Simulation of spectrum in (A) yields gi = [2.002, 2.012, 2.087]. Microwave frequency = 9.729 GHz for (A) 
and 9.758 for (B).  Arrows indicate the magnetic fields at which the ENDOR spectra in (C) and (D) were 
obtained.  (C) 9.7 GHz 13C Davies ENDOR spectra of EcIspG + [4-13C]-5. The principal components of the 
13C hyperfine coupling tensor are Aii (4-
13C) = [5.4, 1.5, 3.8] MHz. Euler angles are  = 32,  =  = 0.  (D) 
9.7 GHz 13C Davies ENDOR of EcIspG + [3-13C]-5. Aii (3-
13C) = [4.5, 3.0, 10] MHz and Euler angles are  = 
80,  = 30 and  = 60. Simulations are in green. 
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Figure 4.9 Amino-HMBPP (7) + PfIspH HYSCORE spectra.  (A) 3420 G,   = 136 ns. (B) 3420 G,  = 
200 ns.  T = 10 K. 
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Figure 4.10  Experimental and simulated HYSCORE spectra of amino-HMBPP (7) + EcIspH.  Magnetic field 
= 3440 G, frequency = 9.665 GHz with (A)  = 136 ns. (B)  = 172 ns. (C) τ = 208 ns. (D)  = 244 ns.  Aii = 
[1.85, 1.25, 3.70] MHz, α = 0∘, β = 22∘, γ = 20∘, e2qQ/h = 0.8 MHz,  = 0.2. 
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Figure 4.11 9.05 GHz CW-EPR and UV-Vis spectra of AaIspH + 8.  (A) CW-EPR spectra of 1.3 mM 
AaIspH + 20 eq dithionite (blue) and 1.3 mM AaIspH + 20 eq dithionite + 10 eq 8 (red). T = 10K, power = 
2 mW.  Inset: CW-EPR spectra of the same two samples with extended magnetic field range (500 G – 
5500 G).  (B) UV-Vis spectra of AaIspH oxidized (blue); reduced (green); + 8 (cyan); + 8 + dithionite (red). 
0.05mM AaIspH, 50 eq dithionite, 50 eq 8. UV-Vis spectra taken in an aneorobic environment (O2 < 2 
ppm) at 25 °C. 
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Figure 4.12 Enzyme activity inhibition curves for EcIspG (A,B), PaIspG (C,D), and AtIspG (E,F) with 7 
and 8. 
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Figure 4.13 [1-17O]-HMBPP + PaIspG HYSCORE spectra.  (A) 3315 G,  = 136 ns. (B) 3315 G,   = 200 
ns.  (C) 3435 G,  = 136 ns.  (D) 3435 G,  = 200 ns.  (E) 3480 G,  = 136 ns.  (F) 3480 G,  = 200 ns.  T = 10 
K. 
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Figure 4.14 [U-13C]-HMBPP + PaIspG HYSCORE spectra (top) and 13C simulations (below) zoomed in 
to [-10 10 0 10] MHz ([xmin xmax ymin ymax]).  (A) 3315 G,  = 136 ns.  (B) 3435 G,  = 136 ns.  (C) 3480 
G,  = 136 ns. (D) 3315 G,  = 200 ns.  (E) 3435 G,  = 200 ns. (F) 3480 G,  = 200 ns.  T = 10 K.  (3-13C) Aii = 
[3.9, -0.3, -0.1] MHz.  (3-13C) [,  ,] = [0, 20, 0] degrees.  (2-13C) Aii = [0.5, 0.7, 4.9] MHz.  (2-
13C) [, , ] 
= [36, 15, 9] degrees.  (1-13C) Aii = [-0.7, -0.9, 2.2] MHz.    (1-
13C) [, , ] = [-30, 0, 30] degrees. 
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Figure 4.15 [1-13C]-HMBPP + PaIspG HYSCORE spectra (top) and 13C simulations (below) zoomed in 
to [-10 10 0 10] MHz ([xmin xmax ymin ymax]).  (A) 3315 G,   = 136 ns.  (B) 3435 G,   = 136 ns.  (C) 3480 
G,   = 136 ns. (D) 3315 G,   = 200 ns.  (E) 3435 G,   = 200 ns. (F) 3480 G,   = 200 ns.  T = 10K.  Aii = [-0.7, 
-0.9, 2.2] MHz.   = -30.  = 0.  = 30. 
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Figure 4.16 [2-13C]-HMBPP + PaIspG HYSCORE spectra (top) and 13C simulations (below) zoomed in 
to [-10 10 0 10] MHz ([xmin xmax ymin ymax]).  (A) 3315 G,   = 136 ns.  (B) 3435 G,   = 136 ns.  (C) 3480 
G,   = 136 ns. (D) 3315 G,   = 200 ns.  (E) 3435 G,   = 200 ns. (F) 3480 G,   = 200 ns.  T = 10 K.  Aii = [0.5, 
0.7, 4.9] MHz.   = 36.  = 15.  = 9. 
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Figure 4.17 [3-13C]-HMBPP + PaIspG HYSCORE spectra (top) and 13C simulations (below) zoomed in 
to [-10 10 0 10] MHz ([xmin xmax ymin ymax]).  (A) 3315 G,  = 136 ns.  (B) 3435 G,  = 136 ns.  (C) 3480 
G,  = 136 ns. (D) 3315 G,  = 200 ns.  (E) 3435 G,  = 200 ns. (F) 3480 G,  = 200 ns.  T = 10K.  Aii = [3.9, -
0.3, -0.1] MHz.   =  = 0.   = 20. 
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Figure 4.18 9.05 GHz CW-EPR freeze-quench spectra of IspG. (A) 500 M EcIspG + 80 eq dithionite + 
20 eq 7, incubated for 10 minutes. (B) 600 M PaIspG* + 80 eq dithionite with no inhibitor added. (C,D) 
600 M PaIspG + 80 eq dithionite + 20 eq 7, incubated 30 seconds (C) and 600 seconds (D). Red arrows 
indicate signal due to bound 2, displaced later (as seen in D) by 7.  Simulation shown in green. T = 8 K, 
Power = 5 mW. 
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Figure 4.19 PaIspG + 7 HYSCORE spectra.  (A) magnetic field = 3650 G,  = 136 ns, T = 6 K.  (B) pH = 
8.6, magnetic field = 3660 G,  = 140 ns, T = 7 K.  (C) pH = 8.6, magnetic field = 3430 G,  = 140 ns, T = 7 K. 
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Figure 4.20 9.05 GHz CW-EPR temperature dependence spectra of PaIspG with 2 or 7.  (A) 600 M 
PaIspG + 40 eq dithionite + 20 eq 2 at 10 (blue) and 20 K (red), incubated for 10 min.  (B) 600 M PaIspG 
+ 80 eq dithionite + 20 eq 7 at 8 (blue) and 20 K (red), incubated for 10 min.  All spectra acquired at 
power = 5 mW. 
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Figure 4.21 CW-EPR spectra of TtIspG D87A.  Microwave frequency  ~ 9 GHz.  Power = 5-10 mW.  T ~ 
8 K.  (A) (reduced, “-L”) 0.9 mM TtIspG D87A + 40 eq dithionite.  (B) 1 mM TtIspG D87A + 20 eq amino-
HMBPP (7) + 30 eq dithionite.  (C)  0.9 mM TtIspG D87A + 20 eq HMBPP (2) + 30 eq dithionite. 
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Chapter 5 
Inhibitor Synthesis 
 
5.1 Notes and Acknowledgements 
 This chapter was adapted from unpublished work by Francisco Guerra, showing synthesis work 
that ultimately contributed to several publications by the Oldfield lab, such as PNAS 2012, 109, 4058-
4063 and Med. Chem. Lett. 2013, 4, 423-427.  This work was supported by the U.S. Public Health Service 
(NIH Grant GM65307). F.G. and Y. Zhang designed the synthesis route.  Y. Zhang, K. Wang, and K. Chang 
helped F.G. with synthesis guidance.  Experimental procedures were conducted by W. Zhu, W. Wang, 
and J.H. No. 
 
5.2 Introduction 
 Bisphosphonates are major drugs used to treat bone-resorption diseases (1).  Nitrogen 
containing bisphosphonates prevent osteoclast bone resorption by inhibiting the enzyme farnesyl 
diphosphate synthase (FPPS) within osteoclasts.  Bisphosphonates also kill tumor cells (2) and many 
parasitic protozoa (3) and can activate γδ T cells of the immune system (4) to kill tumor cells (5) and 
bacteria.(6)  There is thus interest in their use for immunochemotherapy of cancer (7) and in the 
treatment of parasitic protozoan diseases (8), where less avid bone binding might be advantageous.  In 
earlier work (9), we used ITC to probe how different bisphosphonates bind to bone, via 1 or 2 sites.  We 
found that the 1-OH group is critical for binding to 2 sites on bone, displacing 2 Pi, as has been 
demonstrated in vivo (9,10).  Addition of a bulky phenyl group or a long hydrophobic chain also removed 
binding to the 2nd bone binding site.  Interestingly, the 1-OH group is not required to inhibit FPPS.  The 
active site of FPPS from Trypanosoma brucei (the causative agent of African Trypanosomiasis) and of 
Plasmodium vivax GGPPS (the causative agent of recurrent malaria) can accommodate a longer 
hydrophobic chain in the substrate or inhibitor.  Based on the deoxy-zoledronate compound that only 
binds to the weak bone binding site (9), BPH-703 was synthesized (Figure 5.1).  BPH-703 
characteristically lacks the 1-OH and has a 12 C alkyl chain branching from the imidazolium ring, keeping 
with the idea of designing lipophilic FPPS inhibitors that bind less avidly to bone.  A high through-put 
screen involving erythrocytes infected with Plasmodium falciparum, in collaboration with the Institut 
Pasteur Korea, showed that BPH-703 had an IC50 of 0.69 M whereas zoledronate had an IC50 of 167 M 
(11).  I therefore began on work to create a library of alkylated imidazolium bisphosphonates to 
optimize inhibition of FPPS and cell permeability.   
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 The essential 2-C-methylerythritol 4-phosphate (MEP) or ‘non-mevalonate’ isoprenoid 
biosynthesis pathway is found in certain gram-negative bacteria, protozoa, and plants.  Importantly, the 
MEP pathway is not found in humans, but is essential for survival in human pathogens, such as P. 
falciparum (malaria), Mycobacterium tuberculosis (TB), Neisseria gonorrhoeae (gonorrhea), and 
Pseudomonas aeruginosa (pneumonia).  The last two steps of the MEP pathway are 2H+/2e- reductions 
involving the 4Fe4S cluster containing proteins, IspG and IspH.  Earlier, we discovered that alkynyl 
diphosphates (BPH-1061, Figure 5.1) have potent inhibition against both 3-domain (protozoan /plant) 
and 2-domain (bacterial) IspG enzymes (13,14).  These alkynyl diphosphate inhibitors also had potent 
inhibition against bacterial IspH (13,14).  One concern about diphosphate based inhibitors is their 
stability as the diphosphate can hydrolyze, especially in a physiological environment where 
phosphatases are abundant.  Creating propargyl imidazole is a preliminary stage to creating an alkynyl 
bisphosphonate.  We tested propargyl alcohol with the idea that the alkynyl group would coordinate 
with the free Fe in the 4Fe4S cluster and act as an inhibitor.  However, propargyl alcohol proved to be a 
poor inhibitor.  An addition of imidazole might have a better chance as an inhibitor.  I, therefore, began 
to synthesize propargyl imidazole. 
 
5.3 Experimental 
Chemical Synthesis 
2-(N-hexyl-imidazolium-1-yl)ethylidene-1,1-bisphosphonic acid.   
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Scheme 1.  a) K2CO3, Ac, 70 C, reflux, overnight;  b)  TMSBr, CH2Cl2, r.t., overnight;  c) H2O, r.t., 20 min.;  
d) H2O, reflux, overnight. 
 
A mixture of imidazole (100 mmol), hexyl bromide (100 mmol) and K2CO3 (200 mmol) in acetone 
(200 mL) was refluxed overnight. Upon filtration and removal of solvent, the residue was subjected 
to flash chromatography with ethyl acetate as eluant to give N-hexylimidazole with 90 % yield. 
 
To a solution of ethene-1,1-diyldiphosphonic acid (1 mmol) in H2O (5 mL) was added an N-
hexylimidazole (1 mmol), and the solution refluxed overnight with stirring. Upon removal of solvent, 
recrystallization was carried out from H2O/i-PrOH (1/10) to give the products as white powders.  
 
1H NMR (500 MHz, D2O) δ 8.65 (s, 1H), 7.40 (s, 1H), 7.28 (s, 1H), 4.46 (td, J = 13.7, 7.1 Hz, 2H), 4.02 (t, J = 
7.1 Hz, 2H), 2.49 (tt, J = 22.0, 7.0 Hz, 1H), 1.74 – 1.66 (m, 2H), 1.15 – 1.07 (m, 6H), 0.71 – 0.65 (m, 3H). 
31P NMR (202 MHz, D2O) δ: 15.77. Anal. Calcd. for C11H22N2O6P22.6H2O:  C, 34.13; H, 7.08; N, 7.24. 
Found: C, 34.10; H, 6.11; N, 6.59. 
 
Propargyl-imidazole.   
 
 
 
Scheme 2.  a)  K2CO3, Ac, 70 C, reflux, overnight. 
 
A mixture of imidazole (100 mmol), propargyl bromide (100 mmol) and K2CO3 (200 mmol) in 
acetone (200 mL) was refluxed overnight. Upon filtration and removal of solvent, the residue was 
subjected to flash chromatography with ethyl acetate as eluant to give Propargyl-imidazole with 90 
% yield. 
 
1H NMR (500 MHz, CDCl3) δ 7.59 (s, 2H), 7.11 – 7.06 (m, 2H), 7.03 (d, J = 1.3 Hz, 2H), 4.73 (d, J = 2.6 Hz, 
4H), 1.91 (s, 1H). Anal. Calcd. for C6H6N20.4H2O:  C, 63.59; H, 6.05; N, 24.72. Found: C, 63.96; H, 6.05; N, 
23.72. 
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Toxoplasma brucei FPPS and P. vivax GGPPS enzyme inhibition assays.  The Toxoplasma brucei FPPS 
and P. vivax GGPPS inhibition assays were spectrophotometric phosphate release assays measured at 
355 nm (15).  Using a 200 L reaction mixture (reaction buffer 50 mM Tris-HCl (pH 7.4), 1 mM MgCl2, 
and 0.01 % Triton X100) in 96 well plates, the condensation of geranyl diphosphate (100 M final) and 
isopentenyl diphosphate (100 M final) was monitored at room temperature.  The FPPS enzymes were 
pre-incubated with the compounds for 30 min (room temp.) to ensure inhibitor binding occurred before 
substrates were added.  IC50 values were calculated from dose-response curve fits with Prism 4.0 
(GraphPad Software, Inc., La Jolla, CA, www.graphpad.com). 
 
Aquifex aeolicus IspH inhibition assays.  Inhibition assays were all carried out as described previously 
(13).  All assays were carried out in a Coy vinyl anaerobic chamber (Coy Laboratories, Grass Lake, MI) 
with an oxygen level < 2 ppm, and all buffers were degassed by using a Schlenk line.  Various 
concentrations of inhibitor were added to IspH holo-enzyme with methyl viologen (MV) and sodium 
dithionite (DT) (5:1 MV:DT), and then incubated for 10 min.  Initial reaction velocities were measured at 
732 nm immediately following the addition of 7 M HMBPP to the pre-incubated protein solutions.   
 
DH5 E. coli cell growth inhibition assay.  Cell growth inhibition of DH5 E. coli was monitored using a 
MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) cell proliferation assay (ATCC.  
Manassas, VA.  www.atcc.org).  The yellow tetrazolium MTT is reduced by NAD(P)H-dependent 
oxidoreductases to a purple formazan product in actively proliferating cells.  100 L cells are plated in a 
96 well plate with compound for 6-24 hrs.  10 L MTT reagent is added to each well and incubated for 2-
4 hrs until purple formazan is visualized.  100 L detergent is added to each well and incubated (in the 
dark) for 2-4 hrs.  Absorbance is recorded at 570 nm. 
 
5.4 Results and Discussion 
 To determine how a more lipophilic analog of deoxy-zoledronate would inhibit FPPS/GGPPS 
enzymes, 2 enzyme inhibition assays were conducted with T. brucei FPPS and P. vivax GGPPS.  Against 
both T. brucei FPPS and P. vivax GGPPS enzymes, the 2-(N-hexyl-imidazolium-1-yl)ethylidene-1,1-
bisphosphonic acid compound (BPH-1110; BPH-1216 is the same compound as BPH-1110 resynthesized 
by Y. Zhang) exhibited submicromolar inhibition, Tables 5.1 and 5.2.  Eliminating the 1-OH and making 
the deoxy-zoledronate compound more lipophilic will decrease the bisphosphonates affinity for binding 
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to bone.  Computational (SLogP based) bone binding model calculations show zoledronate has a 83.22% 
bone binding value while BPH-1110 has 53.24% bone binding value.  This SLogP based bone binding 
prediction fits previously determined thermodynamic binding properties for zoledronate vs. deoxy-
zoledronate where the deoxy-zoledronate compound only binds to 1 site in bone vs. zoledronate 
binding to 2 sites in bone.  Increasing the lipophilicity of deoxy-zoledronate by adding an alkyl chain will 
not only further decrease the compounds affinity for bone, but also increase the compound’s cell 
permeability (lipophilicity).  A cell growth inhibition assay with DH5 E. coli confirmed that BPH-1110 
has a 16.0 M IC50 while zoledronate has no inhibitory effect. 
 In pursuit of alkynyl based inhibitors of the MEP pathway enzyme, IspH, propargyl imidazole was 
synthesized.  Propargyl imidazole, like propargyl alcohol, had no in vitro inhibition against AaIspH.  
Subsequent assays with PPi (pyrophosphate) against Pseudomonas aeruginosa IspG (another 4Fe4S 
cluster containing enzyme in the MEP pathway) showed that pyrophosphate alone has a ~25 M IC50.  
Propargyl alcohol likewise with PaIspG had no inhibition.  This suggests that the combination of the 
alkynyl group and the diphosphate group are essential to produce potent inhibition of IspG and IspH.   
 
5.5 Conclusions 
 The results presented are very promising as they indicate alkylated imidazolium 
bisphosphonates could be potential new drugs to treat both malaria and trypanosomiasis.  Based on 
previous work assessing the thermodynamic bone binding properties of a small library of 
bisphosphonates, BPH-703 was synthesized.  The subtraction of the 1-OH and the addition of a 
hydrophobic chain to zoledronate indeed did prove to be more cell permeable and effective as an 
inhibitor in cell based assays.  This preliminary work was subsequently followed by several publications 
from the Oldfield lab, PNAS 2012, 109, 4058-4063 and Med. Chem. Lett. 2013, 4, 423-427.  In addition to 
blocking FPP/GGPP synthesis, BPH-1216 (BPH-1110) causes an increase in IPP which has a nanomolar 
stimulatory effect for human -T cells which are able to aid in the fight against pathogens, as well as 
certain cancers (12).  The propargyl imidazole synthesis and in vitro IspH enzyme assay, in combination 
with other enzyme assays against IspG, has shown that inhibitors against IspG and IspH may need to 
include pharmacophores that both coordinate the 4Fe4S cluster and to the site where the disphosphate 
binds.  This work was unpublished, but served as important contributions to the entire lab’s work. 
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5.6 Tables and Figures 
 
Table 5.1  BPH-1110 inhibition test results. 
Assay IC50 (M) 
DH5 E. coli cell growth inhibition assay 16.0 
T. brucei FPPS enzyme inhibition assay 0.081 
 
Table 5.2  BPH-1216 (BPH-1110 resynthesized by Y. Zhang) inhibition results. 
Assay IC50 (M) 
P. vivax GGPPS enzyme inhibition assay 0.48 
 
Table 5.3  Propargyl imidazole inhibition test results. 
Assay IC50 (M) 
A. aquifex IspH > 200 
 
  
 137 
 
Figure 5.1  Compound structures. 
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Chapter 6 
A Combination Therapy for Kras-Driven Lung Adenocarcinomas Using 
Lipophilic Bisphosphonates and Rapamycin 
 
6.1 Notes and Acknowledgements 
 This chapter was adapted from a paper recently accepted for publication in Science 
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Diseases or the National Institutes of Health.  Y.X. and Y.Z. designed, and Y.X. performed the 
experiments with the help of Y.Z., Y.L., Y.Xie, W.Z., F.G. X.Z. (compound synthesis, enzymatic assay, 
crystallization analysis, pharmacokinetics test and cell survival assay), S.S. (animal works), N.Y. 
(quantitative RT-PCR), and W.F. (mass-spec). I.M.V., E.O. and Y.Z. supervised the project. Y.X., E.O. and 
I.M.V. wrote the paper. 
 
6.2 Introduction 
 Lung adenocarcinomas account for about 50% of all non-small cell lung cancers (NSCLC), the 
most common type of human malignancy and a leading cause of cancer related mortality worldwide. 
There has been rapid progress in developing targeted therapies for lung adenocarcinomas over the last 
decade, including gefitinib and erlotinib, which target EGF receptor mutations (1,2) and crizotinib, which 
targets the transforming EML4-ALK fusion gene (3). However, Kras mutations, which are commonly 
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found in smokers, are not efficiently targeted by currently available therapeutics and have lower survival 
rates, as well as frequent drug resistance (4). Kras mutations at amino acid positions 12, 13 or 61 are 
widely found in human cancers, including pancreatic, thyroid, lung and colorectal cancers (5). They 
typically impair GTPase activity and lead to constitutive activation of downstream signaling pathways. 
This unique property makes it difficult to develop potent Kras mutant-specific inhibitors that can directly 
restore intrinsic GTPase activity, although specific inhibitors of KrasG12C have been recently reported 
(6), as have attempts to interfere with mutated Kras function by altering its membrane localization; 
inhibiting its downstream effectors, as well as searching for synthetic lethality (7,8). 
Farnesylation and correct membrane localization are essential for the in vivo biological activity 
of Ras proteins (9,10). CAAX peptido-mimetics; farnesyltransferase and geranylgeranyltransferase 
inhibitors (FTI/GGTIs); farnesylthiosalicylic acid (Salirasib) – which mimics farnesylcysteine, and small 
molecule inhibitors of Kras-PDE interactions have all been developed to circumvent Kras post-
translational modification and membrane anchoring (7,11-13). Knockout mouse models support the 
notion that disruption of protein prenylation severely impairs lung cancer development induced by Kras 
mutations (14,15).  However, there has been little success achieved in clinical trials with these small 
molecule inhibitors, probably due to the existence of “cross-prenylation” (16), in which a FTI can fail due 
to alternative Kras geranylgeranylation, suggesting the need for combination therapies. In addition to 
the protein-prenyltransferase inhibitors, there is interest in the development of compounds, like 
bisphosphonates (see Fig. 6.5), that directly inhibit the biosynthesis of the two prenyldiphosphate 
substrates: farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), catalyzed by the 
respective synthases, FPP synthase (FPPS) and GGPP synthase (GGPPS). Bisphosphonates are used to 
treat a variety of bone resorption diseases and function by blocking FPPS activity in osteoclasts. In 
previous work, we developed “lipophilic” bisphosphonates in which hydrophobic side-chains were 
added to a pyridinium bisphosphonate. These compounds do not bind to bone mineral, but maintain 
inhibitory activity against both FPPS as well as GGPPS (17), both of which can provide membrane 
anchoring 15 and 20-carbon isoprenoid chains for Kras post-translational modification.  
Impaired protein processing, folding and trafficking usually induce ER stress and autophagy if 
the protective unfolded protein response (UPR) is not sufficient to clear the incorrectly processed 
proteins (18).  And indeed, inhibitors of FPP and GGPP biosynthesis such as bisphosphonates and statins 
have been reported to initiate autophagy in cells (19,20). The role of autophagy in tumorigenesis has 
been considered as a “double-edged sword”, since it can either inhibit tumor initiation at an early stage 
or get adopted by tumor cells as survival mechanisms at an advanced stage (21). In this work, we sought 
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a combination therapy that would ultimately stop Kras prenylation and temporally modulate autophagy 
as an effective two-pronged approach against lung adenocarcinomas. 
 
6.3 Experimental 
 
Chemical reagents.  Lipophilic bisphosphonates were synthesized as described before (17,44). Protein 
farnesyltransferase and geranylgeranyltransferase inhibitors (FTI-276 and GGTI-298) were purchased 
from Calbiochem. MEK inhibitor U0126 was purchased from Cell Signaling. Farnesol (FOH) and 
geranylgeraniol (GGOH), ascorbic acid, Trolox, Lipoic acid and chloroquine diphosphate salt were 
purchased from Sigma. Simvastatin was purchased from Tokyo Chemical Industry Co. Rapamycin was 
purchased from Alfa Aesar. 
 
Stable cell lines and cell survival assay.  Mouse lung cancer cell lines (6#, L2 and M3L2) were derived 
from primary tumors of LSL-KrasG12D/+ mice infected with CA2Cre-shp53 lentiviral vector (36). L2 and 
M3L2 cells were derived from mouse tumors with pure C57B and pure FVB background respectively, so 
that they form syngeneic grafts in matched recipient mice. To monitor NF-B activation in tumor grafts, 
L2 cells were stably infected with 5xκB-luci lentiviral vector. Human lung cancer cell lines (A549, A427) 
were purchased from ATCC. MEFs were prepared from mouse embryo with matched genetic 
background and immortalized by shRNAs against p53 and Rb1. Cell survival after drug treatment was 
measured using Cell Proliferation Reagent (Wst-1) from Roche or MTT Cell Proliferation Assay Kit (30-
1010K) from ATCC. Dose-response curves and corresponding IC50s were fitted using GraphPad Prism. 
 
Lentiviral vector mediated mouse lung cancer model and syngeneic graft model.  LSL-KrasG12D/+ 
Rosa26luc/luc mice were used for the lentiviral vector (CA2Cre-shp53) mediated lung cancer model as 
described before (36). Tumor size was monitored by in vivo luciferase imaging system (IVIS 100) from 
Caliper Lifesciences. Syngeneic graft experiments were done by either subcutaneously transplanting 106 
L2 tumor cells in the flank region of C57B mice, or tail vein injection of 2x105 M3L2 cells into FVB mice. 
Subcutaneous tumor size was measured every 7 days after the transplantation. For single drug 
treatment, animals were given the drug every day. For combination therapies, animals were given BPH-
1222 on days 1, 3, 5 and the other drug on days 2, 4, 6, alternately. BPH-1222 and chloroquine were 
diluted in PBS while rapamycin in 75% DMSO and 25% PBS. All drugs were given i.p. in a volume of 100 
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μl. All mice studies were carried out according to the protocols that were approved by the Institutional 
Animal Care and Use Committee of Salk Institute. 
 
Cellular fractionation.  106 Cells treated with drugs for 48 h were washed with PBS and resuspended in 
0.5 ml 0.1M TrisHCl (pH 7.5) with protease inhibitors for 15 min. Supernatant from 10,000 g 30 min 
centrifugation was collected as cytosolic fraction. The pellet was resuspended in 0.5 ml lysis buffer 
containing 1% Triton X-100 for 20 min and centrifuged. The supernatant was collected as membrane-
bound fraction. 
 
Histology, immunofluorescence staining, and immunoblotting analysis.  Mouse lung tumor and 
syngeneic graft samples were fixed with 10% formalin, paraffin-embedded and sectioned for 
haematoxylin and eosin staining (H&E) and immunofluorescence staining. Elite ABC system (Vector labs) 
was applied where staining signal was weak. Immunoblotting analysis was performed according to 
standard protocol. Antibodies were purchased from Millipore (SPC, 1:2000), Cell Signaling (phos-Erk, 
total Erk, phos-Akt, total Akt, phos-MEK, phos-c-Raf, Cleaved Caspase 3, CHOP, BiP, phos-PERK, LC3I/II, 
phos-p70 S6K, phos-4E-BP1, all 1:1000), Abgent (p62, clone 2C11, 1:2000), Vector 21 Labs (Ki-67, 1:500), 
and Santa Cruz Biotechnology (Kras, Hras, Rap1A, HDJ2, Actin, all 1:1000). 
 
Quantitative RT-PCR.  Total RNA isolated from the treated cells was reverse transcribed using 
Superscript III system (Invitrogen) with random primers. Quantitative PCR was performed in triplicate 
using 7900HT Fast Real-Time PCR system with SYBR green method (Applied Biosystems). Results were 
analyzed for the relative expression of mRNAs normalized against GAPDH and cyclophilin. A list of 
primers used for PCR is in Table 6.3. 
 
Kras MALDI-mass spectrum analysis.  Purified protein samples were spotted onto a MALDI target using 
sinapinic acid as the matrix. Spectra (averages of 200 laser shots) were obtained on an Applied 
Biosystems Voyager DE-STR instrument in linear mode with delayed extraction. The accelerating voltage 
was set to 25,000V and the laser repletion rate was 20 Hz. Masses were corrected using human Activin-
A (MH+ave = 25934.8) as an external standard. 
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FPPS and GGPPS inhibition assay and crystallization of FPPS with BPH-1222.  Human FPPS and GGPPS 
proteins were prepared and used for enzymatic inhibition assay as described before (17). Crystallization 
of FPPS with BPH-1222 was carried out as reported (44). Diffraction data was collected at the Life 
Sciences Collaborative Access Team (LS-CAT) beamline 21ID-Gat Argonne National Laboratory. Data was 
collected at 100K with wavelength of 0.97857Å. Data was processed using HKL3000 and refined by using 
CCP4 and Coot (45-47). Crystallographic figures were drawn by using PyMOL (http://www.pymol.org). 
Data collection and refinement statistics are shown in Table 6.2. After refinement, the Ramachandran 
statistics showed that the percentages of the most favorable and additional allowed regions are 97.6% 
and 2.4%, respectively. 
 
Pharmacokinetics test.  Pharmacokinetic studies were performed using 3 female SD rats (230-240 g 
body weight). Plasma concentrations were measured at 1min, 5 min, 15min, 30min, 1h, 2h, 4h, 8h, 24h, 
and 48h following a single i.v. injection of BPH-1222 at 5 mg/kg. 0.3 ml blood was taken each time. Data 
were analyzed using DAS2.0 software. 
 
Statistics.  Statistical significance of the differences of tumor number and Ki-67 positive staining was 
evaluated using Student’s unpaired two-tailed t-test. The Kaplan-Meier curves were analyzed by Log-
rank test. 
 
6.4 Results and Discussion 
 
Bisphosphonates inhibit FPPS and GGPPS activity 
We tested a library of 30 synthetic analogs of zoledronate for growth inhibition of two Kras 
mutant cell lines (6#, L2) and of control mouse embryonic fibroblasts (MEF). We found most anti-growth 
activity with BPH-1222, a zoledronate analog having a C8 sidechain and a 1-OH group (~1 μM IC50, Fig. 
6.1a and Fig. 6.2a,b). Compounds with very short or very long chains inhibited growth the least while 
BPH-1222 and other intermediate chain length compounds had the most activity. In vitro inhibitory 
activities against human FPPS (Ki as low as ~1nM) correlated well with activities in inhibiting cell growth, 
suggesting FPPS as one possible in vivo target (Fig. 6.1b and Table 6.1 and Fig. 6.6c). To uncover how 
BPH-1222 binds and inhibits FPPS, we determined thestructure of the BPH-1222-FPPS complex using 
single crystal X-ray crystallography. As shown in Figure 6.1c, the bisphosphonate, head-group and 
imidazolium ring bind to human FPPS in essentially the same manner as does zoledronate (shown 
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superimposed) with a 0.45 Å rmsd for the common atoms (see Table 6.2 for a summary of structural and 
refinement statistics). 
Moreover, the lipophilic bisphosphonates also inhibit human GGPPS (Fig. 6.1b and Fig. 6.6c and 
Table 6.1). Zoledronate, as well as other bisphosphonates such as risedronate and alendronate, all 
inhibit FPPS, but do not inhibit GGPPS, since the latter lacks the third Asp required for [Mg2+] 
coordination to the bisphosphonate (22). With the lipophilic bisphosphonates binding to GGPPS, the loss 
of the additional binding interaction due to the absence of the third Asp residue is likely made up for, by 
increased van der Waals interactions in the hydrophobic tunnel that normally houses the allylic side-
chains of the growing isoprenoid diphosphate products. The intermediate chain length species process 
the best inhibitory activity for GGPPS, a Ki of ~300 nM for BPH-1222. There is little difference in GGPPS 
enzyme inhibition activity between the 1-hydroxy and 1-desoxy species (Table 6.1), so in this work we 
focused on BPH-1222, the N-octyl analog of zoledronate, over its desoxy analog in order to eliminate the 
possibility of a retro-Michael reaction in vivo. 
As can be seen in Table 6.1, the Kis for FPPS inhibition by zoledronate and BPH-1222 are quite 
similar (~1 nM), but the IC50 values for cell growth inhibition are ~10-20x lower with BPH-1222. This 
likely correlates with the decrease in GGPPS Ki values (>3 μM for zoledronate; 300 nM for BPH-1222) 
and with the higher clogP value for BPH-1222 (0.25) versus zoledronate (-3.9). 
Inhibition of protein farnesylation alone in cells (with FTI -276) had no effect on cell 
proliferation, while inhibition of geranylgeranylation (with GGTI-298) had a minor effect. However, there 
was massive cell death within 3 days with BPH-1222. Supplementation with geranylgeraniol (GGOH, but 
not farnesol, FOH, or anti-oxidants) substantially rescued cells from bisphosphonate-induced cell death 
(Fig. 6.1d). Similar rescue effects are seen with zoledronate (23) as well as the lipophilic pyridinium 
bisphosphonate BPH-714 (17) and with simvastatin, a potent HMG-CoA reductase inhibitor that shuts 
down all isoprenoid biosynthesis (Fig. 6.6e). As noted by Goffinet et al.(23), the chemical target for 
zoledronate is FPPS (not GGPPS), but the main “biological effect” of zoledronate involves protein 
geranylgeranylation. So, dual FPPS/GGPPS-targeting bisphosphonates (such as BPH-1222) are expected 
to be particularly potent since formation of the FPP substrate for GGPP biosynthesis is blocked by FPPS 
inhibition, with GGPP production being particularly important in cell survival. While inhibition of FPPS is 
expected to have effects on diverse metabolic pathways (such as sterol and steroid biosynthesis), these 
effects cannot be major ones responsible for cell death since the effects of BPH-1222 are reversible on 
GGOH addition. 
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We found that BPH-1222 was more toxic to cells harboring Kras mutations, such as cell lines 
derived from a mouse model of Kras-induced lung adenocarcinoma, as well as in mouse embryonic 
fibroblasts transformed by Kras in vitro (Fig. 6.1e,f). Taken together, these results suggest that blocking 
protein prenylation by lipophilic bisphosphonates can be used as a targeted therapy for cancer cells that 
carry Kras mutations, since potentially both FPPS as well as GGPPS can be targeted; the lipophilic 
bisphosphonates have much better clogP values than do more conventional bisphosphonates; and they 
do not bind avidly to bone mineral, which rapidly removes them from the circulatory system (24). 
 
Bisphosphonates block Kras prenylation and induces its degradation 
“Kras addiction” has been shown in a mouse lung cancer model using inducible KrasG12D (25), 
so given the observation that cells bearing Kras mutations were more sensitive to bisphosphonate 
treatment, we were interested in determining if the lipophilic bisphosphonates blocked Kras 
prenylation. We used a cell fractionation assay to check Kras protein prenylation status, since 
unprenylated Kras proteins lose their ability to avidly associate with cell membranes and, consequently, 
appear in the cytosolic fraction (26). BPH-1222 treatment robustly inhibited protein farnesylation as well 
as protein geranylgeranylation, as indicated by Hras degradation and Rap1A dislodgement from the 
membrane fraction respectively (27). Other bisphosphonates, including BPH-714 and zoledronate, 
showed similar effects, but at higher concentrations (Fig. 6.2a). As expected, a substantial amount of 
Kras was unprenylated and was also partially degraded. There was also a reduction of downstream Akt 
activity, elevated by oncogenic Kras expression (Fig. 6.2a). To further verify whether cytosolic Kras 
represents the unprenylated form of the protein, we determined the molecular weight of Kras 
expressed in U2OS cells with BPH-714 treatment (cytosolic fraction), and from untreated cells (whole 
cell lysate) by using mass spectrometry. The results showed that the molecular weights of Kras from 
untreated and treated cells were 22,872.0 and 22,995.3 Daltons, respectively, which fits (with 
experimental error) the calculated molecular weights for farnesylated and un-farnesylated Kras proteins 
(22,877.9 and 22,990.3, Fig. 6.2b, see Fig. 6.7a for calculation).  The effects of a lipophilic 
bisphosphonate on Kras function was further tested in a mouse lung cancer cell line carrying an 
endogenous G12D mutation. BPH-714 treatment significantly reduced the amount of GTP-bound Kras 
(representing the active form of the Kras protein), and led to down-regulation of the Akt pathway as 
well as the activation of massive apoptosis as shown by increase in Caspase 3 cleavage (Fig. 6.2c).  
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Bisphosphonates enhance ER stress and initiate autophagy  
Cancer cells usually exhibit “stress phenotype” that consists of replicative stress, mitotic stress, 
metabolic stress, oxidative stress and proteotoxic or ER (endoplasmic reticulum) stress. They are, 
therefore, vulnerable to further enhancement of these stresses by chemotherapy (28). 
Bisphosphonates, as demonstrated above, potently block protein prenylation by eliminating the source 
of isoprenoid chains and lead to the accumulation of incorrectly folded proteins, inducing the so-called 
Unfolded Protein Response (UPR), or ER stress, as is also observed when cells are treated with HMG-CoA 
reductase inhibitors (29,30). As shown in Figure 6.2d, treatment of cells with the lipophilic 
bisphosphonate BPH-1222 significantly induced CHOP and BiP protein levels, the two main markers for 
the ER stress response (18). Notably, the ER stress response induced by this bisphosphonate is 
specifically due to blockade of protein prenylation, since supplementation with GGOH, but not 
antioxidants, completely abolished the upregulation of CHOP, BiP as well as phospho-PERK induced by 
the bisphosphonate (Fig. 3.7b). When cells are unable to handle excessive ER stress, they activate 
autophagy to eliminate incorrectly processed proteins as a defense mechanism for cell survival. In tumor 
cells treated with BPH-1222, significant autophagy was induced within 2-3 days, as indicated by the 
accumulation of the phosphatidylethanolamine (PE)-conjugated form of LC3 (Fig. 6.2a,d). Similar results 
have been observed in cells treated with other bisphosphonates and it has been proposed that the 
combination of inhibitors of autophagy with GGPPS inhibitors might be a therapeutic strategy, since as 
noted above, autophagy is a defense mechanism (19). 
 
Rapamycin, but not chloroquine, sensitizes tumor cells to bisphosphonates in vivo 
Recent reports have indicated that Kras-driven tumor cells depend on autophagy to help reduce 
reactive oxygen species (ROS), as well as provide substrates to fuel cell metabolism (31,32). We 
therefore tested the hypothesis that blocking autophagy might sensitize tumor cells to bisphosphonate 
treatment. We first determined the effects on cell survival of treatment with a bisphosphonate and an 
autophagy inhibitor, chloroquine (33). Essentially additive (non-synergistic) effects of the 
bisphosphonate and chloroquine were observed in all the lung cancer cell lines derived from the mouse 
Kras lung cancer model (with KrasG12D and p53 knockdown), as well as in human NSCLC cell lines with 
Kras mutations (A549 and A427) (Fig. 6.3a). 
We next tested this combination in a syngeneic graft model using L2 cells derived from a mouse 
lung adenocarcinoma (with KrasG12D and p53 knockdown) developed in C57B mice. Treatment was 
started 3 weeks after subcutaneous transplantation when the tumor mass was palpable. To our surprise, 
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24 days of BPH-1222 plus chloroquine therapy minimally suppressed tumor growth in animals. In 
contrast, BPH-1222 plus rapamycin (a potent autophagy inducer) showed substantially better efficacy 
(Fig. 6.3b). Our results are more in line with those recently reported in pancreatic cancer (KrasG12D and 
p53-/-) development in which it was shown that another autophagy inhibitor, hydroxychloroquine, 
failed to accelerate tumor formation (34). We noticed that tumors treated with BPH-1222 plus 
chloroquine had significantly elevated NF-B activity as shown by in vivo imaging (Fig. 6.3c).This result 
was further confirmed in cultured cells treated with combination of drugs by quantitative RT-PCR of NF-
κB target genes (Fig.6.3d). The NF-κB activity was correlated with p62 protein accumulation in the cells, 
probably due to the blockage of autophagy flux by chloroquine (Fig. 6.8b). Indeed, high p62 protein level 
in cells can activate NF-B through TRAF6-TBK1 pathway (35). We have reported earlier that high NF-B 
activity in tumors may stimulate cell proliferation (36), and this appeared to be the case in tumor 
samples treated with BPH-1222 plus chloroquine (Fig. 6.7e), although these tumors also showed 
increased number of apoptotic cells (Fig. 6.3f). We suggest that the elevated NF-B activity and cell 
proliferation impaired the efficacy of bisphosphonate to reduce the size of tumors (Fig.6.3b). 
The results obtained in Figure 6.3b and e suggested that a combination therapy using a lipophilic 
bisphosphonate together with the autophagy inducer rapamycin might be more effective in treating 
Kras induced lung adenocarcinomas. In the L2 cell syngeneic graft model, the combination of a BPH-
1222 and rapamycin was indeed more effective than either single agent acting alone (Fig. 6.3g). 
Additionally, rapamycin also potently blocked phosphorylation of the two mTOR substrates (p70 S6 
kinase and 4E-BP1) which are important for boosting metabolism in cancer cells (Fig. 6.3h). 
 
Combination therapy using a bisphosphonate and rapamycin 
We next tested the BPH-1222 plus rapamycin combination in treating lung adenocarcinoma in 
both syngeneic orthotropic graft model and lentiviral vector-mediated model, which better represent 
the lung microenvironment. In the orthotropic model, tail veil injection of 2x105 M3L2 cells reproducibly 
generated massive lung tumors in FVB mice with a median survival of 33 days. For the treatment group, 
all mice (n=13) were given BPH-1222 and rapamycin alternately, for a total of 9 doses of each 
compound. The treatment potently suppressed tumor growth, though mice survival was not significantly 
prolonged (37 d, n = 13, compared to 33.5 d, n= 8 in control group, p= 0.06) due to internal bleeding in 
the thoracic cavity even with small tumor burdens (Fig. 6.4a,b,c). 
In the lentiviral vector-mediated model, as we reported previously, lung tumors appeared 
“visible” in the luciferase imaging system at around two months after lentiviral vector infection. The 
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tumors grew rapidly and all mice (n=8) died from full-blown lung cancer with a median survival of 55 
days from when the tumors were first detected by imaging. A combination therapy of BPH-1222 and 
rapamycin was given to 12 mice, for a total of 16 doses of each compound. We monitored the tumor 
load of each mouse every 9-10 days throughout the whole treatment. The 12 mice were divided into 
two groups according to their tumor load at the beginning of treatment—a high burden group (n=6, 
initial luciferase signal >105) and a low burden group (n=6, initial luciferase signal 103-105). The 
combination treatment substantially delayed tumor development and prolonged mice survival in both 
the low burden group (median survival of 75.5 days, compared to 55 days without treatment, p=0.0009), 
and the high burden group (median survival of 54 days, compared to 28 days without treatment, p=0.02, 
Fig. 6.4f). Tumor regression was observed in most of the mice during treatment, although tumor size did 
increase after treatment ceased (Fig. 6.4d,e and Fig. 6.9b,c). Tumors from treated mice showed a 
significant reduction in cell proliferation as indicated by Ki-67 staining, although apoptotic cells were 
rarely found (Fig. 6.4g). Unlike the results we reported previously with an IKK2 inhibitor that suppressed 
tumor progression by reducing Erk signaling (36), there was no significant change of Erk phosphorylation 
after the bisphosphonate plus rapamycin treatment, in vivo (Fig. 6.4g). Notably, BPH-1222 (either alone 
or combined with other agents) even slightly increased Erk phosphorylation in cell culture conditions 
(Fig. 6.7c), although its mechanism of action here is unknown. Nevertheless, we tested if a combination 
with an Erk inhibitor might further improve treatment efficacy. However, Erk inhibitor U0126 increased 
Kras protein, c-Raf, MEK and Akt phosphorylation levels under all conditions tested (Fig. 6.7d), perhaps 
due to the interruption of the Erk negative feedback loop (37). 
 
6.5 Conclusions 
Ras mutations (including Hras, Kras and Nras) are commonly found in a variety of human 
cancers including lung, colon and pancreatic cancers (5).  In this study, we investigated the efficacy of 
treating lung adenocarcinomas carrying a Kras mutation with a combination of a lipophilic 
bisphosphonate, an analog of zoledronate, with rapamycin. Bisphosphonates are a class of drugs widely 
used for treating osteoporosis and for preventing bone metastasis of certain cancers (38). 
Mechanistically, they avidly bind to bone mineral and inhibit FPPS in osteoclasts. This results in impaired 
protein prenylation and function, inducing cell death of osteoclasts. However, this strong binding to 
bone mineral (24) – a desirable feature for a drug to treat bone resorption diseases – makes them less 
suited to treat solid tumors. Lipophilic bisphosphonates, on the other hand, do not bind to bone mineral 
and, in addition to inhibiting FPPS, they also target GGPPS. Compared with the most potent commercial 
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bisphosphonate drug, zoledronate, the lipophilic bisphosphonate BPH-1222 is more efficient in killing 
tumor cells with Kras mutations both in vitro and in vivo (Fig. 6.6e and Fig. 6.8c). This enhanced efficacy 
is due to a combination of factors: good FPPS and GGPPS inhibition, as well as greatly enhanced 
lipophilicity (clogP of 0.25 for BPH-1222 versus -3.9 for zoledronate), and BPH-1222 has good 
pharmacokinetic properties (Fig. 6.6d) (39,40). 
Targeting protein prenylation (including farnesylation and geranylgeranylation) has been 
pursued for more than 20 years, ever since researchers first found that Ras requires posttranslational 
prenylation for their malignancy-transforming activity. FTIs and GGTIs were developed early on to kill 
tumor cells in vitro, however, little success has been achieved using these compounds in animals. More 
interestingly, responses to these inhibitors do not always correspond to Ras mutation status. This 
observation strongly suggests the existence of other targets (27). Here, we show that Kras prenylation 
and activity is largely inhibited by lipophilic bisphosphonate treatment and suggest that this is one of the 
major mechanisms of action of this class of compounds (Fig. 6.2). However, other small G-proteins, such 
as Ral, Rho, Rac and Cdc42, require exclusively geranylgeranylation, and all of these proteins have been 
shown to be involved in Ras induced transformation in a context-dependent manner (15,41-43). Indeed, 
results from this as well as other studies all support the idea that suppression of protein 
geranylgeranylation is critical for bisphosphonate mediated cytotoxicity. Based on this observation, dual 
target (FPPS+GGPPS) inhibitors should be particularly potent in inhibiting tumor cell growth. 
Kras tumors cells have been shown to rely on autophagy for providing metabolic intermediates 
and clearing excess reactive oxygen species (ROS). In vitro, the additive effects of blocking protein 
prenylation and autophagy with chloroquine resulted in additive tumor cell killing.  In animals, the pro-
proliferative effect induced by p62 accumulation and NF-B activation became dominant, leading to an 
ineffective therapeutic combination.  In sharp contrast, the combination of a lipophilic bisphosphonate 
with rapamycin was far more effective since rapamycin not only facilitated autophagy, but also inhibited 
the mTOR pathway that is critical for the tumor cell survival.  In summary, the combination of a lipophilic 
bisphosphonate plus rapamycin offers a promising therapeutic lead for treating Kras-related lung 
cancers.  
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6.6 Tables and Figures 
Table 6.1  FPPS/GGPPS activity and cell growth inhibited by bisphosphonates. 
 
aDetermined from IC50 and enzyme Kmvalues as reported previously (48,49). 
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Table 6.2  Data collection and refinement statisticsa  
 
 
aData from one crystal were used for molecular replacement 
bValues in parentheses are for highest-resolution shell. 
 
  
 152 
 
Table 6.3  PCR primer sets used in the study. 
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Figure 6.1  Bisphosphonates suppress cell growth through inhibiting FPPS and GGPPS. (a) IC50 of zoledronate and 
its analogs was determined in cell lines derived from Kras-shp53 mouse lung cancer model (6# and L2) and control 
mouse embryonic fibroblasts (MEF) using MTT assay. (b) Ki of zoledronate and its analogs was measured in vitro 
against human FPPS or GGPPS. (c) Structure of BPH-1222 binding to FPPS was determined by single crystal X-ray 
crystallography. Zoledronate binding is shown superimposed. (d) mouse lung cancer cells (6#) were treated with 
single drug (FTI-276, 10 μM; GGTI-298, 10 μM; BPH-1222, 10 μM; FOH, 10 μM; GGOH, 10 μM; Ascorbic acid, 50 
μM; Trolox, 5 μM; Lipoic acid, 5 μM; Simvastatin, 0.5 μM) or drug combinations as indicated for 48 h, and images 
were taken under phase-contrast microscope. Scale bars, 100 μm. (e) mouse lung cancer cells (L2) and embryonic 
fibroblasts (MEF, matched genetic background), or (f) mouse embryonic fibroblasts transformed by Kras-shp53 and 
Mycl1-shp53-shRb1 were treated with different concentrations of BPH-1222 for 3 days, and cell survival was 
measured using Cell Proliferation Reagent WST-1 from Roche. 
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Figure 6.2  Bisphosphonates inhibit Kras prenylation and induce ER stress and autophagy. (a) U2OS cells 
expressing Flag-KrasG12D were treated with bisphosphonates (BPH-1222, 10 μM; BPH-714, 10 μM; zoledronate, 
20 μM) or chloroquine (30 μM) for 48 h. Cellular distributions of proteins (Hras, Kras and Rap1A) that require 
prenylation were examined by immunoblotting. p, pellet contains correctly prenylated proteins which bind avidly 
to membrane; s, supernatant contains unmodified proteins in cytoplasm. *, Hras signal left on the membrane. **, 
autophagy activation determined by the presence of LC3-II. (b) Flag-Kras proteins were purified from untreated 
whole cell lysate or BPH-714 (10 μM) treated cytosolic fraction. Molecular weight of Kras was determined by 
MALDI mass-spectrum. (c) mouse lung cancer cells (6#) were treated with BPH-714 for 48 h and analyzed for Kras, 
Akt and Caspase-3 activation. Kras-GTP was pulled down from whole cell lysate with Raf-1 RBD beads and 
immunoblotted with total Kras antibody. (d) BPH-1222 treatment (10 μM) for 1, 2 or 3 days induced ER stress, 
autophagy and apoptosis in mouse lung cancer cell (6#) in a time-dependent manner. 
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Figure 6.3  Rapamycin but not chloroquine sensitizes tumor cells to BPH-1222 treatment in vivo. (a) mouse lung 
cancer cells (6#) were treated with BPH-1222 in the presence of different concentrations of chloroquine for 3 days, 
and cell survival was examined with Cell Proliferation Reagent WST-1. Combination indices for EC50 combinations 
were all greater than 1 indicating lack of synergy. (b) mouse lung cancer cell (L2, infected with 5xκB-luci reporter) 
syngeneic grafts were treated with BPH-1222 (2 mg/kg) plus either chloroquine (60 mg/kg) or rapamycin (2.5 
mg/kg) for 3 weeks. Scale bars, 10 mm. NF-B activity in tumor grafts was examined by in vivo luciferase imaging 
system (IVIS) immediately after the 3-week treatment (c). (d) mouse lung cancer cells (6#) were treated with BPH-
1222 (10 μM) or combinations (CQ, 30 μM; Rapa, 0.1 μM) for 48 h and NF-B target genes were examined by 
quantitative RT-PCR. (e,f) tumor samples treated with different combinations were sectioned and immuno-stained 
with Ki-67 and Cleaved Caspase 3 antibodies. Casp3 positive cells were marked with arrowheads. Scale bars, 100 
μm. Percentages of Ki-67 positive cells were quantified and plotted in (e). (g) mouse lung cancer cells (L2) 
syngeneic grafts were treated with BPH-1222 (2 mg/kg), rapamycin (2.5 mg/kg) or combination for 3 weeks. Scale 
bars, 10 mm. (h) mouse lung cancer cells (6#) were treated with BPH-1222 (10 μM), rapamycin (0.1 μM) or 
combination for 48 h and examined by immunoblotting. 
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Figure 6.4  Combination therapy in orthotropic graft model and Kras-shp53 lentiviral model. (a,b,c) Mouse 
orthotropic grafts were induced by tail vein injection of M3L2 cells. Mice were left untreated or given treatment 16 
days after the inoculation. Lungs were collected when mice reached end-point (a). Tumor lesions larger than 1mm 
in diameter were counted. Ctrl, 29.8 per mouse, n=8; treat, 13.5 per mouse, n=13 (b). Kaplan-Meier curves of mice 
from control group and treatment group. All survived mice were collected on day 50. Median survival time: Ctrl, 
33.5 d, n=8; treat, 37 d, n=13 (c). (d,e,f,g) Mouse lung adenocarcinomas were induced by intra-tracheally infection 
of Kras-shp53 lentiviral vectors. Mice were left untreated or given treatment when luciferase signals from tumors 
were detectable (Ctrl-low and treat-low group, 10
3
-10
5
; Ctrl-high and treat-high group, > 10
5
). (d) Luciferase 
imaging results of one mouse from Ctrl-low group and one mouse from treat-low group, to show the shrinkage of 
tumor after the combination therapy. See Supplementary Fig. 5 for results from all mice. (e) Fold changes of 
luciferase signal after 2-week treatment. Negative value means shrinkage in tumor size. Some mice had tumor 
shrinkage at other time-points during the treatment which was not shown in this plot. (f) Kaplan-Meier curves of 
mice from all groups. Median survival time: Ctrl-low, 55 d, n=8; treat-low, 75.5 d, n=6; Ctrl-high, 28 d, n=8; treat-
high, 54 d, n=6. (g) Tumors from Ctrl-low and treat-low groups were sectioned and immuno-stained with different 
antibodies. Casp3 positive cells were marked with arrowheads. Scale bars, 100 μm (insets in 4E-BP1-p staining: 
scale bars, 20 μm). 
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Figure 6.5  Structural diagram of bisphosphonates. (a) zoledronate, (b) ibandronate and (c) risedronate 
are potent inhibitors of FPPS (50). (d) Digeranyl bisphosphonate inhibits GGPPS but not FPPS (51). (e) 
BPH-714 has hydrophobic side-chain added to a pyridinium bisphosphonate (52). It inhibits both FPPS as 
well as GGPPS, but has higher Ki than BPH-1222. 
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Figure 6.6  Bisphosphonates suppress cell growth through inhibiting FPPS and GGPPS.  (a) mouse lung cancer 
cells (6#) were treated with 10 μM zoledronate (C0) or its analogs (C1-C11 side chain, X= OH or H) for 3 days and 
stained using crystal violet. (b) IC50 of desoxyl-zoledronate and its analogs was determined in cell lines derived 
from Kras-shp53 mouse lung cancer model (6# and L2) and control mouse embryonic fibroblasts (MEF) using MTT 
assay. (c) Ki of desoxyl-zoledronate and its analogs was measured in vitro against human FPPS or GGPPS. (d) 
Pharmacokinetic profile of BPH-1222 following single dose i.v. administration (5 mg/kg) to female SD rats (n=3). (e) 
mouse lung cancer cells (6#) were treated with bisphosphonates alone (BPH-1222, 10 μM; BPH-714, 10 μM; 
zoledronate, 80 μM), or in combination with other compounds (chloroquine, 30 μM; rapamycin, 100 nM; FOH, 10 
μM; GGOH, 10 μM) for 48 h, and images were taken under phase-contrast microscope. 
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Figure 6.7  BPH-1222 induces ER stress by blocking protein prenylation.  (a) Calculation of molecular weight of 
unmodified and farnesylated mouse Kras proteins. (b) mouse lung cancer cells (6#) were treated with Simvastatin 
(0.5 μM), FTI-276 (10 μM), GGTI-298 (10 μM), BPH-1222 (10 μM), or combinations (FOH, 10 μM; GGOH, 10 μM; 
Ascorbic acid, 10 μM; Trolox, 10 μM; Morin hydrate, 10 μM; Lipoic acid, 10 μM) for 48 h, and lysed for 
immunoblotting with ER stress probes. (c) mouse lung cancer cells (6#) were treated with BPH-1222 alone or 
together with rapamycin (0.1 μM) or chloroquine (30 μM) for 48 h, and whole cell lysates were examined for 
MAPK pathway activity by immunoblotting. (d) same cells from (c) were treated with drug combinations in the 
absence or presence of U0126 (10 μM) for 48 h, and lysed for immunoblotting to check MAPK pathway activity. 
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Figure 6.8  Comparison of BPH-1222 plus chloroquine and BPH-1222 plus rapamycin.  (a) Mouse lung cancer cell 
line (6#) and human lung cancer cell lines (A549 and A427) were treated with BPH-1222 (10 μM), chloroquine (30 
μM) or combination for 48 h, and images were taken under phasecontrast microscope. (b) mouse lung cancer cells 
(6#) were treated with BPH-1222 alone or together with rapamycin (0.1 μM) or chloroquine (30 μM) for 48 h, and 
whole cell lysates were examined by immunoblotting. (c) C57B mice carrying L2 cell syngeneic grafts were treated 
with zoledronate (2 mg/kg), BPH-1222 (2 mg/kg), chloroquine (60 mg/kg) or combination for 3 weeks. Each tumor 
was dissected and weighted. 
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Figure 6.9  Combination therapy in Kras-shp53 lentiviral model.  All mice carrying Kras-shp53 tumors described in 
Figure 6.4 were examined for tumor load by in vivo luciferase imaging system (IVIS) every 10 days during the 
treatment. (a) Control, untreated group, n=8. (b) treat-low, mice had low tumor load when treatment was started, 
n=8. *Two mice were collected for histology right after the treatment. (c) treat-high, mice had high tumor load 
when treatment was started, n=6. 
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Figure 6.10  Working model of combination therapy.  Mevalonate pathway provides isoprenoids for protein 
prenylation. Lipophilic bisphosphonate (such as BPH-1222) blocks both FPPS and GGPPS and depletes isoprenoids, 
which leads to impaired protein prenylation. Green ellipse, proteins require proper prenylation for their function. 
Blue lines, pathways in untreated cells for growth and survival. Orange lines, the changes upon BPH treatment. 
Blocking Ras (Kras in lung cancer cells) modification and function leads to the suppression of its downstream 
survival signaling pathways, including Erk and Akt. Blocking small G-proteins also suppresses other cell survival and 
mobility pathways. Furthermore, impaired protein prenylation induces unfolded protein response (UPR) and ER 
stress and initiates autophagy. Interestingly, BPH induced autophagy is not successful, which is probably due to 
impaired Rab protein prenylation. Rab proteins are important for a key step in autophagy–fusion of 
autophagosome to lysosome. Black lines, chloroquine blocks lysosomal enzymes, which further impairs autophagy 
flux and leads to accumulation of p62, NF-κB activation and cell proliferation. Pink lines, rapamycin inhibits mTOR 
and growth pathways, besides, it activates autophagy pathway, which helps the clearance of p62 proteins. 
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Chapter 7 
A Chemical Information System for Academic Drug Discovery 
 
7.1 Notes and Acknowledgements 
 This chapter is the result of computational work to support all research in the Oldfield lab.  The 
first version was created by Michael Hudock.  All subsequent versions and additions have been 
completed by F. Guerra.  W. Zhu recoded an assay activity matrix script into a Java program.  As long as 
new computers, OSs, and software packages are acquired, this system will need constant maintenance. 
 
7.2 Introduction 
 The field of cheminformatics, from the management of laboratory chemical information to the 
application of quantitative structure-activity relationships (QSAR) and molecular dynamics (MD), is 
rapidly growing.  Industrial scale chemical/biological information systems are used by pharmaceutical 
companies to store and process massive information from high through-put screens (1-3).  Resources, 
such as PubChem (Compound, Substance, BioAssay (4, 5)) and ChEBI (6), are based on cheminformatic 
systems that enable researchers across the globe to access chemical data linked to biological data and 
more.  These international and national academic resources, and of course financially secure 
pharmaceutical companies, have large teams working to maintain and develop these highly useful 
computational tools.  The small academic laboratory, without a dedicated team, is not able to store, 
sort, and easily find relationships amongst all the data that is, has been, and will be acquired.  To 
address this issue, we have developed a customizable, low-cost, web browser based cheminformatics 
system using open-source tools, with demonstration of the system’s modularity by adding functionality 
from some commercially available tools.   
 
7.3 Cheminformatic System Architecture 
 The multi-tiered software architecture is based on a MySQL relational database server backend 
to which all information is stored, including chemical structures.  Manual access to the multiple MySQL 
databases that are populated with data is achieved either through the MySQL Client from the command-
line or through a web browser using open source tools, such as PHPMyAdmin 
(http://www.phpmyadmin.net/home_page/index.php).  Because the web server to database 
communication code is SQL based, any other SQL relational database, PostgreSQL for example, may be 
interchanged with the appropriate replacement of library connectors.  Interaction with the MySQL 
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database is processed via MySQL connection libraries.  In versions 1.0 and 2.0, both PHP/JSP scripts and 
ChemAxon JChem-Base libraries handled interaction with the MySQL libraries.  The ChemAxon JChem 
libraries are proprietary Java-MySQL classes that interact with MySQL tables uniquely written by JChem 
libraries.  Access to JChem MySQL tables may be done through traditional MySQL interfaces, but the 
data will likely be corrupted.  Hence, JChem MySQL implementations are meant to be used solely via 
JChem libraries and the JChem GUI Manager.  In version 3.0, the MySQL databased have migrated 
architectures/formats to work with open-source software, such as the Chemistry Development Kit (CDK,  
http://sourceforge.net/projects/cdk/)  and Ambit2 (http://ambit.sourceforge.net/index.html).  All Java 
libraries and MySQL communication operates server-side.  Dynamically generated JSP and PHP pages 
are server-side scripting implementations.  Java applets are embedded within JSP and PHP pages.  
Client-side code is implemented through JavaScript and Ajax (Pydio,  http://pyd.io/).  Figure 7.1 
illustrates the basic architecture of version 3.0. 
 
Authentication and Authorization 
The authentication and authorization handling has undergone major revisions since the first 
version of the system was created.  In version 1.0 of the system, user authentication and authorization 
was handled through a series of handshakes between an LDAP server, MySQL server, and several scripts 
distributed over 3 machines using both Apache HTTPD Server, Apache Tomcat Server, and different OSs 
(RedHat, Sun, and Mac OS).  The latest version of the system has had authentication/authorization 
streamlined to ease modularity and reduce complexity.  All server applications have been consolidated 
to one physical server (running Centos) using a 5.2 hardware RAID.  In versions 2.0 and 3.0, user 
information is stored in an LDAP Server (389 Directory Server) that can be access via both the command-
line and through a GUI.  To preserve legacy applications/scripts written in PHP, JSP, and Java, both 
Apache HTTPD and Tomcat are again used in version 2.0.  However, Apache HTTPD handles all of the 
authentication by connecting with the LDAP server once a user attempts to enter the system.  Apache 
HTTPD acts as a proxy to Apache Tomcat; therefore, Tomcat cannot be accessed without first being 
authenticated via Apache HTTP/LDAP.  Authorization is handled at 2 levels:  1) after authenticating a 
user, the Apache HTTPD server authorizes only those users who are “active” members in the group and 
2) at the script level, written within the header (or first lines) of code that each PHP/JSP page contains.  
Authorization is based on user ID entry into specific LDAP posixGroups.  Using this script level of 
authorization allows for multiple scripts to be placed in a single directory, but for access to be controlled 
by the purpose/action of each page (script).  In this way, an application for compound shipments can be 
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grouped together within one directory rather than divided over several directories solely for the 
purpose of controlling user access to content.  To track and manage authentication, cookies and 
sessions are created through both Apache HTTPD and Tomcat.  
 
SSL/TLS Certificate 
 The current version 3.0 system uses transport layer security (TLS), previously known as secure 
sockets layer (SSL), from a trusted certificate authority (Comodo, http://ssl.comodo.com/;  
CITES/Comodo, https://www.cites.illinois.edu/sslcert/ssl-technical.htm).  Our server that hosts all of our 
(software) servers has been issued a renewable TLS/SSL certificate from Comodo/InCommon/UIUC.  
Only secure (https) connections using a signed TLS/SSL certificate have been administered through the 
LDAP server, MySQL server, Apache HTTP, and Apache Tomcat.   
 
7.4 Applications 
PHP (Apache HTTP) Applications 
 User Login interface (Figure 7.2) 
 Internal Web Main Page (Figure 7.3) 
 Web-based User Administration (interaction with LDAP server) 
 Software documentation 
 (Old) MySQL/PHP Manuscript Database 
 Pydio (Ajax-based) File Server (Figure 7.4) 
 PHPMyAdmin (administration of MySQL databases) 
 Publications List (entry and edit) (Figure 7.5) 
 UV-Vis spectrophotometer data directory access (Figure 7.6) 
 Transmission Electron Microscopy Image Viewer (Figure 7.7) 
 SSNMR (Processed) Spectra Image Viewer (Figure 7.8) 
 Assay Data Manager (Figure 7.9) 
 
JSP (Apache Tomcat, Java) Applications 
 JChem Main Page (Figure 7.10) 
 Assay/Structure Viewer  (Figure 7.11) 
 Assay Data and Structure Exporters (Figure 7.12) 
 Assay and Assay Data Creation and Importers (Figure 7.13) 
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 Compound Lists Creator/Viewer (Figure 7.14) 
 New Compound Registrion (Figure 7.15) 
 Compound Shipment Creator/Viewer/Printer (Figure 7.16) 
 Single Compound and Assay Data Viewer:  displays structure, all assay IC50s for selected 
compound, MOE calculated descriptors, and (nightly recalculated) activity heat maps displaying 
activity of selected compound among all compounds in that assay. (Figure 7.17) 
 JChem Structure Query Viewer 
 JChem Sketch 
 MarvinView, MarvinSketch, MarvinSpace 
 CDK Editor 
 CDK Compound Viewer 
 Report Generator 
o 2 Assay linear regression correlation calculation and plot (ChartDirector JSP/Java) 
(Figure 7.18) 
o Automated assay correlator:  correlates the selected assay against all other assays, 
sorts the results, and plots the results. (Figure 7.19) 
o Calculate and plot linear regression correlation between compound structure property 
(descriptor) against assay data (Figure 7.20) 
 Assay Comparator:  Select and List Compound List and any number of Assays together (Figure 
7.21) 
 Compound Data Sheet Viewer and Printer (Figure 7.22) 
 
Java programs 
 Oldfield lab specific MySQL connector class 
 (Nightly) Assay Data Average IC50 Calculation:  calculates assay average IC50 values for 
each compound for each assay every night.  As new data is imported, this average 
always needs to be updated. 
 Compound-Assay Activity Matrix Calculator 
 Static Publications List Exporter:  exports list of current publications from Oldfield 
Internal web site to Oldfield external web site every night. 
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7.5 Conclusions 
 The combined modular cheminformatics system allows our researchers to interact with all of 
the compound and assay data in a standardized format.  Computational chemistry and drug design can 
proceed as all data can be exported in standard formats (SDF, MolFile, ASCII) for importing into 
commercial applications such as MOE (7), Sybyl (8), Schrodinger Maestro (9), ChemDraw (10), AutoDock 
(11, 12), AutoDock Vina (11-13), Chimera (14), Accelrys Discovery Studio (15), and more.  Open-source 
software, such as OpenTox (16), Ambit2 (17, 18), and Bioclipse (19, 20) are also able to be integrated for 
use with exported/transferred data.  Virtual screening using AutoDock Vina and Schrodinger Maestro 
can be incorporated easily into an online QSAR application, for example with the use of Ambit2 and 
OpenTox.  In addition to the toxicity calculated by Schrodinger Maestro and MOE SVL scripts, data from 
the system can be imported into Bioclipse and used with a number of decision support modules (21) for 
toxicity, mutagenicity, and further QSAR applications.  In turn, all of the desktop processing can be 
uploaded into the cheminformatics management system. 
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7.6 Figures 
Figure 7.1 Software Architecture 
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Figure 7.2 User Login interface  
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Figure 7.3 Internal Web Main Page 
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Figure 7.4 Pydio (Ajax-based) File Server.  (A) Manuscript database login.  (B) Online manuscript 
database explorer. 
 
 
A 
 
 
B 
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Figure 7.5 Publications List.  (A) Publication list (list exported to external web site nightly). (B) Edit 
a publiction. 
 
A 
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Figure 7.5 (cont.) 
 
B 
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Figure 7.6 UV-Vis spectrophotometer data directory access 
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Figure 7.7 Transmission Electron Microscopy Image Viewer  
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Figure 7.8 SSNMR (Processed) Spectra Image Viewer  (A) Data viewer.  (B) Peak and integration 
list. 
A 
 
B 
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Figure 7.9 Assay Data Manager  (A) View by Transaction.  (B) View Uploaded Raw Data. 
 
A 
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Figure 7.9 (cont.) 
 
B 
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Figure 7.10 JChem Main Page  
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Figure 7.11 Assay/Structure Viewer  (A) Interactive view with Java applet.  (B) Printable view. 
 
A 
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Figure 7.11 (cont.) 
 
B 
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Figure 7.12 Assay Data and Structure Exporters  (A) Assay Data and Structure Exporter.  Select 
assay, compound list, file type, and EOL character.  (B) Assay Data and Structure Exporter.  Select 
compound properties and other assay activities to export.  (C)  Assay Data Only Exporter. 
 
A 
 
 
  
 187 
 
Figure 7.12 (cont.) 
 
B 
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Figure 7.12 (cont.) 
 
C 
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Figure 7.13 Assay and Assay Data Creation and Importers  (A) Assay Data Import (pre-file 
selection).  (B) Assay Data Import (post-file selection for data upload review).  (C)  New Assay Creator 
 
A 
 
 
  
 190 
 
Figure 7.13 (cont.) 
 
B 
 
 
  
 191 
 
Figure 7.13 (cont.) 
 
C 
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Figure 7.14 Compound Lists Creator/Viewer  (A) Create/Edit a Compound List.  (B) View Compound 
List structures. 
 
A 
 
B 
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Figure 7.15 New Compound Registrion  (A) Sketch (or upload) a new Compound Structure.  (B) 
Enter data sheet information for the new compound.  (C) New Compound Administrator Approval (or 
Denial). 
 
A 
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Figure 7.15 (cont.) 
 
B 
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Figure 7.15 (cont.) 
 
C 
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Figure 7.16 Compound Shipment Creator/Viewer/Printer  (A) View all compound shipments.  (B) 
Create/Edit a shipment.  (C) Print a Compound Shipment Form. 
 
A 
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Figure 7.16 (cont.) 
 
B 
 
C 
 
  
 198 
 
Figure 7.17 Single Compound and Assay Data Viewer.  Displays structure, all assay IC50s for selected 
compound, MOE calculated descriptors, and (nightly recalculated) activity heat maps displaying activity 
of selected compound among all compounds in that assay.  (A) Viewer with embedded interactive Java 
applet.  (B) Printable Viewer. 
 
A 
 
B 
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Figure 7.18 Report Generator:  2 Assay linear regression correlation calculation and plot 
(ChartDirector JSP/Java)  (A) Report Generator Main Page.  Select 2 Assays to correlate.  (B) Select data 
points to plot, export to a CSV file, or export to a compound list.  (C) Linear regression plot with 95% 
confidence intervals. 
 
A 
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Figure 7.18 (cont.) 
B 
 
 
C 
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Figure 7.19 Report Generator:  Automated assay correlator.  Correlates the selected assay against 
all other assays, sorts the results, and plots the results.  (A) Select the primary assay.  (B) View ranked 
correlation plot thumbnail images.  Each thumbnail plot can be selected and enlarged. 
 
A 
 
 
B 
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Figure 7.20 Calculate and plot linear regression correlation between compound structure property 
(descriptor) against assay data  (A) Select compound structure property and assay.  (B) Select data 
points to export and/or plot.  (C) View linear regression plot. 
 
A 
 
B 
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Figure 7.20 (cont.) 
 
C 
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Figure 7.21 Assay Comparator.  Select and List Compound List and any number of assays together.  
(A) View assay data for the selected compound lists.  (B) Create a new assay comparator.  Select all assay 
data to view together and (optionally) the compound list to use. 
 
A 
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Figure 7.21 (cont.) 
 
B 
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Figure 7.22 Compound Data Sheet Viewer.  (A)  Compound data sheet viewer with embedded 
interactive Java applet.  (B) Printable compound data sheet. 
 
A 
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Figure 7.22 (cont.) 
 
B 
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